Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Education and Training in Anesthesia and Intensive Care Medicine: Current Challenges and Future Directions" in Advances in Medical Education and Practice.

Anesthesia and intensive care medicine are rapidly evolving disciplines in which patient safety, technological advancement, and increasing clinical complexity place high demands on clinicians. High-quality education and training are therefore essential to ensure not only technical proficiency, but also strong decision-making, communication, and teamwork skills. In recent years, training frameworks have increasingly moved toward competency-based approaches that emphasize clearly defined outcomes and demonstrated clinical competence rather than time-based progression. This shift aims to improve transparency, consistency, and quality of training across diverse healthcare systems. However, it also requires adaptation of curricula, teaching strategies, and assessment methods, as well as an expanded role for educators as facilitators, assessors, and role models. Exploring effective approaches to education and professional development is thus central to sustaining excellence in anesthesia and intensive care medicine.

This is important because anesthesia and intensive care medicine have a direct impact on patient safety and perioperative outcomes in high-risk clinical settings. As patients become older and more complex and technologies more advanced, clinicians must be equipped to deliver safe, effective care under pressure. Modern, competency-based training supports the acquisition of both technical expertise and essential non-technical skills such as decision-making, communication, and teamwork. Clear and standardized training frameworks promote consistency, quality, and equity across institutions and healthcare systems, while also reducing errors and improving outcomes. Investing in education and professional development in anesthesia and intensive care is therefore a core patient safety and healthcare quality priority.

The general theme of this Article Collection is the contemporary approach to medical education in anesthesia and intensive care. Topics of interest include curriculum development, innovative and interactive teaching strategies, modern assessment methods, integration of non-technical skills, simulation-based education, and the development of new standards that promote fair, equitable, and patient-centred care. All article types are welcome, including viewpoints, narrative or systematic reviews, original research, surveys, and observational studies.
Keywords

• Anesthesiology education
• Intensive care training
• Competency-based medical education
• Curriculum development
• Professional development

Please review the journal’s aims and scope and author instructions prior to submission. Please submit your manuscript through the Dovepress website. During submission, enter the promo code 3B60D to indicate that your article should be considered for this Collection. The manuscript submission deadline is 31 March 2027.

Please contact Francis Straw at [email protected] with any queries and discount codes regarding this Article Collection.

Guest advisor

Professor Vojislava Neskovic is a staff anesthetist and Associate Professor of Anesthesia and Intensive Care at the Military Medical Academy in Belgrade, Serbia. Since 2012, she has also contributed to the ESAIC Teach the Teachers (TTT) Masterclass, where she is a member of the TTT Masterclass Committee. Professor Neskovic is one of the authors of the UEMS European Training Requirements for the specialty of anesthesiology, pain, and intensive care medicine. She serves as an examiner for the Part Two EDAIC (European Diploma in Anaesthesiology and Intensive Care) and hosts the Part One (written) EDAIC examination in Belgrade. Currently, she is a member of the EACTA Thoracic Subcommittee, represents Serbia as a Council Member of the ESAIC, and is a member of the WFSA Diversity, Equity and Inclusion (DEI) Committee.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Thriving in Training: Mental Health and Wellbeing of Health Professional Students and Trainees" in Advances in Medical Education and Practice.

The mental health of medical students and postgraduate trainees is a growing area of concern and opportunity. As future healthcare providers, they are often exposed to intense academic demands, long working hours, severe competition, and high emotional stress - all of which can impact their wellbeing and mental health. In light of current workforce shortages and growing demands on healthcare systems, it is more important than ever to prepare medical students and trainees to become adaptable doctors who can sustain their wellbeing throughout their careers. By fostering supportive learning and working climates, institutions can help future doctors thrive in the face of professional challenges - ensuring they are not only clinically competent, but also mentally prepared for the realities of modern medical practice. These environment plays a crucial role in promoting mental wellbeing and reducing stigma around seeking help, empowering students and trainees to manage their mental health proactively.

Research into the mental health of medical students and postgraduate trainees is essential for understanding the unique challenges they face and developing effective strategies to support their wellbeing. Mental health issues can significantly impact students’ personal lives, leading to emotional distress, impaired relationships, and reduced academic performance. Left unaddressed, these challenges can also compromise clinical judgment, empathy, and communication skills - ultimately threatening the quality and safety of patient care. Furthermore, mental health issues can cause students and trainees to drop-out of their education and training, jeopardizing our already understaffed healthcare workforce even further. Institutions must therefore prioritize creating supportive learning environments alongside the design and implementation of evidence-based interventions that promote wellbeing, reduce stigma, encourage help-seeking, minimize attrition, and ultimately foster a healthier, more effective medical workforce capable of meeting growing healthcare demands.

This Article Collection will focus on understanding and improving medical students’ and trainees’ mental health. Theoretical as well as practical contributions are welcomed. Subtopics include, but are not limited to:

• The role of learning and working environments and institutional culture: investigating how curriculum design, assessment practices, student-teacher relationships, institutional or organizational culture and study or working conditions influence mental wellbeing.
• Help-seeking and barriers to support: examining barriers to seeking help and identifying strategies to overcome these barriers.
• Interventions to help students and trainees thrive: focusing on ways to build psychological resilience, self-care practices, self-compassion, peer support programs and other initiatives that can help foster long-term wellbeing.
• Mental health, attrition and workforce: addressing the impact of mental health issues on academic performance and drop-out as well as on building a sustainable workforce.
• Mental health and quality of care: examining the impact of mental health on patient safety and quality of care.

All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author instructions prior to submission.

Please submit your manuscript through the Dovepress website. During submission, enter the promo code DAD72 to indicate that your article should be considered for this Collection.

Please contact Francis Straw at [email protected] with any queries and discount codes regarding this Article Collection.

The manuscript submission deadline is 31 May 2026.

Guest advisors

Dr. Milou Silkens, Erasmus University 

[email protected]

Dr. Milou Silkens is an Assistant Professor in the Erasmus School of Health Policy & Management at the Erasmus University in the Netherlands. She holds a Master of Science (MSc) in Health Sciences and a PhD in Medical Education. Her work centres on workforce issues in healthcare, with a strong focus on the impact of digital transformation and how technological innovations can support healthcare delivery and improve doctors’ working conditions. She also examines the mental health of healthcare professionals and medical students, aiming to better understand how to achieve a resilient and future-ready workforce.

Dr. Asta Medisauskaite, University College London

[email protected]

Dr. Asta Medisauskaite is a Principal Research Fellow at UCL Medical School. She obtained her PhD in Organizational Psychology from Birkbeck, University of London, on understanding and improving the occupational health of medical doctors. Her research continues to explore the mental health and wellbeing of both medical students and doctors. She is particularly interested in how psychological and organizational factors shape their experiences, from training through to long-term career development. Through her work, she aims to create a healthier and more sustainable medical careers, through better understanding mental health and attrition in the healthcare workforce.

Dr. Renée Scheepers, Erasmus University 

[email protected]

Dr. Renée Scheepers is an Assistant Professor in Health Workforce Well-being at the Erasmus School of Health Policy & Management. She is an occupational health psychologist focusing on clarifying and improving well-being of healthcare professionals (and medical) students. Specifically, she performs research on the effects of working conditions and healthcare provider well-being on patient care quality.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Transformative Learning: The Next Step in Medical Education" in Advances in Medical Education and Practice.

Medical education finds itself at a crossroads. As healthcare systems grow increasingly complex, facing pressures from demographic shifts, rising costs, and enduring and increasing health disparities, educators are called to prepare future professionals not only to function within these systems, but to transform them. Traditional pedagogical models often fall short in equipping learners with the mindset, competencies, adaptability, and critical consciousness needed for a role as change agent. Transformative learning theory offers a compelling response. Rooted in fostering deep, structural shifts in perspective, this educational approach enables learners to question assumptions, engage in critical reflection, and develop the capacity to act ethically and innovatively in the face of uncertainty. As medical education seeks to remain relevant and future-oriented, the integration of transformative learning becomes increasingly vital.

Embracing transformative learning in medical education is not merely theoretical: it is a practical necessity. Healthcare professionals must be prepared to navigate moral complexity, collaborate across and beyond academic disciplines, and confront the hidden curriculum that shapes professional identity. Transformative learning encourages these capabilities by supporting learners in making meaning from experience, developing agency, and challenging existing power structures. When integrated into medical education, it fosters a culture of continuous learning, critical inquiry, and social responsibility. Such a shift can enhance professional resilience, promote equity in care, and ultimately contribute to the sustainability of healthcare systems. In doing so, transformative learning has the potential to empower healthcare workers not just to adapt to change, but to lead it.

This Article Collection invites contributions that explore the integration, theory, and practice of transformative learning in medical education. We welcome a range of article types, including empirical research (both qualitative and quantitative), conceptual papers, case studies, curriculum innovation reports, and commentaries. Submissions may address topics such as the design of transformative learning environments, critical reflection practices on transformative learning theory, inter- and trans-disciplinary education, the role of the hidden curriculum, embodied learning, and the development of change agency and change makers among learners. Contributions should align with the journal’s focus on advancing health professions education through scholarship and innovation. By gathering diverse perspectives and experiences, this collection aims to shape a new narrative in health professions education, one that places transformation at its core.

All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author instructions prior to submission.

Please submit your manuscript through the Dovepress website. During submission, enter the promo code F1E5A to indicate that your article should be considered for this Collection. The manuscript submission deadline is 31 July 2026.

Please contact Francis Straw at [email protected] with any queries and discount codes regarding this Article Collection.

Guest advisors

Dr. Efraim Hart, OLVG / VU University, Amsterdam, Netherlands

[email protected]

Dr. Efraim Hart is a medical doctor, a PhD-candidate, and education consultant from the Netherlands. His research is focused on health activism and transformative learning.

Dr. Frederique Demeijer, Vrije Universiteit Amsterdam, Amsterdam, Netherlands

[email protected]

Dr. Frederique Demeijer is an assistant professor at the Athena Institute of the Vrije Universiteit Amsterdam. Her research and education are centred around complex societal issues, which she aims to address by working together with diverse groups in a transdisciplinary setting. Her current research focuses on transformative learning, inter- and transdisciplinary education and research, competency development, and community engaged learning.

Prof. Dr. Fedde Scheele, University of Amsterdam & Vrije Universiteit, Amsterdam, Netherlands

[email protected]

Prof. Dr. Fedde Scheele is Dean of ACTA (Faculty of Dentistry, Amsterdam), Professor of Health Systems Innovation and Education at VU University Amsterdam, and Chair of European Foundation for Women’s Health. His research focuses on designing socially relevant, future-oriented healthcare education, and his goal is to deliver respectful healthcare in an open culture where education, research, and societal responsibility flourish.

View all papers in this article collection

Breast Cancer: Targets and Therapy is pleased to announce an upcoming Article Collection dedicated to the transformative role of antibody-drug conjugates in the treatment of breast cancer. 

Antibody-drug conjugates (ADCs) consist of monoclonal antibodies linked to cytotoxic drugs, allowing for selective delivery of the therapeutic agent directly to cancer cells and minimizing damage to healthy tissues. Advances in ADC research have led to numerous approvals for clinical use, with significant impact on breast cancer therapy, as ADCs can effectively reduce tumor size and improve progression-free survival. With the ongoing identification of novel targets and indications, ADCs are poised to become a leader in the era of targeted therapies for breast cancer. 

We welcome submissions of original research articles, reviews, and perspectives that contribute to the understanding and advancement of these therapies, including mechanisms of action, clinical efficacy, optimal combinations and ordering, and understanding and overcoming resistance. 

This Article Collection will be included in a wider Game Changer Series focused on breakthrough therapies across medicine. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor & Francis and Dove Medical Press, increasing the discoverability and visibility of your research.

The deadline for submissions is 1 June 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website. Submitting authors are eligible for a 20% discount on the Article Publishing Charge. To apply this discount, enter the code NRLJP when prompted during submission. 

Please contact Commissioning Editor Cassie Houtz at [email protected] with any questions.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Breast Cancer Biomarkers in Diagnostic and Translational Pathology" in Breast Cancer: Targets and Therapy.

Breast cancer diagnostics has undergone a significant transformation with the expanding integration of immunohistochemistry-based biomarker assessment into routine pathology practice. Beyond traditional morphologic classification, contemporary evaluation increasingly incorporates predictive and prognostic markers. In breast pathology, biomarkers such as hormone receptors and HER2 have long served as foundational tools; however, recent developments have broadened this landscape to include more nuanced categories of expression and emerging targets. This evolving framework reflects a shift toward more refined histopathologic evaluation. As a result, breast cancer pathology now sits at the intersection of diagnostic evaluation and translational science, with biomarker assessment forming a core component of how these tumors are classified and understood.

Breast cancer diagnostics has undergone a significant transformation with the expanding integration of immunohistochemistry-based biomarker assessment into routine pathology practice. Beyond traditional morphologic classification, contemporary evaluation increasingly incorporates predictive and prognostic markers. In breast pathology, biomarkers such as hormone receptors and HER2 have long served as foundational tools; however, recent developments have broadened this landscape to include more nuanced categories of expression and emerging targets. This evolving framework reflects a shift toward more refined histopathologic evaluation. As a result, breast cancer pathology now sits at the intersection of diagnostic evaluation and translational science, with biomarker assessment forming a core component of how these tumors are classified and understood.

This Article Collection will focus on investigating immunohistochemical and molecular biomarker testing in breast cancer, with particular emphasis on optimizing reproducibility and standardization in routine practice.

Topics of interest include (but are not limited to):

• Technical and interpretative challenges that pathologists and oncologists must consider, especially in the assessment of low and ultra-low HER2 expression and their implications for targeted therapies.
• Predictive biomarkers in breast cancer immunotherapy, as well as emerging markers that inform treatment selection and response.
• Integration of digital pathology approaches and translational surgical pathology studies.

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

The deadline for submissions is 31 January 2027. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code C2928 to indicate that your submission is for consideration in this Article Collection.

Please contact Rebecca Turner at [email protected] with any questions or requests for discount codes relating to this Article Collection.

Guest Advisors

Dr. Eyas Alzayadneh is a surgical pathologist with training in gynecologic and breast pathology. His work focuses on the integration of histopathologic, immunohistochemical, and molecular features in tumor evaluation and clinical practice. He has contributed to research across multiple areas of cancer pathology, with an interest in biomarker-based diagnostics and their clinical applications.

Dr. Rofieda Radi Abdel Rahman Alwaqfi is an Assistant Professor of Pathology at the Johns Hopkins Hospital.

View all papers in this article collection

Cancer Management and Research is pleased to announce an upcoming Article Collection dedicated to the transformative role of CAR-T therapy in the management of cancer.

Since the 2017 US FDA approval of the use of anti-CD19 CAR-T cell therapy for use against B-cell malignancies, CAR-T therapy has demonstrated significant clinical benefits in treating hematologic malignancies, showing clinical efficacy and durability even in patients who have been refractory to other treatments. Research is underway to develop and evaluate CAR-based therapies for application in solid tumors. 

Despite the remarkable impact of CAR-T therapies, challenges remain, including antigen escape, limited persistence, and overcoming the immunosuppressive microenvironment. Further, life-threatening toxicities, the high costs of manufacturing, and the need for a well-trained workforce currently limit the widespread use of CAR-T for cancer treatment.

Given the impact and continued importance of CAR-T cell therapies in cancer treatment, Cancer Management & Research welcomes submissions of original research articles, reviews, and perspectives on CAR-T, including basic science, translational research, clinical efficacy, and real-world implementation. 

This Article Collection is part of a wider Game Changer Series focused on breakthrough therapies across medicine. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor & Francis and Dove Medical Press, increasing the discoverability and visibility of your research. 

The deadline for submitting manuscripts is 1 April 2026. Please review the journal’s Aims and Scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website. Submitting authors are eligible for a 20% discount on the Article Publishing Charge. To apply this discount, enter the code TFRFH when prompted during submission.

Please contact Commissioning Editor Cassie Houtz at [email protected] with any questions.

View all papers in this article collection

Cancer stem cells (CSCs) are a therapy-resistant subpopulation that drives tumor initiation, progression, metastasis, and recurrence. Their capacity for self-renewal, plasticity, and adaptation underpins resistance to chemotherapy, radiotherapy, and immunotherapy, making them a central obstacle to long-term therapeutic success. Eradicating CSCs is thus recognized as a critical goal in improving long-term patient survival.

However, CSC research and targeted therapy face numerous challenges. Currently, there is a lack of universally applicable CSC-specific biomarkers, making it difficult to precisely target CSCs without damaging normal stem cells. Furthermore, CSCs continuously interact with the tumor microenvironment, including hypoxic homeostasis, matrix support, and immune regulation; these external conditions further enhance CSC survival and drug resistance. Recent advances in single-cell omics, spatial omics, and artificial intelligence technologies have provided new tools for revealing the heterogeneity, metabolic characteristics, and regulatory networks of CSCs. Based on these technological innovations, new strategies such as metabolic inhibition, synthetic biology intervention, and immunotherapy are being studied to target CSCs, with the potential to overcome CSC-mediated therapeutic resistance.

This Article Collection aims to gather the latest research progress in the field of cancer stem cells and to facilitate exchange and discussion on key issues such as drug resistance mechanisms, biomarker discovery, and clinical translation. Selected high-quality contributions from the 2026 International Conference on New Models for Cancer Prevention and Treatment (NMCPT 2026, http://www.nmcpt.com/), together with externally submitted manuscripts, will be included. Both original research articles and authoritative reviews are welcome.

Topics of interest include, but are not limited to:
• Molecular Mechanisms & Biomarkers: Intrinsic and microenvironment-mediated resistance pathways; discovery and validation of CSC-associated biomarkers for diagnosis, prognosis, and treatment stratification.
• Tumor Ecosystem: The role of the tumor microenvironment (immune, stromal, metabolic) in sustaining CSCs and fostering therapeutic escape.
• Innovative Therapeutics: Novel strategies targeting CSC vulnerabilities, including small molecules, immunotherapies, epigenetic modulators, and rational combination therapies.
• Translational & Clinical Research: Preclinical validation in advanced models (e.g., patient-derived organoids, in vivo models); pilot and early-phase clinical trials of CSC-targeting agents; studies on minimal residual disease and recurrence.

Submitting authors are eligible for a 10% discount on the Article Publishing Charge. To apply this discount, enter the code B4C3A when prompted during submission.

Manuscript deadline:
31 October 2026

Guest Advisor:
Dr. Peixin Dong, Hokkaido University, Japan, [email protected]

View all papers in this article collection

Taylor & Francis’s Gastroenterology and Hepatology journals, together with Guest Advisors Professor Henning Grønbæk, Professor Knut Lundin, and Associate Professor Purnima Bhat, are pleased to invite you to submit your research to the Article Collection “Innovations in Gastroenterology & Hepatology.”
The Collection aims to discuss clinically focused papers highlighting novel successes in precision medicine, from innovations at a molecular level all the way through to diagnostics and treatments in a variety of settings (including low resource).

Possible subtopics include:

• Novel multi-omic molecular / biomarker technologies for diagnosis, treatment response and prognosis in hepatology and gastroenterology
• Repurposing and recycling in low-resource settings 
• Novel imaging technologies 
• Novel diagnostic and therapeutic endoscopic tools 
• Wearable technologies 
• Robotics 
• Point-of-care diagnostics
• Novel therapeutics 
• Precision medicine 
• Digital health and artificial Intelligence in hepatology and gastroenterology
• Remote patient care and telehealth / telemedicine 
• Novel endoscopy techniques. 
• Psychosocial treatment innovations 
• New strategies and improvements in healthcare system approaches 

The collection spans both Open Access and hybrid journals including: Clinical and Experimental Gastroenterology, Hepatic Medicine: Evidence and Research, Colorectal Cancer, Expert Review of Gastroenterology & Hepatology, Gastrointestinal Oncology: Management and Care, Hepatic Oncology and Scandinavian Journal of Gastroenterology. See here for more information on the journals included and our Guest Advisors.

All Manuscripts submitted to the Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript. 

The deadline for submissions is 15 January 2027.

Please submit your manuscript on our website, quoting the promo code 0D8F7 to indicate that your submission is for consideration in this Article Collection.

For any questions or discount queries regarding the Collection, please email Rebecca Kearns at [email protected].

Guest advisors

Professor Purnima Bhat, Canberra Hospital and Australian National University

Professor Knut E A Lundin, University of Oslo

Professor Henning Grønbæk

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Aging in Otolaryngology – Head and Neck Surgery" in Clinical Interventions in Aging.

Demographic shifts toward an increasingly aged global population demand heightened attention to age-related pathophysiology within otorhinolaryngology–head and neck surgery. This Article Collection explores the multifaceted impact of senescence on audiovestibular, sinonasal, laryngopharyngeal, and head and neck surgical disciplines. Conditions such as presbycusis, presbystasis, presbylarynx, presbyphagia, and age-related immunosenescence present distinctive diagnostic and therapeutic challenges. Molecular mechanisms underlying age-related deterioration - including oxidative stress pathways, mitochondrial dysfunction, and altered inflammatory cascades - warrant particular consideration.

Moreover, geriatric frailty and polypharmacy significantly influence perioperative risk stratification and postoperative rehabilitation. The intersection of gerontology and otolaryngology–head and neck surgery requires innovation in clinical approaches, including targeted interventions that address the unique physiological, cognitive, and functional considerations of the older patient population within this surgical domain.

The significance of age-focused otolaryngology is multidimensional. Demographically, individuals over 65 years will constitute an increasing proportion of the global population in the coming decades, accompanied by a growing incidence of age-related otolaryngologic conditions. Clinically, senescent changes in head and neck structures directly affect speech, voice, swallowing, breathing, hearing, and balance - fundamental aspects of human function. Economically, appropriately tailored interventions can reduce healthcare expenditures through fewer complications and hospitalizations. Scientifically, advancing our understanding of the molecular basis of otolaryngologic aging contributes to broader gerontological paradigms. Ethically, addressing these age-related conditions supports dignity, autonomy, and quality of life, representing both a clinical priority and a moral imperative.

We invite systematic reviews, state-of-the-art reviews, and original research articles that examine the impact of aging across the full spectrum of otolaryngology–head and neck surgery. Submissions may address clinical, translational, or basic science aspects in the following areas, including but not limited to:

• Laryngology: age-related voice disorders (presbylarynx), dysphagia (presbyphagia), laryngeal neuromuscular degeneration, and innovations in diagnosis and voice therapy or surgical interventions for older adults
• Head and Neck Surgery: surgical outcomes, risk stratification, reconstructive techniques, and perioperative management in geriatric patients undergoing procedures for benign or malignant conditions
• Oncology: epidemiology, tumor biology, and treatment responses of head and neck cancers in older adults
• Otology and Neuro-otology: presbycusis, balance disorders (presbystasis), cochlear implantation in the elderly, age-related central auditory processing, and vestibular rehabilitation strategies
• Rhinology: chronic rhinosinusitis, olfactory dysfunction, age-associated mucosal changes, and surgical or medical management tailored to geriatric physiology

A focus will be done for innovation in medical and surgical fields of otolaryngology in older adults.

Please submit your manuscript on our website, quoting the promo code A944F to indicate that your submission is for consideration in this Article Collection.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submissions is 31 July 2026.

Guest Advisors:

Jerome R. Lechien, University of Mons, Belgium

[email protected]

Jerome R. Lechien is professor and chair of surgery in University of Mons, Belgium. He is consultant in robotic and laryngeal surgery in Foch Hospital, Paris, France and member of several scientific societies, including American College of Surgery (ACS), ABEA, CEORL, UEP, and ELS.

Lise Sogalow, University of Mons, Belgium

[email protected]

Dr. Sogalow is medical doctor and PhD candidate in Artificial Intelligence in University of Mons, Belgium.

Antonino Maniaci, University of Enna

[email protected]

Prof. Dr. Antonino Maniaci, born in Messina in 1989, is an Associate Professor of Otolaryngology at the University of Enna Kore, Italy, specializing in rhinology, head and neck oncology, and sleep apnea disorders. He holds a Ph.D. in Biomedical Sciences and has completed advanced training and fellowships in prestigious institutions across Europe, including Marseille and Forlì. With over 287 scientific publications and an H-index of 27, his research focuses on inflammatory and oncological diseases, genetic alterations, and innovative treatments in otolaryngology. He serves as European Secretary of YoIFOS and is actively involved in coordinating international research projects, conferences, and fellowships. Prof. Maniaci has received numerous awards, is a member of editorial boards of high-impact journals, and frequently speaks at international conferences.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Hormone Replacement Therapy in Aging - Benefits, Risks, and Clinical Considerations for Older Adults" in Clinical Interventions in Aging.

We are pleased to announce a new Article Collection in Clinical Interventions in Aging, dedicated to the game-changing role of hormone replacement therapy (HRT) in healthy aging and the management of age-related disorders.

For eligible patients, HRT has revolutionized aging-related healthcare, offering significant benefits in restoring hormonal balance, alleviating menopause and andropause symptoms, reducing osteoporosis and cardiovascular risks, and ultimately enhancing health span and quality of life for older adults.

Given the importance of HRT in aging medicine, Clinical Interventions in Aging invites submissions of original research articles, reviews, and perspectives exploring the mechanisms of action, clinical efficacy, safety, and real-world application of these transformative therapies.

The collection, edited by the Editor-In-Chief Prof. Nandu Goswami, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.

While the call is open to receive manuscripts across the broad spectrum of HRT in aging medicine, the Editors are particularly interested in manuscripts highlighting the role of HRT for older adults in the following area, including but not limited to:

• Osteoporosis and sarcopenia – HRT’s impact on bone density, fall prevention, and frailty
• Cardiovascular and metabolic effects – HRT’s role in heart disease, diabetes, and inflammation
• Cognitive and neurological effects– HRT’s potential in Alzheimer’s disease and cognitive aging
• Long-term risks and monitoring – HRT’s potential risks in cancer and thromboembolism
• Mental health and quality of life – HRT’s impact on mood, depression, sleep, and sexual health
• Efficacy and safety – considerations in late initiation of HRT in older adults

Please submit your manuscript on our website. Submitting authors will be eligible for a 20% discount of the Article Publishing Charge by applying the following code at the point of submission RFPTL. If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor Sam Zhang at [email protected].

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submissions is 1 April 2026.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Innovative Care Models for Older Adults: The Role of Telehealth and Emerging Technologies" in Clinical Interventions in Aging.

The rapid growth in the older adult population is driving health care systems to adopt a wide range of technology-enabled solutions to deliver care to this segment of the population. This approach has transformed how older adults receive care by offering diverse benefits, including greater accessibility, improved chronic disease management, and enhanced satisfaction for both patients and caregivers. Timely interventions and reduced travel demands are especially valuable for individuals with mobility limitations or those residing in rural areas. However, despite these benefits, widespread adoption of digital solutions remains challenging. Overcoming hurdles and tailoring interventions to meet the unique needs of older adults are crucial. This Article Collection will highlight evidence-based research and innovative strategies that advance person-centered and high-quality care for older adults.

Older adults are increasingly using digital health technologies, such as telehealth, mobile health, patient portals, and wearable devices.¹ However, some older adults still face barriers in adopting technology-enabled care that can lead to inequities. Barriers include challenges in learning or accessing new technologies, age-related biases, and difficulty using technologies that are not designed to support patients with age-related issues such as cognitive decline or sensory impairments.²

To address these gaps, health care providers and health systems must ensure that technology-enabled care meets the needs of older adults and addresses the barriers they face. The Principles and Guidelines for Telehealth and Aging offer a roadmap for delivering telehealth in ways that are person-centered, equitable, accessible, integrated, and coordinated.³ Beyond telehealth, the same principles can guide broader technology-enabled care strategies to ensure solutions are tailored to the unique needs of older adults, leading to improved care delivery and outcomes.

This Article Collection for Clinical Interventions in Aging seeks submissions that explore how technology-enabled care can be delivered to older adults in ways that meet their needs and that are person-centered, equitable, accessible, integrated, and coordinated. We welcome evidence-based research, interventions, and insights highlighting solutions that overcome barriers to technology adoption and improve clinical outcomes in aging populations. Potential topics include:

• Evidence-based virtual and hybrid care models that expand health care access for older adults in underserved areas
• Innovative digital health tools designed to address age-related health challenges
• Advanced technologies that facilitate data exchange across electronic health records, improving care coordination for older adults with complex needs
• Caregiver integration tools that enhance support for older adults, particularly those experiencing cognitive decline

The goal of this Article Collection is to provide actionable insights that advance effective, equitable care practices to improve health and quality of life for older adults.

Sources

1. James CA, Basu T, Nallamothu BK, Kullgren JT. Use of digital health technologies by older US adults. JAMA Network Open. 2025;8(1).

2. Leff B, Ritchie CS, Rising KL, Cannon K, Wardlow L. Addressing barriers to equitable telehealth for older adults. Frontiers in Medicine. 2025;12.

3. Wardlow L, Leff B, Biese K, et al. Development of telehealth principles and guidelines for older adults: A modified Delphi Approach. Journal of the American Geriatrics Society. 2022;71(2):371-382.

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 31 May 2026.

Please submit your manuscript on our website, quoting the promo code ENBIV for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

Please contact Sam Zhang at [email protected] with any queries.

Guest Advisors

Dr. Liane Wardlow, PhD, West Health Institute

[email protected]

Liane Wardlow, PhD, is the Senior Director of Clinical Research and Telehealth at the West Health Institute. With 20 years of experience in research across various disciplines, industries, and organizations, Dr. Wardlow has contributed to initiatives at the U.S. Department of Education’s Institute of Education Sciences, the University of California, San Diego’s Alzheimer’s Disease Research Center, Pearson Education, and now the West Health Institute. Her current research focuses on improving health service delivery to enhance the lives of older adults. This includes optimizing care-in-place models, such as telehealth, home-based primary care, home-based palliative care, and Programs of All-Inclusive Care for the Elderly (PACE). These healthcare delivery models aim to improve health outcomes, quality of life, and care experiences while reducing costs and enabling older adults to age in place with dignity.

Dr. Laurie Archbald-Pannone, MD, MPH, University of Virginia

[email protected]

Laurie Archbald-Pannone, MD, MPH, serves as the Claude Moore Associate Professor of Geriatrics, as well as in Infectious Diseases, at the University of Virginia School Of Medicine. As a geriatrician and infectious disease specialist with extensive experience in geriatric medicine and facility-based infection control and prevention, Dr. Archbald-Pannone has over 15 years of clinical and research expertise in the post-acute and long-term care setting (PALTC). She serves as an invited member of the Virginia Department of Health's Long-Term Care Advisory Task Force and, with funding support from VDH, serves as the medical director of the Virginia IMPACT. She is actively involved in medical education, currently serving as College Dean for Student Affairs at the University Of Virginia School Of Medicine.

Dr Suzanne M. Gillespie, MD, University of Rochester School of Medicine and Dentistry

[email protected]

Suzanne Gillespie, MD, is a geriatrician and Certified Medical Director. She is an Associate Professor of Medicine in the Division of Geriatrics and Aging at the University of Rochester School of Medicine and Dentistry and the past president of the Society for Post-Acute and Long-Term Care Medicine.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Comprehensive Management of Complex Cataracts: Surgical Innovations and Postoperative Strategies" in Clinical Ophthalmology.

Complex cataracts represent a diverse group of challenging cases that require advanced surgical skills, tailored techniques, and meticulous perioperative care. These cases may involve coexisting ocular comorbidities, traumatic cataracts, zonular instability, small pupils, corneal opacities, pseudoexfoliation, uveitis-related lens changes, or high myopia. The variability in presentation demands that surgeons not only master technical adaptations but also integrate multidisciplinary management approaches to optimize patient outcomes. 

As global cataract surgery volumes rise, the proportion of cases with added complexity is increasing. Inadequate planning or inappropriate intraoperative decision-making in such cases can lead to sight-threatening complications and poor visual rehabilitation. At the same time, recent innovations - from femtosecond laser-assisted cataract surgery and capsular tension devices to advanced intraocular lens (IOL) technologies and enhanced imaging - offer unprecedented opportunities to improve safety and outcomes. By systematically addressing complex cataracts through both surgical and post-surgical lenses, clinicians can reduce complication rates, enhance visual quality, and improve patients’ quality of life. 

This Article Collection seeks to explore all aspects of complex cataract management, including preoperative evaluation, surgical decision-making, intraoperative innovations, complication prevention, and comprehensive postoperative care. 

Subtopics may include: 

• Surgical approaches for eyes with weak zonules, coexisting corneal pathology, or previous ocular surgeries
• Management of cataracts in uveitis, glaucoma, or high myopia
• IOL selection and fixation techniques
• Perioperative medical management
• Rehabilitation strategies

We welcome original research articles (including surgical technique papers), review articles, perspectives, and commentaries.

All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author instructions prior to submission.

Please submit your manuscript through the Dovepress website. During submission, enter the promo code 9B736 to indicate that your submission is for consideration in this Article Collection. Please note that normal Article Processing Charges will apply.

The manuscript submission deadline is 31 May 2026. If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Guest advisers

Dr. Bharat Gurnani, Gomabai Netralaya and Research Centre, Neemuch, Madhya Pradesh, India

Dr. Kirandeep Kaur, Gomabai Netralaya and Research Centre, Neemuch, Madhya Pradesh, India

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "The Choroid in Health and Disease" in Clinical Ophthalmology.

The investigation of choroidal dynamics has been gaining increasing and critical interest in the recent years due to its pervasive involvement in the pathogenesis and progression of numerous sight-threatening chorioretinal disorders. Choroidal structural, circulatory, or inflammatory perturbations are now recognized as a core etiology in multiple conditions including age-related macular degeneration, pathological myopia, central serous chorioretinopathy and related pachychoroid disorders, hypertensive and diabetic eye disease, and diverse posterior uveitides.

Crucially, the recent advancements of non-invasive imaging modalities, notably swept-source optical coherence tomography (OCT) and widefield OCT, has propelled in vivo assessment of the choroid, facilitating quantitative analysis of its thickness, vasculature, and underlying morphological changes. This technological leap now facilitates essential quantitative analysis of its thickness, vasculature, and underlying morphological changes. These tools are the foundation for the next generation of diagnostics and treatment monitoring.

This Article Collection, "The Choroid in Health and Disease", aims to gather cutting-edge research illuminating the complex physiological and pathological states of this essential tissue. We solicit contributions covering the latest advancements in:

• Quantitative choroidal imaging and biometrics
• The choroid's role in the refractive error pathway and myopia control
• Choroidal vascular alterations in systemic conditions
• The mechanistic contribution of choroidal changes to macular pathologies
• Novel insights into choroidal inflammation, immunology, and targeted therapeutics

We welcome the submission of original research articles, rigorous systematic reviews, and technically-focused brief reports that contribute significantly to the molecular, structural, and clinical understanding of choroidal biology.

All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author instructions prior to submission.

Please submit your manuscript through the Dovepress website. During submission, enter the promo code 14701 to indicate that your submission is for consideration in this Article Collection. Please note that normal Article Processing Charges will apply.

The manuscript submission deadline is 1 August 2026. If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Guest advisors

Dr. Yousef Fouad, Ain Shams University, Egypt

Dr. Sumit Randhir Singh, Akhand Jyoti Eye Hospital Center of Excellence, India

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Clinical Pharmacology and Pharmacotherapeutics of Anti-Infective Agents" in Clinical Pharmacology: Advances and Applications.

This Article Collection focuses on the clinical pharmacology and therapeutic applications of anti-infective agents, including antibiotics, antivirals, antifungals, and antiparasitic drugs. It aims to explore pharmacokinetic/pharmacodynamic (PK/PD) relationships, drug interactions, resistance mechanisms, and individualized dosing strategies in diverse patient populations. The Collection also welcomes research on novel therapeutic approaches, therapeutic drug monitoring (TDM), and the optimization of anti-infective regimens in clinical practice.

The global rise in antimicrobial resistance and the challenges in treating complex infections underscore the urgent need for advanced pharmacological insights. Understanding the clinical pharmacology of anti-infectives is critical for maximizing efficacy, minimizing toxicity, and curbing resistance. This Collection seeks to bridge the gap between pharmacological science and clinical practice, supporting evidence-based therapeutic decisions and contributing to global antimicrobial stewardship efforts.

We invite submissions of Original Research, Reviews, Case Reports, and Perspectives that align with the scope of the journal. Topics of interest include but are not limited to: PK/PD modeling of anti-infectives, TDM in special populations, drug–drug interactions, pharmacogenomics, resistance mechanisms, and clinical outcomes related to anti-infective therapy. All submissions should adhere to the journal’s guidelines and will undergo full peer review.

Keywords

• Anti-infective agents
• Clinical pharmacology
• Pharmacotherapeutics
• PK/PD modeling
• Antimicrobial stewardship

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 30 September 2026.

Please submit your manuscript on our website, quoting the promo code 7189C to indicate that your submission is for consideration in this Article Collection.

Please contact Catherine Teng at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors

Dr Bin Lin, Changxing People’s Hospital

[email protected]

Dr Jiao Xie, The Second Affiliated Hospital of Xi'an Jiaotong University

[email protected]

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to the upcoming Article Collection on “Phototherapy in Dermatology and Cosmetology: Current Advances, Clinical Applications, and Future Directions” in Clinical, Cosmetic and Investigational Dermatology.

Phototherapy has become an essential and rapidly evolving modality in dermatology and cosmetology, offering effective, non-invasive treatment options for a wide range of skin conditions. The use of ultraviolet (UV), visible light, and laser-based technologies has significantly improved therapeutic outcomes in inflammatory, autoimmune, pigmentary, and neoplastic skin disorders, as well as in aesthetic and anti-aging procedures.

This Article Collection aims to highlight recent advances in phototherapeutic techniques, including narrowband UVB, PUVA, excimer light, photodynamic therapy (PDT), low-level light therapy (LLLT), and emerging laser and LED-based systems. Emphasis is placed on clinical applications, treatment protocols, mechanisms of action, safety considerations, and patient-specific approaches in both medical and cosmetic dermatology.

In addition, this Collection seeks to explore translational research and technological innovations shaping the future of phototherapy, such as personalized light-based treatments, combination therapies, artificial intelligence–assisted treatment planning, and novel photosensitizers. By integrating basic science, clinical evidence, and forward-looking perspectives, this Collection aims to provide clinicians, researchers, and industry professionals with a comprehensive overview of the current state and future potential of phototherapy in dermatology and cosmetology.

Phototherapy plays a crucial role in patient care because it offers effective, evidence-based treatment options that are both non-invasive and well tolerated. For many dermatological and cosmetological conditions, phototherapy provides significant clinical improvement while minimizing the need for systemic medications, which may be associated with serious side effects or long-term risks.

Key subtopics include, but are not limited to: Mechanisms of action of phototherapy and light–skin interactions; Clinical applications in dermatology (e.g., psoriasis, atopic dermatitis, vitiligo, acne, cutaneous lymphoma); Photodynamic therapy and novel photosensitizers; Laser and light-based technologies in cosmetology and aesthetic medicine; Treatment safety, adverse effects, and long-term outcomes; Personalized and combination phototherapy approaches; Technological innovations, including LED systems, targeted phototherapy, and AI-assisted treatment planning.

Keywords

1. Phototherapy
2. Skin diseases
3. Light-based therapies
4. Dermatology
5. Cosmetology

Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 10 November 2026.

Please submit your manuscript on our website, quoting the promo code 914F0 to indicate that your submission is for consideration in this Article Collection. Please note that normal Article Processing Charges will apply.

Guest editors

Dr Karolina Chilicka-Hebel, Department of Health Sciences, Institute of Health Sciences, University of Opole, Opole, Poland

[email protected]

Professionally, a research and teaching staff member, professor at the Institute of Health Sciences, University of Opole. Coordinator of the scientific group “Modern Cosmetology”. As a lecturer, specializes in cosmetic devices, while as a researcher focuses on studies on the effects of modern devices on the skin condition of people suffering from common acne.

Dr Danuta Nowicka, Division of Aesthetic Dermatology and Regenerative Medicine of the Skin, Wroclaw Medical University, 50-368 Wroclaw, Poland

[email protected]

A Polish physician and scientist, specializing in dermatology and venereology. She is a university professor and lecturer, affiliated among others with the Medical University and the University of Physical Education in Wrocław. She conducts scientific, teaching, and clinical work and is also the author of publications in the field of dermatology.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Behavioral and Psychosocial Aspects in the Management and Treatment of Diabetes and Obesity" in Diabetes, Metabolic Syndrome and Obesity.

Diabetes and obesity remain major challenges for modern societies, not only because of their rising prevalence but also due to the substantial burden they place on people living with these conditions and their families. Although medical care has advanced significantly—with new medications, improved insulin formulations, and modern technologies—clinical outcomes often remain suboptimal. Increasing evidence highlights that behavioral and psychosocial factors play a crucial role in the effectiveness of treatment and long-term outcomes. Psychological functioning, self-management behaviors, emotional distress, and social context interact with biological and medical factors in shaping the course of diabetes and obesity.

It seems unlikely that progress in managing diabetes and obesity will result from identifying a single crucial factor. Rather, improvement is expected to come from recognizing and addressing a range of contributing factors.

Despite remarkable progress in pharmacotherapy and technological innovations, many individuals still experience challenges achieving optimal disease management. Behavioral barriers, psychosocial burden, and difficulties in sustaining effective self-management remain major contributors to unmet needs in diabetes and obesity care. Improving behavioral and psychosocial support may therefore represent one of the most transformative avenues for enhancing treatment outcomes. This Article Collection aims to gather studies that deepen understanding of behavioral and psychosocial mechanisms and translate this knowledge into practical strategies that can improve management, adherence, and quality of life.

This Collection focuses exclusively on behavioral and psychosocial aspects relevant to the management and treatment of diabetes and obesity. We particularly welcome submissions addressing:

• Behavioral determinants of diabetes and obesity management: self-care behaviors, adherence, lifestyle patterns, motivation, decision-making, and behavioral interventions.
• Psychosocial mechanisms influencing the course and treatment of diabetes and obesity: emotional distress, coping styles, well-being, social support, stigma, self-efficacy, illness perceptions.
• Behavioral and psychosocial aspects of technology use: psychological adaptation to diabetes technologies, human-technology interaction, digital burden, digital literacy, and the impact of technology on self-management behaviors.
• Interventions integrating behavioral and psychosocial components: structured education, psychotherapy, digital behavioral programs, and multidisciplinary approaches.
• Psychosocial and behavioral dimensions of obesity as a risk factor for diabetes: lifestyle behaviors, weight-related distress, family and social influences.

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, entering the promo code 503C6 to indicate that the paper is for consideration in this Article Collection. The deadline for submitting manuscripts is 30 September 2026.

Please contact Menghan Li at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors

Kokoszka Andrzej, The Medical University of Warsaw, Poland

[email protected]

Tomasz Klupa, Department of Metabolic Diseases Jagiellonian University Medical College, Poland

[email protected]

Katarzyna Cyranka, Unit of Psychodiabetology, Department of Metabolic Diseases Jagiellonian University Medical College

Department of Psychiatry Jagiellonian University Medical College, Poland

[email protected]

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Co-occurring Obesity and Eating Disorders: Challenges, Mechanisms, and Intervention Strategies" in Diabetes, Metabolic Syndrome and Obesity.

Obesity and eating disorders often occur together, creating complex clinical profiles that challenge conventional treatment approaches. While obesity is most frequently associated with binge-eating disorder, it may also coexist - albeit less commonly - with bulimia nervosa, night eating syndrome, and atypical anorexia nervosa. In some cases, obesity develops before the eating disorder, functioning as a potential risk factor; in others, it emerges as a consequence of eating disorders. A striking aspect of this comorbidity is the marked gender disparity, with women disproportionately affected compared to men. The coexistence of these conditions is linked to heightened medical complications, greater psychological distress, and diminished quality of life. Shared biological, psychological, and sociocultural mechanisms likely play a role in their onset and persistence, while stigma, diagnostic overshadowing, and fragmented healthcare pathways often delay recognition and impede effective, integrated treatment.

Despite its significant clinical and public health implications, the coexistence of obesity and eating disorders remains under-recognized and under-researched. Many patients present with overlapping symptoms that do not fit neatly into traditional diagnostic categories, leading to misdiagnosis or delayed intervention. This gap in recognition can exacerbate both physical and mental health outcomes, increasing the risk of type 2 diabetes, cardiovascular disease, and severe psychiatric comorbidities. The lack of integrated treatment models means that obesity and eating disorders are often addressed separately, resulting in fragmented care that fails to address the interplay between them. Increased awareness and targeted research are essential to understand shared risk factors better, develop practical screening tools, and design multidisciplinary treatment strategies. Addressing this comorbidity could significantly improve long-term health outcomes, reduce stigma, and promote more effective prevention and intervention efforts in both obesity and eating disorder care.

This Collection invites submissions that explore the intersection of obesity and eating disorders within the context of metabolic health, psychological well-being, and clinical care. Relevant topics include epidemiological studies on prevalence and risk factors; research on shared biological pathways; the influence of sociocultural and environmental determinants; and the role of stigma and weight bias in clinical outcomes. It also welcomes studies evaluating screening tools, diagnostic criteria, and integrated treatment models, particularly those that address both physical and psychological aspects. Articles examining the impact of comorbidity on diabetes risk, glycaemic control, and other obesity-related complications are especially encouraged. The Collection will consider a range of formats, including original research articles, systematic reviews, meta-analyses, clinical case studies, and perspectives from multidisciplinary teams. By fostering cross-disciplinary dialogue, this initiative aims to advance understanding and improve prevention, early detection, and treatment strategies for individuals affected by both obesity and eating disorders.

All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.

Please submit your manuscript on our website, entering the promo code 190D6 to indicate that the paper is for consideration in this Article Collection. The deadline for submitting manuscripts is 31 May 2026.

Guest Advisor

Dr. Riccardo Dalle Grave, Villa Garda Hospital, Italy

[email protected]

View all papers in this article collection

We are pleased to announce a new hot-topic Article Collection in Diabetes, Metabolic Syndrome and Obesity dedicated to the game-changing role of GLP-1 receptor agonists in type 2 diabetes and obesity. Since their clinical introduction, GLP-1 receptor agonists have revolutionized patient care, offering significant benefits in glycemic control, weight loss and management, and cardiovascular and renal diseases for eligible patients. 

Given the recognized importance of GLP-1 agonists in managing type 2 diabetes and obesity, and the accumulating new evidence showing several pleiotropic effects, Diabetes, Metabolic Syndrome and Obesity invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these transformative therapies. 

The Collection, edited by the Editor-In-Chief Professor Rebecca Conway and the Section Editor Professor Ernesto Maddaloni, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes. 

While the call is open to receive manuscripts across the broad spectrum of GLP-1 agonists in managing type 2 diabetes and obesity, the Editors are particularly interested in manuscripts relating to the following areas:

• Obesity
• Diabetes complications, particularly cardiovascular disease, nephropathy, diabetic bone disease
• The brain (reduction in cognitive decline, addition) in diabetes
• Pediatric obesity and diabetes or type 1 diabetes

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.

Please submit your manuscript on our website. Submitting authors will be eligible for a 20% discount on the Article Publishing charge by entering the code BOUZT.

The deadline for submitting manuscripts is 1 April 2026.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Real World Evidence for the Pharmacological Treatment of Diabetes: From Clinical Trials to Routine Practice" in Diabetes, Metabolic Syndrome and Obesity.

Diabetes mellitus represents one of the most pressing global health challenges of the 21st century, affecting over 500 million adults worldwide. The pharmacological landscape for diabetes has expanded rapidly, with the introduction of incretin-based therapies, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and dual-acting agents alongside established glucose-lowering drug classes. While randomized controlled trials (RCTs) remain the gold standard for evaluating therapeutic efficacy, their strict inclusion criteria, controlled settings, and limited follow-up durations often restrict the generalizability of findings to diverse, real-world patient populations. Real world evidence (RWE), derived from electronic health records, claims databases, patient registries, and post-marketing surveillance, has emerged as an essential complement to RCT data for evaluating how antidiabetic pharmacotherapies perform in routine clinical practice. This Article Collection aims to present the latest advances in RWE research specifically pertaining to the pharmacological treatment of diabetes, ultimately informing evidence-based prescribing and clinical decision-making.

The importance of RWE for antidiabetic pharmacotherapy cannot be overstated. Despite the growing number of glucose-lowering agents available, significant gaps persist between the outcomes observed in clinical trials and those achieved in everyday practice. Patient adherence to prescribed regimens, treatment persistence over time, individualized glycemic targets, and the influence of polypharmacy and comorbidities all shape therapeutic outcomes in ways that RCTs cannot fully capture. Furthermore, regulatory agencies such as the U.S. Food and Drug Administration and the European Medicines Agency increasingly incorporate RWE into their drug approval and post-marketing evaluation frameworks, recognizing its value in supplementing trial-based efficacy data. Understanding how specific antidiabetic drug classes and treatment sequences perform across diverse ethnicities, age groups, and comorbidity profiles is essential for optimizing individualized prescribing strategies, improving glycemic control, and reducing treatment-related adverse events in the real-world setting.

This Article Collection invites original research articles, systematic reviews, meta-analyses, and narrative reviews that utilize real world data to evaluate the pharmacological treatment of diabetes. Topics of interest include, but are not limited to: the effectiveness and safety of emerging and established glucose-lowering agents in routine clinical practice; comparative effectiveness studies of antidiabetic drug classes, including SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and insulin formulations, across diverse patient populations; real world treatment patterns, prescribing trends, and therapeutic sequencing strategies; the impact of medication adherence and persistence on glycemic control and long-term clinical outcomes; safety profiles and tolerability of antidiabetic pharmacotherapies as observed in post-marketing surveillance and pharmacovigilance databases; and health economic analyses and cost-effectiveness evaluations of glucose-lowering therapies derived from real world data sources. Contributions should align with the scope of Diabetes, Metabolic Syndrome and Obesity.

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, entering the promo code E00B9 to indicate that the paper is for consideration in this Article Collection. The deadline for submitting manuscripts is 31 December 2026.

Please contact Menghan Li at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors

Dr. Yun Shen, Pennington Biomedical Research Center, USA

[email protected]

Prof. Gang Hu, Pennington Biomedical Research Center, USA

[email protected]

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Drug Design, Development and Therapy on "Advances in p53 Drug Discovery", organized by Dr. Andreas Joerger (Goethe University, Germany), Dr. Alexander Dömling (Palacky University in Olomouc, Czech Republic) and Editor-In-Chief Dr. Frank M. Böckler (Eberhard Karls University Tübingen, Germany).

Often referred to as the "guardian of the genome", p53 plays an important role in maintaining cellular homeostasis by regulating and orchestrating cell cycle arrest, DNA repair, apoptosis, and senescence. Mutations in the TP53 gene which encodes p53, are found in a broad range of human cancers, leading to loss of its tumor-suppressive functions and contributing to cancer progression and metastasis. In addition, some gain-of-function (GOF) p53 mutants can acquire new oncogenic activities affecting genomic instability, metabolic reprogramming, and the tumor microenvironment, while promoting invasion, metastasis, and cancer cell proliferation. The complexity of p53's structure and function, particularly its role as a transcription factor and its interactions with a large number of cellular signaling pathways, has made it a challenging target for drug discovery. However, recent advances in structural biology, computational methods, and medicinal chemistry have opened new avenues for the development of drugs that can restore or enhance p53 function, offering hope for more effective cancer therapies. Furthermore, additional targets, such as MDM2/X, HAUSP, Cop-1, Pirh-2, Wip-1, PTEN, AKT, and Siah-1, could become points of therapeutic intervention, influencing p53 and its signaling and regulation network.

Playing a core role in tumor suppression, the ability to modulate p53 activity holds the potential to transform cancer treatment. The development of drugs that can restore the function of mutant p53 or enhance the activity of wild-type p53 is a critical area of research with significant implications for improving patient outcomes and survival rates in cancer.

To help raise the profile of this important area of research, Drug Design, Development and Therapy is publishing a timely Article Collection on p53 drug discovery. The Collection is led by Dr. Andreas Joerger, Prof. Dr. Alexander Dömling, and the Editor in Chief, Prof. Dr. Frank Böckler. 

Potential topics include, but are not limited to, the following:

• Structural and Molecular Biology of p53 Elucidating its Therapeutic Value
• Small Molecule Modulators of Targets Involved in p53 Signalling and Regulation
• Rescue of Loss-of-function Mutant p53 or Restraint of Gain-of-function Mutant p53
• p53-targeted Gene / Immune Therapies
• Clinical Translation of p53-based Therapies
• Challenges and Future Directions

Please submit your manuscript on our website, using the promo code XITLT for 20% off the advertised article processing charge and to indicate that your manuscript will be considered for the “Advances in p53 Drug Discovery” Collection. We will be welcoming relevant papers up until the 30th of September 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection. 

Guest Advisors

Dr. Andreas Joerger, Goethe University

[email protected]

Andreas C. Joerger obtained his doctoral degree from the University of Freiburg, Germany in 2000. He then assumed a postdoc position in the group of Prof. Sir Alan Fersht at the Medical Research Council (MRC) Centre for Protein Engineering in Cambridge, United Kingdom, initially working on protein design. He stayed on as a senior scientist in structural biology until 2010, before moving to the MRC Laboratory of Molecular Biology in Cambridge (2010-2015). During his long spell at the MRC, he made key contributions towards unraveling the complex structural biology of the tumor suppressor p53 and related proteins. He determined the first crystal structures of p53 cancer mutants, which led to the Y220C mutant being used as a paradigm for the development of mutant p53 rescue drugs based on protein stabilization. In 2016, Dr. Joerger joined the group of Prof. Stefan Knapp at the Institute of Pharmaceutical Chemistry at Goethe University, Frankfurt am Main. Since 2018, he is Principal Investigator on p53 drug discovery and transcriptional regulation at the Structural Genomics Consortium (SGC) Frankfurt. His other research interests include the evolutionary history of the p53 pathway, protein design, epigenetic targets and E3 ubiquitin ligases. 

Dr. Alexander Dömling, Palacky University in Olomouc

[email protected]

Alex Dömling studied Chemistry & Biology at the Technische Universitat Munchen (TUM). He performed his Ph.D. with Ivar Ugi and his postdoc – funded by a Feodor Lynen stipend from the Alexander von Humboldt Foundation – with double Nobel Laureate Barry Sharpless. After his habilitation at TUM, he became a professor at the University of Pittsburgh, then chair of the Department of Drug Design at the University of Groningen, and most recently ERA Chair at Palacky University. He also started several biotech companies. He is the author of over 300 publications and over 70 patent applications. His current lab works according to the mantra ‘Automation + Miniaturization = Acceleration’ on the ERC-funded project of engineering an autonomous drug discovery platform called AMADEUS.

Alexander Dömling is a world-renowned researcher in the area of miniaturization, automation of synthetic chemistry, and multicomponent reaction chemistry. Professor Dömling applies multicomponent reaction chemistry to solve problems in drug discovery and related areas. Notably, he introduced the Acoustic Droplet Ejection technology platform to perform precise high throughput synthetic chemistry and demonstrated its applicability to multiple different chemistries and chemical biology projects.

Dr. Frank M. Böckler, Eberhard Karls University Tübingen

[email protected]

At the Institute of Pharmaceutical Sciences, Frank Böckler heads the laboratory of Molecular Design & Pharmaceutical Biophysics, which combines Chemical Biology, Molecular and Structural Biology and Biophysics, as well as Computational Chemistry, Machine Learning and Molecular Design. In addition, he is a member of the Institute for Bioinformatics and Medical Informatics (IBMI). In 2004, he received his Ph.D. in Medicinal Chemistry with summa cum laude at Friedrich-Alexander University in Erlangen (Germany). Joining Prof. Sir Alan R. Fersht as a postdoc at the MRC Center for Protein Engineering in Cambridge/UK, he discovered p53 mutant stabilizers as potential new cancer therapeutics. In 2008, he was appointed Professor (W2tt) for Bioanalytics at Ludwig-Maximilians University (LMU) Munich, before moving to Tübingen in 2010 as a full professor. His work is dedicated to understanding molecular interactions, such as halogen and chalcogen bonds, as the foundation for chemical biology and drug discovery and to apply theoretical, fragment-based, biophysical, and structural methods to cancer research, particularly involving the human kinome and the network of the tumor suppressor p53.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Drug Design, Development and Therapy on "‘Digital Drugs’ for Musculoskeletal Pain: From Evaluation Tools to Rehabilitation and Therapy Solutions", organized by Prof. Giacomo Farì (University of Salento, Italy) and Prof. Andrea Bernetti (University of Salento, Italy).

Musculoskeletal (MSK) pain represents a major global health challenge, contributing to significant disability and reduced quality of life. Conventional therapeutic approaches often fail to fully address the complex biopsychosocial dimensions of chronic pain, leading to the need for innovative, integrative strategies. In recent years, the concept of "Digital Drugs" has emerged, referring to digital health solutions that modulate pain perception through technology-driven interventions. These include virtual reality (VR), augmented reality (AR), mobile health applications, and biofeedback devices, which can reduce pain and enhance function without pharmacological side effects. By complementing classical pharmacotherapy, these digital therapeutics offer a more holistic approach to pain management, addressing both physical and psychological aspects of chronic pain. Furthermore, "Digital Drugs" provide advanced tools for evaluating pain-related behaviors and functional impairments in real-time, enabling personalized rehabilitation protocols through remote monitoring and adaptive feedback. This integrative model holds promise for optimizing musculoskeletal pain management by combining assessment, therapy, and patient engagement in a comprehensive, technology-enhanced care pathway.

Effective pain management is crucial for improving quality of life, especially in individuals suffering from chronic or complex pain conditions such as mixed pain syndromes. Traditional pharmacological treatments alone sometimes fail to fully address the multifaceted nature of chronic pain, which involves not only nociceptive and neuropathic components but also nociplastic mechanisms. Integrating multimodal approaches—such as physical therapy, psychological support, neuromodulation, and complementary therapies—provides a more comprehensive and patient-centered strategy. Notably, the combination of digital therapeutics with classical pharmacotherapy has the potential to address one of the most pressing challenges in pain management: reducing opioid reliance. By offering alternative methods to manage pain effectively, "Digital Drugs" can help mitigate the risks associated with opioid use, including dependence and adverse side effects. Addressing the biopsychosocial aspects of pain can help prevent long-term disability, reduce healthcare costs, and foster innovation in therapeutic protocols, encouraging personalized care and evidence-based clinical practice.

This Collection aims to highlight innovative approaches in the treatment, rehabilitation, and evaluation of musculoskeletal pain. Submissions of original articles and systematic reviews are encouraged on emerging strategies such as personalized pain management, integrative rehabilitation protocols, digital therapeutics, neuroplasticity-driven interventions, and advances in biomechanical and functional assessment tools. Particular interest lies in research exploring the interplay between musculoskeletal pain and psychosocial factors, as well as the implementation of remote and AI-assisted rehabilitation systems. Studies utilizing novel imaging, wearable sensors, and patient-reported outcome measures (PROMs) to enhance clinical evaluation are also welcome. Additionally, research focusing on the integration of digital therapeutics with classical pharmacotherapy to optimize treatment outcomes and improve patient care is highly encouraged. By addressing these topics, the Collection seeks to advance the understanding and application of innovative, technology-enhanced solutions for musculoskeletal pain management.

Please submit your manuscript on our website, using the promo code 8E84E to indicate that your manuscript will be considered for this Collection. We will be welcoming relevant papers up until the 31st of July 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest advisors

Prof. Giacomo Farì, University of Salento

[email protected]

Medical Doctor, Specialized in Physical and Rehabilitation Medicine; PhD in Sport Sciences; Adjunct Professor at the University of Salento, Lecce, Italy.

Prof. Andrea Bernetti, University of Salento

[email protected]

Medical Doctor, Full Professor of Physical and Rehabilitation Medicine at the Department of Experimental Medicine – University of Salento, Lecce, Italy; General Secretary of the Italian Society of Physical and Rehabilitation Medicine.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Drug Design, Development and Therapy on "Exploring Fragment-Based Approaches in Drug Discovery", organized by Prof. Anna K. H. Hirsch (Saarland University, Germany), Dr. Walid A. M. Elgaher (Saarland University, Germany), Prof. Oliver Koch (Universität Münster, Germany) and Editor-In-Chief, Prof. Frank M. Böckler (Eberhard Karls University Tübingen, Germany).

With the emergence of fragment-based drug discovery (FBDD), the field of drug discovery has undergone significant changes. Unlike traditional high-throughput screening techniques, FBDD is based on identifying low molecular weight compounds (fragments) with a low affinity to the biological target. These initial fragment hits are then developed into drug-like molecules through a range of techniques, including fragment merging, growing, and linking, to produce a lead with a higher affinity.

FBDD has the capacity to streamline the drug discovery process by initiating a bottom-up process of combining fragments with high ligand efficiencies. Structural insights from X-ray crystallography have fostered hopes that fragments with strong local interaction networks could be extended to target a wider binding site, often boosting the affinity substantially. The method not only increases the probability of identifying active compounds compared to random screening but also allows an in-depth exploration of the chemical and biological space surrounding these fragments. In 2024, 52 fragment-derived candidates had made it to different phases of clinical studies (phase 1–3), while seven drugs (Asciminib, Capivasertib, Erdafitinib, Pexidartinib, Sotorasib, Vemurafenib, and Venetoclax) have already been approved. This highlights the great relevance and potential of this approach for drug discovery.

To help raise the profile of this important area of research, Drug Design, Development and Therapy is publishing a timely Article Collection on fragment-based drug discovery. The Collection is led by Prof. Anna K. H. Hirsch, Dr. Walid A. M. Elgaher, Prof. Oliver Koch, and Editor in Chief, Prof. Frank M. Boeckler.

Potential topics include, but are not limited to, the following:

• Advancements in Fragment Screening Techniques
• Specialized Fragment-Libraries and Library Design
• Structural Biology and Fragment-Based Design
• Chemical Biology and Fragment Evolution
• Case Studies and Success Stories
• Challenges and Future Directions

Please submit your manuscript on our website, using the promo code SODHO for 20% off the advertised article processing charge and to indicate that your manuscript will be considered for the “Advances in p53 Drug Discovery” Collection. We will be welcoming relevant papers up until the 31st of October 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest Advisors

Prof. Dr. Anna K. H. Hirsch, Saarland University, Germany

[email protected]

Anna Hirsch read Natural Sciences with a focus on Chemistry at the University of Cambridge and spent her third year at the Massachusetts Institute of Technology, doing a research project with Prof. Timothy Jamison. She carried out her Master’s research project in the group of Prof. Steven V. Ley at the University of Cambridge. She received her Ph.D. from the ETH Zurich in 2008 and worked on the de novo structure-based design and synthesis of inhibitors for an anti-infective target enzyme in the group of Prof. François Diederich. Subsequently, she joined the group of Prof. Jean-Marie Lehn at the Institut de Science et d’Ingénierie Supramoléculaires (ISIS) in Strasbourg as an HFSP postdoctoral fellow, before taking up a position as assistant professor at the Stratingh Institute for Chemistry at the University of Groningen in 2010 where she was promoted to associate professor in 2015. In 2017, she moved to the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), where she heads the department for drug design and optimization. Her work focuses on anti-infective drug design by adopting rational approaches such as structure- and fragment-based drug design in combination with the target-guided strategies dynamic combinatorial chemistry and kinetic target-guided synthesis. 

Dr. Walid A. M. Elgaher, Saarland University, Germany

[email protected]

Dr. Walid A. M. Elgaher studied Pharmacy at Assiut University (Egypt). He was awarded a scholarship from the German academic exchange service (DAAD) for doctorate study in Germany. In 2016, he got his Ph.D. in Medicinal Chemistry under the supervision of Prof. Rolf W. Hartmann, Saarland University. He then returned to Egypt and was appointed as a Lecturer of Pharmaceutical Organic Chemistry at the Faculty of Pharmacy, Assiut University. In 2017, he joined the group of Prof. Anna K. H. Hirsch as a postdoctoral fellow at HIPS, and since 2024 has been a habilitand at Saarland University. His work focuses on the application of modern drug design approaches tackling un(der)exploited therapeutic targets and the use of biophysical and computational techniques for drug discovery and optimization. 

Prof. Dr. Oliver Koch, Universität Münster, Germany

[email protected]

Oliver Koch is Heisenberg-Professor of Computational Drug Discovery at the Institute of Pharmaceutical and Medicinal Chemistry, University of Münster. His interests lie in the development and application of computational methods in rational drug design with focus on ‘big data’ driven decisions and artificial intelligence combined with fragment- and structure-based design. The methods are applied to develop bioactive molecules and to understand selectivity, promiscuity and polypharmacology of protein-ligand interactions. In an interdisciplinary way, the in-silico work is combined with biochemical evaluation, x-ray crystallography and preparative organic synthesis. He received his Ph.D. in Pharmaceutical Chemistry in 2007 at Philipps-University Marburg in the group of Gerhard Klebe and also completed a postgraduate program computer science with focus on machine learning and data science. He worked as a postdoc at CCDC in Cambridge/UK and afterwards for MSD Animal Health Innovation GmbH, Schwabenheim, Germany. In 2012, he became an Independent Junior Group Leader of „In-silico Medicinal Chemistry“ at Technical University Dortmund, Germany. From 2019-22 he was Independent Group Leader for “Computational Medicinal Chemistry and Molecular Design” at University of Münster, where he became a Heisenberg-Professor for Computational Drug Discovery in 2022. 

Prof. Dr. Frank M. Böckler, Eberhard Karls University Tübingen

[email protected]

At the Institute of Pharmaceutical Sciences, Frank Böckler heads the laboratory of Molecular Design & Pharmaceutical Biophysics, which combines Chemical Biology, Molecular and Structural Biology and Biophysics, as well as Computational Chemistry, Machine Learning and Molecular Design. In addition, he is a member of the Institute for Bioinformatics and Medical Informatics (IBMI). In 2004, he received his Ph.D. in Medicinal Chemistry with summa cum laude at Friedrich-Alexander University in Erlangen (Germany). Joining Prof. Sir Alan R. Fersht as a postdoc at the MRC Center for Protein Engineering in Cambridge/UK, he discovered p53 mutant stabilizers as potential new cancer therapeutics. In 2008, he was appointed Professor (W2tt) for Bioanalytics at Ludwig-Maximilians University (LMU) Munich, before moving to Tübingen in 2010 as a full professor. His work is dedicated to understanding molecular interactions, such as halogen and chalcogen bonds, as the foundation for chemical biology and drug discovery and to apply theoretical, fragment-based, biophysical, and structural methods to cancer research, particularly involving the human kinome and the network of the tumor suppressor p53.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Drug Design, Development and Therapy on "Nanotechnology in Drug Delivery for Neurodegenerative Diseases", organized by Dr. Pravin Hivare (University of Utah, US).

Neurodegenerative diseases (NDs), including Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Huntington’s disease (HD), are marked by progressive neuronal loss, resulting in severe cognitive and motor impairments. According to the World Health Organization, AD alone affects over 50 million people globally, with projections suggesting this number could triple by 2050. Current treatments are limited in efficacy, primarily due to the blood-brain barrier (BBB), which restricts the entry of most therapeutic agents into the brain. Furthermore, the complex pathophysiology of NDs necessitates innovative approaches for developing effective disease-modifying therapies.

Nanotechnology offers a promising solution to overcome the challenges posed by the BBB. Nanoparticles (1–100 nm), nanomaterials, and DNA-based devices with specific properties such as size, shape, and surface modifications can facilitate targeted drug delivery to the brain. Nanocarriers like liposomes, polymeric nanoparticles, and dendrimers enhance drug solubility and stability, enabling controlled release, minimizing side effects. Recent advances demonstrate nanotechnology’s potential to deliver diverse therapeutics, including small molecules and gene therapies, revolutionizing treatment for neurodegenerative diseases.

This Article Collection aims to showcase cutting-edge research and promote interdisciplinary collaboration in nanotechnology for drug delivery in NDs. We invite submissions on a variety of topics, including but not limited to: novel nanocarrier design and synthesis, strategies to enhance BBB penetration, in vitro and in vivo evaluation of nanotech-based therapies, clinical translation and trials, safety and toxicity assessments, and emerging fields such as theranostics and personalized nanomedicine. We welcome original research articles, systematic reviews, meta-analyses, clinical trial reports, and perspective pieces that detail the development process of nanotech-based drug delivery systems, from initial design to clinical application. By consolidating the latest research, this collection seeks to accelerate the translation of innovative therapies into clinical practice, ultimately improving outcomes for patients with neurodegenerative diseases.

Please submit your manuscript on our website, using the promo code 975F1 to indicate that your manuscript will be considered for this Collection. We will be welcoming relevant papers up until the 30th of April 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest advisor

Dr. Pravin Hivare, University of Utah, US

[email protected]

Dr. Pravin Hivare is a Postdoctoral Fellow in the Department of Neurology at the University of Utah, where he investigates the molecular mechanisms of neurodegenerative diseases using advanced techniques like RNA sequencing, rodent models, and microscopy. His expertise in bionanomaterials, including DNA-based nanodevices, nanomaterials, and hydrogels, supports innovative therapeutic strategies. Dr. Hivare has published extensively in high-impact journals, contributing to neuroscience and drug delivery advancements.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Drug Design, Development and Therapy on "New Trends in Formulations for Oral Inhalation", organized by Prof. Eleonore Fröhlich (Medical University of Graz, Austria) and Dr. Sarah Zellnitz-Neugebauer (Research Center Pharmaceutical Engineering GmbH, Austria).

Inhalation is a promising, noninvasive method of delivering active pharmaceutical ingredients to the lungs. It can achieve high local and systemic concentrations in a short amount of time. However, oral inhalation poses problems as well. Formulating some drugs in high enough amounts, delivering large molecules as stable aerosols, and generating particles of the optimal size (1-5 µm) are challenges. Additionally, inconsistent absorption due to differences in patient anatomy and physiology can lead to less predictable topical and systemic drug levels. The potential of systemic treatment by oral inhalation has not been fully realized. The thin air-blood barrier poses a risk of lung damage, and biocompatibility may be an issue.

The prevalence of chronic pulmonary diseases is increasing worldwide due to an aging population, delayed diagnosis, and air pollution. The prevalence of communicable pulmonary diseases remains a significant global health challenge. The incidence of tuberculosis has peaked due to the outbreak of the novel coronavirus, and pneumonia continues to cause high mortality rates. Engineered dry powders, co-formulations, improved targeting methods (e.g., mucoadhesion), innovative carrier systems (e.g., exosomes), and new therapeutic agents (e.g., biologics) offer opportunities for improved pulmonary treatment. It is also important to understand which anatomical or physiological patient properties may influence drug efficacy and toxicity.

This Collection is interested in tools that may improve the success of orally inhaled formulations in clinics, including new drug particles, targeted delivery approaches, fixed dose combinations, and innovative carriers or drug delivery techniques. This also includes in silico tools that can identify promising drug formulations or predict efficacy and toxicity in patients. Additionally, studies that can explain interpatient differences in pulmonary formulations, and any methods that increase the efficiency of pulmonary delivery are welcome. Further, there is room for a more precise assessment of the biocompatibility and long-term effects of pulmonary formulations.

Please submit your manuscript on our website, using the promo code 0EB1F to indicate that your manuscript will be considered for this Collection. We will be welcoming relevant papers up until the 31st of May 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest advisors

Prof. Eleonore Fröhlich, Medical University of Graz

[email protected]

Eleonore Fröhlich is a biochemist and medical doctor with specialization in anatomy, histology, and embryology. She is affiliated with the Medical University of Graz (Director of the Core Facility Imaging, 2007–2024), the Eberhard-Karls University Tübingen (Extraordinary Professor since 2007), and the Research Center Pharmaceutical Engineering (Key Researcher since 2013). Her research activities started with studies on the retina, skin cancer, and thyroid disease at the University of Tübingen. Since the 2010s, her research has focused on the toxicological effects of nano- and microparticles, particularly those inhaled, at the Center for Medical Research in Graz. 

Dr. Sarah Zellnitz-Neugebauer, Research Center Pharmaceutical Engineering GmbH

[email protected]

Sarah Zellnitz-Neugebauer is a pharmacist by training. During her PhD at the Graz Technical University (AT) she focused on glass beads as new model carries in dry powder inhalers (DPIs) and gained expertise in particle engineering via surface modification and detailed material characterization. She currently holds the position of Senior Scientist at the Research Center Pharmaceutical Engineering (RCPE) in Graz (AT). Meanwhile, her work centers on tailoring DPI formulations via mechanistic understanding of the interplay of material properties, formulation properties, adhesive-cohesive force balance and drug detachment. Recently, she also took up the field of co-processing of API combinations for inhalation therapy.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Drug Design, Development and Therapy on "Next-Generation Treatments for Depression: From Novel Compounds to Optimized Use of Available Drugs", organized by Dr. Vassilis Martiadis (Local Health Authority Napoli 1 Centro, Italy) and Dr. Domenico De Berardis (Local Health Authority Teramo, Italy).

Depression is one of the most prevalent and debilitating mental health conditions worldwide. It encompasses a range of clinical presentations, from unipolar major depression to bipolar depression. Furthermore, despite the wide availability of pharmacological treatments, many patients fail to achieve remission. In recent years, there has been a surge in research into novel pharmacological agents, ranging from rapid-acting antidepressants to drugs that target previously unexplored neurobiological mechanisms. At the same time, repurposing established compounds or optimizing existing treatment strategies has opened up new avenues of therapy, particularly for patients with treatment-resistant forms of depression. This article collection aims to explore the full range of emerging pharmacological treatments for depressive disorders.

The need for more effective, individualized pharmacological treatments for depression is greater than ever before. The expansion of pharmacotherapeutic options, including NMDA receptor modulators, multimodal antidepressants and novel mood stabilizers, has introduced promising alternatives to conventional monoaminergic approaches. Additionally, combining therapies or re-evaluating established medications through novel dosing regimens or indications has demonstrated initial efficacy in challenging patient groups. This collection invites studies that critically evaluate the efficacy, safety, mechanisms of action and clinical application of these emerging treatments for unipolar and bipolar depression, including treatment-resistant forms.

We welcome submissions covering a wide range of topics related to the pharmacological treatment of depression. These topics include, but are not limited to, novel antidepressants, glutamatergic agents, fast-acting compounds, polypharmacy strategies, pharmacogenetics and augmentation or combination therapies. We encourage submissions that address both clinical and translational research, as well as systematic reviews, meta-analyses and real-world evidence studies. Particular emphasis will be placed on research related to treatment-resistant and bipolar depression, and on the repositioning of known compounds in new therapeutic contexts. Accepted article types include original research articles, review articles, brief reports and case series.

Please submit your manuscript on our website, using the promo code B3D62 to indicate that your manuscript will be considered for this Collection. We will be welcoming relevant papers up until the 31st of May 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest advisors

Dr. Vassilis Martiadis, Local Health Authority Napoli 1 Centro

[email protected]

Dr. Vassilis Martiadis is a psychiatrist and researcher with a strong focus on treatment-resistant depression, psychopharmacology, and personalized mental health care. He collaborates on various national and international projects exploring novel therapeutic strategies for mood disorders. He has authored over 50 peer-reviewed publications (h-index: 23). 

Dr. Domenico De Berardis, Local Health Authority Teramo

[email protected]

Dr. Domenico De Berardis is a psychiatrist with extensive clinical and academic experience in mood disorders and psychopharmacology. He collaborates with the University of Chieti-Pescara and L'Aquila, and is Visiting Professor at Samara State Medical University. He has authored over 220 peer-reviewed publications (h-index: 47). His expertise focuses on innovative pharmacological approaches to depression.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Drug Design, Development and Therapy on "Sol Gel-Based Hybrid Materials in Drug Delivery and Biotherapeutic Stabilization", organized by Dr. Chinmay S. Potnis (Duke University, US) and Prof. Gautam Gupta (University of Louisville, US).

The development of advanced drug delivery systems is essential for improving the efficacy and shelf-life of sensitive biomolecules, including proteins, peptides, and nucleic acids. Among emerging technologies, sol gel-derived hybrid materials, particularly silica-based matrices, have gained prominence as versatile platforms for therapeutic stabilization and delivery. These materials offer mild synthesis conditions, tunable porosity, and excellent biocompatibility, allowing for the gentle encapsulation and sustained release of bioactive agents. The inorganic-organic hybrid nature imparts both structural integrity and customizable functionality, making sol gels highly adaptable for diverse pharmaceutical applications, from gene delivery to biologic preservation.

This area of research is vital, due to the inherent instability and degradation risks associated with many biologics, which can limit their therapeutic use. Sol gel materials create protective microenvironments that safeguard biomolecules while enabling site-specific and sustained delivery. Their design flexibility allows for the inclusion of targeting ligands and stimuli-responsive elements, advancing the frontiers of nanomedicine and personalized treatment. This collection highlights breakthroughs in sol gel technologies that translate to meaningful therapeutic improvements and clinical relevance.

We welcome original research articles, reviews, expert opinions, commentaries, and clinical studies aligned with the journal's scope. Topics may include sol gel synthesis and characterization, strategies for encapsulating biomolecules and small molecules, development of bioresponsive or targeted sol gels, and nanomedicine formulations. Manuscripts demonstrating translational outcomes such as in vitro and in vivo efficacy, safety profiles, and manufacturability are especially encouraged. This Collection aims to foster interdisciplinary contributions that integrate material science with drug design and therapeutic application.

Please submit your manuscript on our website, using the promo code CB47D to indicate that your manuscript will be considered for this Collection. We will be welcoming relevant papers up until the 31st of October 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest advisor

Dr. Gautam Gupta, University of Louisville

[email protected]

Dr. Gautam Gupta is Associate Professor of Chemical Engineering. His research focuses on electrochemistry, sol gel encapsulation for biomolecules, wastewater treatment, and perovskite solar cells. Funding to support his research comes from a range of federal agencies and industrial sponsors, including NSF, NIH, DOE, EPRI and LG&E. Dr. Gupta has published extensively, has two patents, and has submitted another six research disclosures.

Dr. Chinmay S. Potnis, Duke University

[email protected]

Dr. Chinmay Potnis is a Postdoctoral Associate at Duke University with a strong background in formulation development, drug delivery, and organic synthesis. His current work focuses on designing and evaluating novel excipients to improve the stability and delivery of small-molecule drugs and nucleic acids. Through the use of silica-based sol-gels, he has developed innovative encapsulation strategies that enable controlled release and protection under stress conditions. With additional expertise in mechanistic organic synthesis, he bridges molecular design with advanced formulation approaches. He is passionate about creating scalable, real-world solutions for complex drug delivery challenges.

View all papers in this article collection

Taylor & Francis’s Gastroenterology and Hepatology journals, together with Guest Advisors Professor Henning Grønbæk, Professor Knut Lundin, and Associate Professor Purnima Bhat, are pleased to invite you to submit your research to the Article Collection “Innovations in Gastroenterology & Hepatology.”
The Collection aims to discuss clinically focused papers highlighting novel successes in precision medicine, from innovations at a molecular level all the way through to diagnostics and treatments in a variety of settings (including low resource).

Possible subtopics include:

• Novel multi-omic molecular / biomarker technologies for diagnosis, treatment response and prognosis in hepatology and gastroenterology
• Repurposing and recycling in low-resource settings 
• Novel imaging technologies 
• Novel diagnostic and therapeutic endoscopic tools 
• Wearable technologies 
• Robotics 
• Point-of-care diagnostics
• Novel therapeutics 
• Precision medicine 
• Digital health and artificial Intelligence in hepatology and gastroenterology
• Remote patient care and telehealth / telemedicine 
• Novel endoscopy techniques. 
• Psychosocial treatment innovations 
• New strategies and improvements in healthcare system approaches 

The collection spans both Open Access and hybrid journals including: Hepatic Medicine: Evidence and Research, Clinical and Experimental Gastroenterology, Colorectal Cancer, Expert Review of Gastroenterology & Hepatology, Gastrointestinal Oncology: Management and Care, Hepatic Oncology and Scandinavian Journal of Gastroenterology. See here for more information on the journals included and our Guest Advisors.

All Manuscripts submitted to the Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submissions is 15 January 2027.

Please submit your manuscript on our website, quoting the promo code DC842 to indicate that your submission is for consideration in this Article Collection.

For any questions or discount queries regarding the Collection, please email Rebecca Kearns at [email protected].

Guest advisors

Professor Purnima Bhat, Canberra Hospital and Australian National University

Professor Knut E A Lundin, University of Oslo

Professor Henning Grønbæk

View all papers in this article collection

We are pleased to announce a new Article Collection in HIV/AIDS - Research and Palliative Care, dedicated to the transformative role of pre-exposure prophylaxis (PrEP) in HIV prevention. Since its clinical introduction, PrEP has revolutionized HIV care, providing significant benefits in preventing transmission, enhancing prevention confidence, and reducing anxiety for at-risk populations.

Given the global importance of PrEP, HIV/AIDS - Research and Palliative Care invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of this transformative strategy.

The collection, edited by Editor-In-Chief Professor Olubunmi Akindele Ogunrin, will be included in Taylor & Francis’ Game Changer Series. This series features Article Collections focused on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

While the call is open to receive manuscripts across the broad spectrum of PrEP in HIV prevention, the Editors are particularly interested in manuscripts relating to the following areas:

• Agents in PrEP strategy
• Delivery models
• Target populations
• Barriers and support
• Education, acceptability, adoption, adherence and retention

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 1 April 2026.

Please submit your manuscript on our website. Submitting authors are eligible for a 20% discount on the Article Publishing charge by applying the following code at the point of submission F4375. 

If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor at [email protected].

Guest Advisors

Olubunmi Akindele Ogunrin, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom

View all papers in this article collection

ImmunoTargets and Therapy is pleased to announce a new Article Collection dedicated to examining CombImmunoTherapy (CIT) as a game-changing oncology treatment strategy.

This Collection, edited by the Editor-In-Chief Prof. Michael R. Shurin, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, and technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.

In 2011, the first immunotherapy for cancer was approved. Since then, the FDA has approved at least 11 immune checkpoint inhibitors and other types of immunotherapies, including CAR T-cell therapies. Currently, there are more than 1,000 immunotherapy clinical trials underway across the United States alone, with 15-20% of patients experiencing robust results. While immunotherapy has significant promise, traditional methods of cancer treatment, such as chemotherapy and radiation therapy, still prevail as the first line of treatment. As we learn more about factors such as the tumor microenvironment that influence treatment efficacy, one thing remains clear – there is a great need for personalized combination therapy. CIT provides a more tailored approach, allowing oncologists flexibility to effectively treat each individual patient.

While this call is open to receive manuscripts highlighting all aspects of CIT, the Editors are particularly interested in manuscripts relating to the following areas:
• Preclinical models investigating combinatorial immunotherapy strategies
• Promising combinatorial approaches currently in trial
• Interaction, safety, and contraindication data
• Current therapeutic drugs/antibodies in the pipeline
• Mechanistic action, targets, and immune effects of CIT
• Immunotherapy in combination with traditional chemotherapy and/or radiation therapy
• Cancer vaccines for CIT
• Combinational immunotherapy of patients with cancer and comorbid immune-mediated diseases

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

Submitting authors are eligible for a 20% discount on the Article Publishing charge by applying the following code at the point of submission: 0A8F9. All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.

Please submit your paper on our website. The deadline for submitting manuscripts is 1 June 2026.

If you have any queries regarding the Article Collection or would like to discuss a submission, please email the Commissioning Editor, Ashley Ambros at [email protected].

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Future-Ready CAR-T Cells: Integrating Gene Editing, Multi-Antigen Targeting, Translational Advances and Microenvironment Reprogramming" Guest Edited by Dr. Vinay Kumar and Dr. Anuradha Tyagi in ImmunoTargets and Therapy.

Chimeric Antigen Receptor T-cell (CAR-T) therapies have transformed the landscape of cancer treatment, offering unprecedented outcomes in relapsed and refractory hematologic malignancies. Despite these breakthroughs, significant obstacles; including antigen escape, T-cell exhaustion, off-tumor toxicity, limited durability of responses, and restricted success in solid tumors still constrain their broader therapeutic potential. In parallel, rapid innovations in gene editing, synthetic biology, vector engineering, and tumor microenvironment modulation are driving the next generation of CAR-T technologies. Given the expanding field and urgent need for new solutions, this Article Collection aims to gather cutting-edge research and authoritative reviews that highlight transformative advances, emerging challenges, and forward-looking strategies in CAR-T cell–based immunotherapies.

Global research and clinical activity in CAR-T therapy is rapidly accelerating, yet critical gaps remain in mechanistic understanding, therapeutic optimization, and practical implementation. A focused collection in ImmunoTargets and Therapy will provide a comprehensive and influential resource for clinicians, immunologists, translational scientists, and biotech innovators, catalyzing advancements that can reshape patient outcomes. Hence this Article Collection, will serve as a forward-looking platform to capture breakthrough developments and foster innovation in one of the most rapidly evolving domains of modern immunotherapy.

This Collection welcomes high-impact original research, reviews, mini-reviews, perspectives/commentaries, methodology papers and graphical reviews/visual communications focusing on the diverse scientific and translational innovations reshaping CAR-T therapy. Key themes include, but are not limited to: 1. Engineering Next-Generation CAR-T Cells; 2. Addressing Antigen Escape and Heterogeneity; 3, Toxicity Mitigation and Safety Engineering; 4, Advanced Gene-Editing and Synthetic Engineering Platforms; 5, Innovations in Tumor Microenvironment (TME) Reprogramming; 6, Clinical Advances, Safety Innovations, and Combination Therapies; 7, Expanding CAR-T Horizons Beyond Cancer

Keywords

1. CAR-T cell therapy
2. Next-generation CAR-T
3. Multi-antigen targeting
4. Tumor microenvironment (TME) modulation
5. Clinical trial innovations

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code A6829 to indicate that your submission is for consideration in this Article Collection. The deadline for submitting manuscripts is 15 October 2026.

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors

Vinay Kumar, Penn State University

[email protected]

Dr. Vinay Kumar is a Researcher (junior faculty) at the Heart and Vascular Institute, Pennsylvania State University, where his work focuses on dissecting dysregulated innate and adaptive immune networks in myocardial infarction (MI) and chronic heart failure (HF). His research emphasizes understanding the roles of distinct T-cell subsets and the time-dependent phenotypic shifts these cells undergo during chronic HF. Additionally, Dr. Kumar is dedicated to developing innovative immunomodulatory strategies to reverse pathological immune alterations and facilitate their translation from bench to bedside.

Anuradha Tyagi, Department of cBRN, Institute of Nuclear Medicine & Allied Sciences

[email protected]

Dr. Anuradha Tyagi is a biomedical researcher specializing in inflammation biology, wound healing, and host–pathogen interactions. Her work demonstrates that timely modulation of the inflammatory phase is crucial for proper wound closure and tissue repair, particularly in conditions like radiation dermatitis. She has highlighted the therapeutic potential of secondary bile acids in chronic wound management, showing their ability to inhibit biofilm formation, neutralize bacterial virulence factors, modulate pro-inflammatory cytokines, and promote angiogenesis. Dr. Tyagi’s research advances our understanding of immune responses, microbial dynamics, and tissue regeneration, with important translational implications for chronic wound therapy.

View all papers in this article collection

ImmunoTargets and Therapy is pleased to announce a new Article Collection dedicated to examining immunotherapy strategies to treat comorbid immune-mediated diseases.

Patients with comorbid immune-mediated diseases have at least two or more autoimmune, allergic, infectious or inflammatory diseases that significantly impact their quality of life. Some conditions typically co-occur together, such as Sjogren’s Syndrome and Systemic Lupus Erythematosus. Other diseases may be a result of shared inflammatory signaling pathways or caused by the primary immune-mediated disease. Treating patients with comorbid immune-mediated diseases presents a unique challenge, as treatment may require a multidrug regimen with multiple opportunities for drug interaction.

In this Article Collection, we seek to explore the mechanistic underpinnings of immune-mediated disease comorbidities and potential opportunities for immunotherapeutic treatment. While this call is open to receive manuscripts highlighting all aspects of comorbid immune-mediated disease therapy, the Editors are particularly interested in manuscripts relating to the following areas:
• Cell-based therapeutics such as stem cell and CAR-T cell-mediated therapies
• Novel preclinical models, shared disease pathway targets, and mechanism of action studies
• Emerging immunotherapeutic treatment options and strategies
• Clinical management strategies such as combination therapy and therapeutic resistance
• Special patient populations, including immune disorders involving multiple systems
• Immune-related adverse events while treating comorbid diseases
• New use cases for already-approved immunotherapy to target multiple disease pathways
• Regulation of immunological balance in treating comorbid diseases

All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.

Please submit your paper on our website, quoting the promo code 86788 to indicate that the paper is intended for the Article C0llection. The deadline for submitting manuscripts is 1 June 2026.

If you have any queries regarding the Article Collection or would like to discuss a submission, please email the Commissioning Editor, Ashley Ambros at [email protected].

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Integrating One Health in Infectious Disease Prevention and Control" in Infection and Drug Resistance.

It is increasingly recognized that the management of infectious diseases can be improved through intersectoral or interdisciplinary collaborations. One of the most prominent examples is the development of the rabies vaccine, which first demonstrated efficacy in dogs and was later adapted as post-exposure prophylaxis in humans. In 1964, Calvin Schwabe, a distinguished veterinarian and epidemiologist, coined the term “One Medicine” in response to the separation of human and veterinary medicine. This concept was later reintroduced in the 21st century and evolved into “One Health.” Following its adoption and advocacy by public health agencies, One Health is now defined as “an integrated, unifying approach that aims to sustainably balance and optimize the health of humans, animals, plants, and ecosystems. It recognizes that the health of humans, domestic and wild animals, plants, and the wider environment (including ecosystems) are closely linked and interdependent.”

Several case studies have demonstrated the public health benefits of implementing One Health principles. For instance, CIPARS (the Canadian Integrated Program for Antimicrobial Resistance Surveillance) is an integrated antimicrobial resistance surveillance network that primarily monitors enteric bacteria from humans, animals, and the environment. This program has not only informed policy development but has also led to stewardship interventions (e.g., the banning of ceftiofur use in poultry due to resistant Salmonella). Since the SARS-CoV-2 pandemic, there has been renewed interest in zoonotic diseases. To this end, a joint vaccination program for humans and animals has been piloted under the One Health framework. Despite its promise, more work is needed before One Health principles can be fully realized. One current challenge is the emergence of Aspergillus fumigatus, an environmental fungus that causes resistant invasive fungal infections and is linked to the use of dual-use antifungals in agriculture. Tackling this issue will require not only clinicians but also the agricultural sector.

In this article collection, we welcome submissions that advance our understanding of infectious diseases and their management through the broader lens of One Health, incorporating animal and environmental health. This may include fundamental research, policy proposals, and initiatives or implementation studies. Case studies, reviews, perspectives, and short communications are also welcome.

Keywords

• One Health
• Communicable Diseases
• Drug Resistance, Microbial
• Antimicrobial Stewardship
• Environmental Health

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your paper on our website, entering the promo code 2311A to indicate that the paper is intended for the Article Collection. The deadline for submitting manuscripts is 28 February 2027.

Please contact Zhiyuan Zhang at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisor

Aditya K. Gupta, University of Toronto, Canada

[email protected]

Dr Aditya K. Gupta is a dermatologist with about 35 years of experience and more than 900 publications. Dr. Gupta received his medical degree from the University of Southampton, UK. He completed a dermatology residency/clinical research fellowship at the University of Michigan, Ann Arbor, and has received a Ph.D. from the University of Göteborg, Sweden. He is Professor of Dermatology at the University of Toronto Temerty Faculty of Medicine. He is a Principal Investigator of the Mediprobe Research Inc., Canada. He has organized and conducted active clinical trial units in London, Ontario, and is the director of a basic research laboratory. His clinical research has focused on superficial fungal infections (onychomycosis, tinea pedis, tinea capitis), psoriasis, atopic dermatitis, acne, actinic keratosis, and skin cancer.

View all papers in this article collection

Dove Medical Press is pleased to announce a new Article Collection in Infection and Drug Resistance, dedicated to the game-changing role of personalised antimicrobial strategies in managing infectious disease.

In contrast to the standard “one-size-fits-all" approach to prescribing antibiotics, personalized antimicrobial strategies involve using advanced diagnostics and data-driven approaches to determine the best course of treatment for an individual patient. Bringing a precision medicine approach to infectious disease management improves patient outcomes and promotes antimicrobial stewardship.

In light of the growing importance of personalized antimicrobial techniques, Infection and Drug Resistance invites submissions of original research articles, reviews, and perspectives that advance our understanding and use of these strategies.

The Collection, Edited by Editor-In-Chief Professor Oliver Planz, will be included in Taylor & Francis’ Game Changer Series. This series features Article Collections focused on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.

While the call is open to receive manuscripts across the broad spectrum of personalized antimicrobial strategies, the Editors are particularly interested in manuscripts relating to the following areas:

• Molecular diagnostics
• Microbiome analysis
• Resistance profiling
• Clinical implementation & therapeutic drug monitoring
• Personalized therapy in specific populations, including pregnancy.
• Economics and cost-effectiveness
• Ethical and regulatory considerations
• Patient education and engagement

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submissions is 1 June 2026.

Please submit your manuscript on our website, quoting the promo code LTMAV for a 20% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

Please contact Zhiyuan Zhang at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisor

Oliver Planz, University of Tübingen, Germany

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Impact of comorbidities on COPD" in the International Journal of Chronic Obstructive Pulmonary Disease.

Chronic obstructive pulmonary disease is a leading cause of morbidity and mortality worldwide with an economic and social burden that is both substantial and increasing. A number of meta-analyses and systematic reviews provide evidence that prevalence of COPD is appreciable higher in smokers compared to non-smokers, in those >40 years of age compared to those <40, and in men compared to women. COPD is a progressive respiratory condition often accompanied by various comorbidities that significantly affect patient outcomes. It is estimated that 80% of COPD patients are likely to have at least one comorbidity. An increasing number of people in any aging population will suffer from multi-morbidity, defined as the presence of two or more chronic conditions, and COPD is present in most multi-morbid patients. The systemic involvement in patients with COPD, as well as the interactions between COPD and its comorbidities, justify the description of chronic systemic inflammatory syndrome.

The pathogenesis of COPD is closely linked with aging, as well as with cardiovascular, endocrine, musculoskeletal, renal, and gastrointestinal pathologies. These complex interactions are based on chronic low-grade systemic inflammation, chronic hypoxia, and multiple common predisposing factors, and are currently under intense research. The incidence of comorbidities increases later in life, decreasing the quality of life of patients with COPD, as well as complicating the management of the disease.

We welcome reviews and original articles. Potential topics of this Article Collection include but are not limited to:

• Assessment of COPD comorbidities by HRCT
• Lung cancer as fatal COPD comorbidity
• Overlap syndrome: COPD and sleep apnea
• Impact of diabetes on COPD
• Management of heart failure in COPD
• Risk of atherosclerosis in chronic respiratory diseases
• Link between COPD and autoimmune diseases
• New phenotype IPF plus emphysema

Keywords

• COPD
• Comorbidities
• Obstruction

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 30 June 2026.

Please submit your manuscript on our website, quoting the promo code 5293F to indicate that your submission is for consideration in this Article Collection.

Please contact Zhiyuan Zhang at [email protected] with any queries regarding this Article Collection.

Guest Advisors

Alexandru Corlateanu, Nicolae Testemitanu State University of Medicine and Pharmacy, Moldova

[email protected]

Dr. Alexandru Corlateanu is the Professor and chief of Department of Respiratory medicine at State University of Medicine and Pharmacy "Nicolae Testemitanu", Chisinau, Moldova. He is National Leader for Moldova at The Global Initiative for Chronic Obstructive Lung Disease (GOLD) and member of the The Global Initiative for Asthma (GINA) Assembly for Moldova. He has written over 50 peer-reviewed articles and several book chapters. He is a reviewer for multiple reputed journals in the field of respiratory diseases.

Alexandr Ceasovschih, Grigore T. Popa University of Medicine and Pharmacy, Romania

[email protected]

MD, PhD, Assistant Professor in Grigore T. Popa University of Medicine and Pharmacy, Internal Medicine and Cardiology Consultant in Clinical Emergency Hospital Sfântul Spiridon, Iași, România. His Clarivate Web of Science h-index and consistent publication record reflect meaningful academic involvement, with a focus on areas of Internal Medicine. He is young fellow of European Society of Atherosclerosis and deputy editor in the European Journal of Preventive Cardiology, as well as reviewer in many Clarivate Web of Science journals.

Pradeesh Sivapalan, Herlev & Gentofte University Hospital, Denmark

[email protected]

Pradeesh Sivapalan is a respiratory physician and clinical researcher based in Denmark. His research focuses on acute and chronic respiratory infections, COPD, and the use of biomarkers and randomized trials to guide treatment strategies. He has authored several high-impact publications and leads or co-leads multiple national and international research projects, including large pragmatic trials and registry-based studies. Pradeesh is also involved in medical education and mentoring of early-career researchers.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Non-Pharmacological Interventions for Improving Physiological, Physical, and Psychological Health Outcomes in Individuals with COPD" in the International Journal of Chronic Obstructive Pulmonary Disease.

Optimal management of COPD includes non-pharmacological interventions including pulmonary rehabilitation, smoking cessation, disease self-management, medication adherence, routine vaccinations, oxygen therapy and ventilatory support, and physical activity promotion. This Article Collection highlights new and innovative non-pharmacological interventions for improving physiological, physical, and psychological outcomes in individuals with COPD.

COPD is a leading cause of morbidity, disability, and mortality worldwide. The disease affects the whole person impacting physiological (e.g., lung function), physical (e.g., physical activity, exercise capacity), and psychological (i.e., depression) outcomes. Non-pharmacological interventions are part of guideline-based care for COPD. Yet, gaps in the management of COPD exist. Many non-pharmacological interventions are underutilized and/or benefits dwindle over time. For example, while pulmonary rehabilitation remains the gold-standard for improving an array of health outcomes, it remains severely underused and benefits begin to wane after 12 months. New and novel non-pharmacological intervention can supplement existing non-pharmacological interventions for individuals with COPD with the potential to improve physiological, physical, and psychological outcomes.

This Article Collection seeks articles focused on intervention development and testing (from preliminary/pilot to effectiveness, implementation and dissemination studies) of interventions targeting improvement in physiological, physical, and/or psychological outcomes. We welcome original research articles, short reports, and systematic reviews. Study protocols of highly innovative non-pharmacological interventions will also be considered. Interventions may include a single component (e.g., balance training) or multiple components (e.g., complex behavioral interventions). Interventions that include chronic pain management, treatment of sleep disturbances, integrative therapies such as mind-body interventions, and psychotherapies (i.e., cognitive behavioral therapy) are salient to this Article Collection. Outcomes should broadly fall within the categories of: physiological, physical, and psychological domains and may include primary and/or secondary outcomes, as well as secondary analysis of completed trials. Moderator and/or mediation analyses of completed trials asking how and for whom interventions work are also welcomed.

Keywords

• Non-pharmacological interventions
• Physiological
• Physical
• Psychological
• Outcomes

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 31 July 2026.

Please submit your manuscript on our website, quoting the promo code 15402 for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

Please contact Zhiyuan Zhang at [email protected] with any queries regarding this Article Collection.

Guest Advisors

Patricia M. Bamonti, VA Boston Healthcare System, Harvard Medical School, USA

[email protected]

Patricia M. Bamonti, PhD, ABPP, Assistant Professor of Psychology, Department of Psychiatry, Harvard Medical School, is a Staff Psychologist at VA Boston Healthcare System. Dr. Bamonti studies the impact of depression and anxiety symptoms on health outcomes in the context of pulmonary rehabilitation and physical activity interventions. She is currently developing and testing an integrated physical activity intervention with cognitive behavioural therapy for individuals with COPD and comorbid depression and/or anxiety.

Marilyn L. Moy, VA Boston Healthcare System, Harvard Medical School, Boston University Chobanian & Avedisian School of Medicine, USA

[email protected]

Marilyn L. Moy, M.D., M.Sc., Associate Professor of Medicine, Harvard Medical School, is a Staff Pulmonary Physician at VA Boston Healthcare System. She is Medical Director of the Pulmonary Rehabilitation Program, accredited by the American Association of Cardiovascular and Pulmonary Rehabilitation. Dr. Moy studies the role of physical activity in the risk stratification of COPD, technology-based interventions to promote PA, and the biological mechanisms underlying the beneficial effects of PA on COPD outcomes.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Relationship, Intimacy and Sexual Health in COPD: Dyadic Processes, Biopsychosocial Perspectives and Interventions" in the International Journal of Chronic Obstructive Pulmonary Disease.

Chronic obstructive pulmonary disease (COPD) is a progressive condition that impacts patients' lives far beyond respiratory impairment, limiting everyday functioning, changing identity and influencing interpersonal relationships. Increasingly, attention has turned toward how COPD influences relationship dynamics, intimacy and sexual health. These domains are central to quality of life but have historically been underexplored in respiratory research. This Article Collection seeks to advance a comprehensive understanding of how COPD intersects with relational and sexual wellbeing within a biopsychosocial framework. It emphasizes both individual and dyadic perspectives, recognizing that COPD affects not only those diagnosed but also their partners and broader relational contexts.

The topic of this Article Collection has direct implications for good patient care and patient-centered outcomes in COPD. While traditional clinical management often prioritizes physiological symptoms, evidence suggests that relational and sexual wellbeing significantly influence mental health, treatment adherence and overall quality of life. Unaddressed challenges in intimacy and partnership can contribute to social isolation, psychological distress and reduced coping capacity for both patients and partners. Conversely, supportive relationships and adaptive dyadic coping strategies can enhance resilience and facilitate adjustment to chronic illness. Despite this, healthcare systems frequently overlook these dimensions due to stigma, lack of training, or limited evidence-based guidance. By consolidating research in this area, this collection aims to inform clinical practice, promote open dialogue and support the development of interventions that address relational and sexual health as integral components of COPD care.

This Collection welcomes research spanning a broad range of topics related to relationship dynamics, intimacy, and sexual health in COPD. Relevant subtopics include but not limit to dyadic coping and adjustment, communication patterns, caregiver-partner experiences, sexual function and wellbeing, and the influence of gender and sex differences. Studies addressing diverse relationship forms – including heterosexual and same-sex partnerships – are encouraged, as are investigations focusing exclusively on partners. The collection also invites work on multimorbidity within individuals and couples, exploring how co-occurring conditions shape relational and sexual outcomes. Both descriptive and interventional research are within scope, including studies evaluating psychosocial, behavioral or clinical interventions. Submissions may include original research articles (quantitative, qualitative or mixed methods), systematic and narrative reviews, brief reports and perspectives, provided they align with the journal’s focus on COPD and contribute to advancing knowledge in this emerging and clinically relevant field.

Keywords

• Chronic respiratory disease
• Intimacy or intimate relations
• Sexual wellbeing
• Dyadic coping
• Partnership

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website. The deadline for submitting manuscripts is 31 March 2027.

Please contact Zhiyuan Zhang at [email protected] with any queries regarding this Article Collection.

Guest Advisors

Ingeborg Farver-Vestergaard, Lillebaelt Hospital, University of Southern Denmark, Denmark

[email protected]

Dr Farver-Vestergaard is a clinical psychologist and an associate professor in health psychology and respiratory care. She has conducted and supervised several studies within the field of sexual health and chronic respiratory conditions.

Yoon Frederiksen, Aarhus University, Aarhus University Hospital, Denmark

[email protected]

Dr Frederiksen is a clinical psychologist, certified in health psychology as well as clinical sexology. She is an associate professor in health psychology and clinical sexology.

Anders Løkke, Lillebaelt Hospital, University of Southern Denmark, Denmark

[email protected]

Prof Løkke is a respiratory physician and a professor of intersectorial research and care. He has conducted and supervised numerous clinical and epidemiological studies focusing on biopsychosocial aspects and interventions in respiratory diseases, mainly COPD.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Innovations and Integrations in regenerative medicine" in the International Journal of General Medicine.

Regenerative medicine is increasingly recognized as a central pillar of future healthcare. Unlike conventional treatments that primarily focus on managing symptoms, regenerative approaches aim to restore or replace damaged tissues and organs. This shift is particularly important as chronic diseases, degenerative conditions, and organ failure continue to increase in prevalence worldwide. Advances in stem cell biology, biomaterials, tissue engineering, gene editing, and immunomodulation are driving progress toward therapies that have the potential to provide lasting functional recovery. This Collection, "Innovations and Integrations in Regenerative Medicine" presents recent developments that demonstrate scientific discoveries and how they are being translated into clinical practice. By bringing together contributions from basic science, translational research, and clinical studies, the series highlights the potential of regenerative strategies to redefine treatment pathways and set new standards of care in modern medicine.

Regenerative medicine tackles health problems that current treatments often fail to resolve. Chronic conditions such as heart disease, diabetes, neurodegenerative disorders, and organ failure are typically managed, not cured. Regenerative approaches seek to restore the structure and function of damaged tissues and organs, directly addressing root causes rather than symptoms. This field promises to overcome critical limitations like organ transplant shortages and immune rejection by enabling growth or restoration of tissues using a patient’s own cells. It also holds cross-cutting potential for different targets, such as cardiovascular repair, neurological disorders, autoimmune diseases, and more. There are many of these therapies have already reached clinical or commercial stages, including FDA-approved treatments for wounds and orthopedic injuries, strengthening the path from research to real-world impact.

This Collection centers on regenerative medicine within the framework of internal medicine, reflecting the journal's commitment to enhancing understanding of pathogenesis, diagnosis, treatment protocols, patient outcomes, and quality of life. It invites contributions that explore areas such as stem-cell therapies, biomaterial innovations, tissue engineering, gene editing, immune modulation, and their clinical applications in cardiovascular, endocrine, neurological, and multi-system diseases. Articles that integrate basic research and clinical trials are especially welcome.

Keywords

1. Regenerative Medicine
2. Stem Cell Therapy
3. Tissue engineering
4. Biomaterials
5. Translational Medicine

All manuscripts submitted to the Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code 9D1C8 to indicate that your submission is for consideration in this Article Collection. The deadline for submitting manuscripts is July 6 2026.

Guest Advisors

Ke Huang, Texas A&M University

[email protected]

Dashuai Zhu, Columbia University 

[email protected]

Dr. Dashuai Zhu is a biomedical researcher specializing in regenerative medicine and therapeutic biomaterials. His work focuses on engineering advanced delivery platforms to promote tissue repair and modulate immune responses. Dr. Zhu has contributed extensively to translational research, bridging innovative laboratory discoveries with clinical applications.

Panagiotis Tasoudis, UNC Hospital 

[email protected]

Dr. Panagiotis Tasoudis is a surgery resident with a strong focus on advanced cardiothoracic procedures and transplant medicine. His clinical and research interests include lung and heart transplantation, LVAD therapy, aortic disease management, and regenerative medicine. Dr. Tasoudis is dedicated to integrating surgical innovation with translational research to improve patient outcomes.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Today in Pulmonary Medicine from the Bench to Bedside and Beyond" in the International Journal of General Medicine.

The International Journal of General Medicine seeks to publish innovations in clinical, translational, and basic science that improve our knowledge and management of pulmonary diseases. Although the scope of pulmonary medicine is vast, we seek impactful contributions that use state-of-the-art approaches to promote lung health in the areas of obstructive airways disease, fibrosis, pulmonary hypertension, sleep, neural control of breathing, environmental medicine, and population health. Topics may also include new therapeutics, biomarkers, diagnostics, devices, and new research methodology.

Lung diseases represent one of the most widespread and severe categories of medical conditions globally. In the United States alone, tens of millions of people are affected by various forms of lung disease, ranging from mild respiratory issues to life-threatening conditions. These diseases include chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis, and lung cancer, among others. The primary causes of lung disease are well established: tobacco smoke—both firsthand and secondhand exposure—remains the leading risk factor. In addition, respiratory infections such as pneumonia and influenza can significantly damage lung function, particularly in vulnerable populations. Genetic factors also play a critical role, with inherited conditions like cystic fibrosis contributing to chronic respiratory problems. Environmental pollutants, occupational exposures, and lifestyle factors further compound the risk, making lung health a critical area of public health concern.

Article types such as Original Research, Reviews and Commentaries are welcomed. Case reports/series are not sought; any submitted to the International Journal of General Medicine will be diverted to the International Medical Case Reports Journal.

Topics of interest include but are not limited to:
Innovative pulmonary therapeutics

• Chronic obstructive pulmonary disease (COPD)
• Pulmonary hypertension
• Pulmonary fibrosis
• Genetic factors of pulmonary health
• Environmental and lifestyle factors affecting pulmonary health

Keywords

1 Respiratory
2. Lung
3. Airways
4. Fibrosis
5. Population health

All manuscripts submitted to the Article Collection will undergo a full peer-review; the Guest Advisor for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code 5E564  to indicate that your submission is for consideration in this Article Collection. The deadline for submitting manuscripts is 31 July 2026.

Guest Advisor

Professor Reynold A. Panettieri, Jr., MD, Rutgers University, New Brunswick, NJ USA

[email protected]

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in the International Journal of Nanomedicine on "Advanced Nanomedicine Strategies for Targeted Drug Delivery and Precision Therapeutics", organized by Prof. Jonghoon Choi (Chung-Ang University, South Korea).

The field of nanomedicine has revolutionized the landscape of modern therapeutics by offering unprecedented control over the delivery of pharmaceutical agents. By utilizing engineered nanomaterials, researchers can now navigate complex biological environments to deliver drugs specifically to diseased tissues while minimizing systemic side effects. This Article Collection focuses on the latest breakthroughs in nanocarrier design, including the development of bio-responsive materials, lipid-based nanoparticles, and metallic nanostructures. We aim to explore how these platforms are being refined to improve solubility, stability, and the pharmacokinetic profiles of both small molecules and biologics.

Despite significant laboratory success, the clinical translation of nanomedicine remains a critical challenge. Understanding the interaction between nanomaterials and the biological milieu—such as the protein corona and immune system evasion—is essential for developing effective therapies. This Collection is vital because it bridges the gap between fundamental materials science and clinical application. By highlighting strategies that overcome physiological barriers, such as the blood-brain barrier or the dense stroma of solid tumors, this collection provides a roadmap for the next generation of precision medicine that can adapt to individual patient needs.

We invite submissions that cover a broad spectrum of nanomedicine applications, including but not limited to:

• Mitochondrial targeting and organelle-specific delivery.
• Stimuli-responsive drug release mechanisms (pH, temperature, or enzyme-activated).
• Nano-bio interactions and toxicity assessments.
• Scale-up and manufacturing challenges for clinical trials. We welcome Original Research articles, and Comprehensive Reviews. All manuscripts must align with the journal's scope of advancing drug delivery technology.

Please review the journal’s aims and scope and author submission instructions prior to submission.

Please submit your manuscript through the Dovepress website. During submission, enter the promo code 54176 to indicate that your submission is for consideration in this Article Collection. The manuscript submission deadline is 31 January 2027.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest advisor

Prof. Jonghoon Choi, Chung-Ang University

[email protected]

Professor Choi is a full professor at the Chung-Ang University specializing in nanomedicine and biotechnology. His research focuses on the development of advanced drug delivery systems and functional nanomaterials for therapeutic applications. He has published extensively in high-impact journals regarding the medical applications of biodegradable materials and targeted delivery platforms. He is committed to advancing the field of bioengineering through both research and academic leadership.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in the International Journal of Nanomedicine on "Artificial Intelligence Enabled Nanotechnology for Precision Theranostics", organized by Prof. Mohamed Kchaou (University of Bisha, Saudi Arabia) and Prof. Md Faiyazuddin (ARAM Institute, India).

Artificial Intelligence (AI)-enabled nanotechnology is rapidly reshaping the design and application of advanced nanomaterials for biomedical diagnostics and drug delivery systems. The convergence of AI techniques—such as machine learning, deep learning, and predictive modeling—with functional nanomaterials (e.g., nanoparticles, nanocomposites, and stimuli-responsive systems) enables the rational design of highly efficient and adaptive healthcare solutions. This coupling between computational intelligence and material engineering facilitates precise control over physicochemical properties, targeted delivery, and real-time biological interactions. In diagnostics, AI-driven nanoplatforms enhance sensitivity and specificity through intelligent signal processing and biomarker recognition, enabling early and accurate disease detection. In parallel, AI-assisted optimization of drug loading, release kinetics, and targeting mechanisms significantly improves therapeutic outcomes while minimizing side effects. This Article Collection aims to explore recent advances at this interdisciplinary interface, highlighting how AI–nanomaterial integration is driving the development of next-generation, data-driven, and patient-centered diagnostic and therapeutic systems.

This convergence is critical as healthcare systems face increasing demands for early diagnosis, personalized treatment, and improved therapeutic efficiency. Conventional diagnostic and drug delivery approaches often suffer from limited sensitivity, poor targeting, and high variability in patient response. AI-enabled nanomaterials address these challenges by enabling data-driven design, predictive performance, and adaptive functionality at the nanoscale. This leads to faster, more accurate diagnostics and safer, more effective therapies. Ultimately, such integrated technologies have the potential to reduce healthcare costs, accelerate clinical translation, and support the transition toward precision and personalized medicine.

This Article Collection covers the development and application of AI-enabled nanotechnology, particularly nanomaterials, within the scope of nanomedicine, focusing on their roles in advanced diagnostics and targeted drug delivery. Topics of interest include:

• Design of functional nanoparticles (e.g., lipid-based, polymeric, metallic, and hybrid nanostructures),
• AI-assisted nanotechnology optimization, and intelligent nanosystems for disease detection and therapy,
• Biosensing platforms, imaging-enhanced nanodiagnostics, stimuli-responsive drug delivery, and nano–bio interactions,
• Computational modeling, data-driven design, and translational nanomedicine.

Please review the journal’s aims and scope and author submission instructions prior to submission.

Please submit your manuscript through the Dovepress website. During submission, enter the promo code 9A8F2 to indicate that your submission is for consideration in this Article Collection. The manuscript submission deadline is 31 January 2027.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest advisors

Prof. Mohamed Kchaou, University of Bisha

[email protected]

Prof. Mohamed Kchaou is a Full Professor at the University of Bisha, Saudi Arabia, and a Senior Researcher in sustainability and advanced materials. He is ranked among the Stanford–Elsevier World’s Top 2% Scientists (2025) and has received multiple awards for excellence in research, innovation, and academic leadership. He has authored more than 200 scientific contributions, including over 130 peer-reviewed journal articles, and has established a strong international collaboration network with leading universities and research centers worldwide. His research focuses on the integration of artificial intelligence with advanced nanomaterials for healthcare, energy, and circular economy applications, with a particular emphasis on AI-enabled nanomedicine and emerging technologies for societal impact.

Prof. Md Faiyazuddin, ARAM Institute

[email protected]

Prof. Md Faiyazuddin is Professor & Principal at ARAM Institute, India, and Former Dean (R&D) and Professor of Pharmaceutics at Al-Karim University. He also serves as Adjunct Professor at SIMATS and UniKL Global Research Fellow (GloRe). With over 19 years of experience across academia and industry in India and Saudi Arabia, he has held senior leadership roles, including Business Director at Nano Drug Delivery® USA. His research focuses on AI-enabled nanomedicine and advanced drug delivery systems, integrating artificial intelligence with engineered nanomaterials to develop targeted therapeutic platforms. He has authored more than 200 scientific contributions, including over 130 peer-reviewed journal articles, with over 2400 citations (h-index 25). A recipient of the DST Young Scientist and Dr. P.D. Sethi Awards, his work emphasizes translational innovation in pharmaceutical sciences.

View all papers in this article collection

We are pleased to announce a new Article Collection in the International Journal of Nanomedicine, dedicated to the game-changing role of lipid nanoparticles (LNP) in the area of mRNA Therapeutics. Since their clinical introduction, mRNA-LNP therapeutics have revolutionized patient care, offering significant benefits in speed of development, therapeutic efficacy, and targeted delivery for eligible patients.

Given the global importance of mRNA-LNP vaccines in COVID-19, and their potential for use in other infectious diseases, cancer, and genetic disorders, the International Journal of Nanomedicine is inviting submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these transformative therapies.

The Collection, edited by Editor-In-Chief Prof. RDK Misra, will be included in Taylor and Francis’ Game Changer Series. This series features Article Collections focused on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

While the call is open to receive manuscripts across the broad spectrum of LNP in mRNA therapeutics, the Editors are particularly interested in manuscripts relating to the following areas:

• Novel lipid nanoparticle formulations and characterization
• Optimization of mRNA delivery systems and targeting strategies
• Scalable manufacturing processes & stability optimization
• mRNA-based vaccines for infectious disease
• mRNA-based therapies for genetic diseases including metabolic disorders, hemophilia, and neurological conditions
• Cancer vaccines and immunotherapies

Please review the journal’s aims and scope and author submission instructions prior to submission. 

Please submit your manuscript through the Dovepress website. During submission, enter the promo code 0BEC2 for a 20% discount on the publishing fee and to indicate that your submission is for consideration in this Article Collection. The manuscript submission deadline is 30 June 2026.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in the International Journal of Nanomedicine on "Nanomedicine for Cancer and Autoimmune Immunotherapy", organized by Dr. Yonghyun Lee (Ewha Womans Unniversity, South Korea).

Immune-mediated diseases, including autoimmune disorders and cancer, represent major global health burdens arising from immune system dysfunction. Conventional therapies aim to suppress or activate immune responses, yet their lack of specificity often results in systemic toxicity, off-target effects, and limited therapeutic efficacy. Current immunotherapies often involve a trade-off between therapeutic efficacy and safety. In autoimmune diseases, broad immunosuppression increases infection risk, causes systemic side effects, and provides limited activity at disease sites. In cancer, immunotherapies such as immune checkpoint blockade, cancer vaccines, and tumor microenvironment (TME) modulators aim to activate antitumor responses but often lack specificity, leading to systemic toxicity and limited effectiveness. Therefore, the development of nanotechnology-based therapeutic strategies is urgently needed to enhance target-site efficacy while minimizing systemic side effects in both cancer immunotherapy and autoimmune disease treatment.

Nanomedicine has emerged as a promising approach to address these challenges by enabling precise control over drug release, biodistribution, and immune cell targeting. Using nanocarriers, immunomodulatory agents can be selectively delivered to inflamed tissues or lymphoid organs via various administration routes, including intravenous, subcutaneous, intramuscular, oral, and mucosal. With rational nanocarrier design and route optimization, nanomedicine facilitates context-specific immune modulation—tailoring therapies to induce either anti-inflammatory or immunostimulatory effects with high precision. This strategy offers particular promise for achieving localized immunosuppression in autoimmune diseases and enhancing tumor-specific immunity in cancer therapy.

This Collection aims to spotlight recent advances in nanomedicine that harness diverse delivery strategies to fine-tune immune responses in both autoimmune diseases and cancer immunotherapy. Thus, this Collection invites submissions focused on nanomedicine-based strategies for immune modulation in both autoimmune diseases and cancer immunotherapy. We welcome original research articles and comprehensive reviews. Interdisciplinary contributions that integrate pharmaceutics, nanotechnology, immunology, and translational science are particularly encouraged.

Relevant topics include, but are not limited to: (1) nanomedicine for cancer immunotherapy, including the targeted delivery of antigens, immune enhancers, or modulators to tumors or lymphoid tissues; and (2) nanomedicine for autoimmune diseases, involving site-specific delivery of antigens or immunosuppressive agents to inflamed tissues or immune organs.

This Collection aims to catalyze the development of next-generation immune-modulating therapies that are safer, more effective, and precisely targeted.

Please review the journal’s aims and scope and author submission instructions prior to submission.

Please submit your manuscript through the Dovepress website. During submission, enter the promo code 855FE to indicate that your submission is for consideration in this Article Collection. The manuscript submission deadline is 30 April 2026. 

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection. 

Guest advisor

Prof. Yonghyun Lee, Ewha Womans Unniversity

[email protected]

Professor Yonghyun Lee is an Associate Professor at the College of Pharmacy, Ewha Womans University. He is focusing on the development of innovative strategies, aimed at targeted-modulating gut microbiome, apoptosis, and/or immune systems for the effective management of inflammation-related diseases, especially inflammatory bowel diseases, and cancer. He has published extensively in high-impact journals such as Nature Materials, Nature Communications, Angewandte Chemie, and ACS Nano. Also, he has been recognized with multiple research excellence awards including the KAST Promising Young Scientist Award and Ewha’s Award for Research Excellence.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in the International Journal of Nanomedicine on "Smart Colloidal Systems for Biomedical Applications", organized by Prof. Xin Li, Prof. Zhiyuan Shi, and Prof. Andrij Pich.

Smart colloidal systems are an innovative class of materials capable of undergoing significant and reversible changes in response to external stimuli such as temperature, pH, light, electric and magnetic fields, or biological signals. Due to their tunable properties, biocompatibility, and degradability, these materials have garnered significant attention in the field of biomedical applications. They are widely utilized in areas such as controlled drug delivery, tissue engineering, biosensors, medical device coatings, and wound healing. The advantages of smart colloidal systems include high sensitivity, specificity, and customizability for different biomedical needs. However, challenges remain in their synthesis, scalability, long-term biocompatibility, and cost-effectiveness. Despite these hurdles, smart colloidal systems hold tremendous potential to revolutionize healthcare by offering advanced and responsive solutions tailored to the dynamic requirements of biological systems.

The study of smart colloidal systems for biomedical applications is of paramount importance due to their potential to address critical challenges in modern healthcare. These advanced materials offer unique capabilities, such as responsiveness to external stimuli (e.g., temperature, pH, light, and biological signals), which enable precise control over their behavior in complex biological environments. This responsiveness allows for the development of innovative solutions, such as targeted drug delivery systems that improve therapeutic efficacy while minimizing side effects, and stimuli-sensitive colloids that promote tissue regeneration in a controlled manner.

Furthermore, smart colloidal systems can mimic or interact with biological systems, making them highly suitable for applications like biosensors, implant coatings, and wound healing materials. Their biocompatibility and degradability ensure that they can be safely integrated into the body or used in temporary applications without long-term adverse effects. Moreover, as the prevalence of chronic diseases, drug resistance, and aging-related conditions continues to rise, smart colloidal systems provide a versatile platform for developing more effective and personalized medical treatments.

Research in this area also drives innovation in materials science, enabling the creation of more efficient, cost-effective, and sustainable colloidal systems. Ultimately, understanding and advancing smart colloidal systems is crucial for improving healthcare outcomes, reducing treatment burdens, and addressing the growing global demand for advanced medical technologies.

Smart colloidal systems represent a transformative research area at the intersection of materials science and biomedicine, offering innovative solutions to address pressing healthcare challenges. This Collection focuses on advances in the design, synthesis, and biomedical applications of smart colloids, emphasizing their stimuli-responsive properties and their ability to interact with complex biological systems. Subtopics of interest include, but are not limited to, smart colloids for drug delivery systems, tissue engineering scaffolds, biosensors, medical device coatings, and wound healing materials. Studies exploring polymer biocompatibility, biodegradability, and scalability for clinical applications are also highly encouraged.

The Collection welcomes original research articles, reviews, and perspectives that provide critical insights or highlight emerging trends in this rapidly evolving field. Contributions focusing on translational research, including preclinical or clinical evaluations of smart colloidal systems, are particularly valued, as they align with the journal’s aim to bridge fundamental science and biomedical innovation.

Please review the journal’s aims and scope and author submission instructions prior to submission.

Please submit your manuscript through the Dovepress website. During submission, enter the promo code 4FCD0 to indicate that your submission is for consideration in this Article Collection. The manuscript submission deadline is 31 July 2026.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest advisors

Prof. Xin Li, City University of Hong Kong, China

[email protected]

Xin Li is a Research Assistant Professor at Department of Biomedical Engineering, City University of Hong Kong. He received his doctoral degree from RWTH Aachen University (Germany). Subsequently, he conducted research at DWI-Leibniz-Institute for Interactive Materials (Germany), The Hong Kong University of Science and Technology, and The Chinese University of Hong Kong. His current research focus on smart microgels for biomedical applications, and he has published 80+ research articles/book chapters, 100+ patents, and 20+ international/national awards.

Prof. Zhiyuan Shi, Tianjin University, China

[email protected]

Zhiyuan Shi is a Professor and Principal Investigator (PI) at the School of Pharmaceutical Science and Technology, Tianjin University. She completed her undergraduate studies in Biology at the University of Göttingen, Germany, and subsequently obtained a Master's degree in Biomedical Engineering and a Ph.D. in Chemistry from the RWTH Aachen University, Germany. From 2020 to the end of 2022, she worked on bispecific antibody development at the University of Cologne, Germany. In 2023, she joined Tianjin University full-time to conduct independent scientific research. Dr. Shi has been dedicated to research in the fields of sonopharmacology and sonogenetics. She pioneered the introduction of mechanical switch structures into drug systems, using ultrasound and other mechanical forces to regulate the chemical properties of drugs, thereby achieving precise control over their pharmacodynamics and pharmacokinetics. She has developed various mechanochemical prodrug activation systems, providing a novel theoretical and technical framework for drug development.

Prof. Andrij Pich, RWTH Aachen University, Germany

[email protected]

In 2009 Andrij Pich was appointed to Lichtenberg Professor for Functional and Interactive Polymers at RWTH Aachen University. Since 2019 he is also a Professor for Biobased Polymers at Maastricht University (part time professorship). After studying chemical technology in Lviv/Ukraine he received his PhD from the Technical University Dresden in 2001. In 2006/2007 he was a postdoctoral fellow at the University of Toronto/Canada. In 2007 he received the Georg Manecke Award of the GDCh (German Chemical Society) and completed his habilitation in 2008 at Technical University Dresden. His research focusses on the synthesis of functional polymers and polymer colloids with variable chemical structures and morphologies and their use for the design of functional and interactive materials.

View all papers in this article collection

We are pleased to announce a new Article Collection in the International Journal of Women’s Health, dedicated to the game-changing role of screening in the management of cervical cancer. Since their introduction, cervical cancer screening programs have revolutionized patient care, offering significant benefits in the early detection and prevention of advanced disease. As a cost-effective public health strategy, screening has reduced cervical cancer mortality rates worldwide, particularly in countries with organized screening programs. 

Given its global importance, the International Journal of Women’s Health is welcoming the submission of original research articles, reviews, and perspectives on the topic of cervical cancer screening. 

The collection, edited by the Editor-In-Chief Professor Elie D. Al-Chaer, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, technologies, or protocols that have significantly altered the standard of care.

While the call is open to receive manuscripts across the broad spectrum of screening in cervical cancer, the Editors are particularly interested in manuscripts relating to the following areas:

• Technological advancements in screening methods: HPV-based testing, AI-assisted cytology, and novel biomarkers for early detection.
• Addressing health disparities: strategies to improve screening access in low-resource settings, marginalized communities, and high-risk populations.
• Implementation challenges: cost-effectiveness, national program scalability, and overcoming cultural/behavioral barriers to screening adherence.
• Follow-up and clinical management: protocols for abnormal results, colposcopy, biopsy and treatment of precancerous lesions, balancing overtreatment risks and undertreatment delays
• Emerging paradigms: role of self-sampling, telemedicine, and vaccination-screening synergies in eradicating cervical cancer.

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 1 April 2026.

Please submit your manuscript on our website, quoting the promo code 2341B for a 20% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in the International Medical Case Reports Journal on “Advancing Oncology through Clinical Case Reports: Insights, Challenges, and Future Directions”, organized by our Associate Editors-in-Chief Prof. Xudong Zhu from University of Kentucky, USA, and Prof. Jiawen Bu from Shengjing Hospital of China Medical University, China.

Clinical case reports in oncology provide critical insights into rare malignancies, atypical treatment responses, and novel therapeutic approaches. These reports bridge the gap between theoretical research and real-world clinical practice, offering clinicians and researchers actionable knowledge to improve patient outcomes.

This Article Collection aims to compile high-quality case studies that highlight diagnostic dilemmas, innovative therapies, and multidisciplinary management strategies in oncology.

Oncology is a rapidly evolving field where individualized patient care is paramount. Case reports serve as foundational tools for identifying emerging trends, unexpected side effects, and therapeutic breakthroughs. By documenting unique clinical scenarios, this collection will foster a deeper understanding of tumor biology, resistance mechanisms, and personalized treatment paradigms. Such knowledge is vital for advancing global cancer care and informing future clinical trials.

We invite submissions of case reports, case series, and clinical vignettes that address the following subtopics:

• Rare or underreported malignancies
• Unusual presentations or complications of common cancers
• Innovative uses of targeted therapies, immunotherapies, or combination regimens
• Ethical and logistical challenges in oncological care
• Long-term survivorship and quality-of-life considerations

All submissions must align with the journal's scope of translational and clinical research.

Please submit your manuscript on our website, using the promo code FB6C1 for 20% off the advertised article processing charge and to indicate that your manuscript will be considered for the “Advancing Oncology through Clinical Case Reports: Insights, Challenges, and Future Directions” Collection. We will be welcoming relevant papers up until the 31st December 2026.

Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Diagnostic Dilemmas and Therapeutic Insights in Cardiovascular Case Reports", in the International Medical Case Reports Journal, organized by our Associate Editors-in-Chief Dr. Vinay Kumar from Pennsylvania State University Hershey Medical Center, USA, and Ms. Anuradha Tyagi from Institute of Nuclear Medicine & Allied Sciences, India.

Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide, spanning a broad spectrum of presentations, complexities, and therapeutic challenges. Case reports play a unique and indispensable role in cardiology by capturing novel presentations, rare complications, unexpected treatment responses, and innovative diagnostic approaches. This Article Collection aims to highlight clinically significant case reports that enhance our understanding of cardiovascular and vascular conditions and inform frontline clinical decision-making.

Despite rapid advances in cardiovascular medicine, clinicians continue to encounter unexpected or atypical patient scenarios. Case reports serve as valuable educational tools, offering real-world insights beyond the confines of large trials and guidelines. They often provide the first glimpse of emerging diseases, drug side effects, procedural innovations, and complex comorbidities. By systematically gathering high-quality case reports, we create a platform that promotes shared clinical learning and fosters global dialogue on rare and instructive cardiovascular phenomena.

This Article Collection invites submissions that align with the scope of Case Reports in Cardiology, focusing on all aspects of heart and vascular health. Subtopics may include - but are not limited to - ischemic heart disease, structural heart defects, electrophysiological disorders, valvular diseases, cardiomyopathies, vascular anomalies, endovascular interventions, and cardio-oncology. We welcome classical case reports, case series, clinical images, and brief communications that offer new insights, challenge existing paradigms, or prompt further investigation. Submissions should clearly articulate the educational value and clinical relevance of the case, ideally supported by imaging, histopathology, or procedural documentation where applicable.

Please submit your manuscript on our website, using the promo code 71858 for 20% off the advertised article processing charge and to indicate that your manuscript will be considered for the “Diagnostic Dilemmas and Therapeutic Insights in Cardiovascular Case Reports” Collection. We will be welcoming relevant papers up until the 31st December 2026. 

Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to the upcoming Article Collection “Advances in Rhinology and Allergy: From Disease Mechanisms to Treatment Innovations” in the Journal of Asthma and Allergy.

Rhinologic and allergic disorders, such as acute/chronic rhinosinusitis, nasal polyposis, allergic/non-allergic rhinitis etc., frequently cause physical and mental illness. Despite the rapid progress of medicine, some rhinologic disorders remain complex and have a significant impact on the global economy in the modern era.

Early detection and proper management of the rhinologic disorders based on disease mechanisms deserve further attention. Advances in disease mechanisms and treatment innovations would provide practical information about precise medicine and prediction in response to medical or surgical therapy and are therefore pivotal.

This Article Collection aims to highlight recent advances in the disease mechanisms and treatment innovations in rhinology and allergy. Rapid progress in basic science, translational medicine, and biomedical technology has significantly improved our understanding of the pathophysiology underlying rhinologic and allergic disorders. We invite authors to submit original research articles, reviews, and clinical studies that investigate the molecular and cellular mechanisms of diseases in rhinology and allergy, as well as innovative diagnostic and therapeutic methods.

Keywords

• Chronic rhinosinusitis
• Rhinitis
• Allergy
• Nasal surgery
• Pathophysiology

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

Please review the journal scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 31 December 2026.

Please submit your manuscript on our website, quoting the promo code 4F6E6 to indicate the paper is intended for consideration in the Article Collection.

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

Please be sure to select the appropriate Article Collection from the drop-down menu in the submission system.

Guest Advisor

Professor Chien-Chia Huang, Division of Rhinology, Department of Otolaryngology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan

[email protected]

Prof. Chien-Chia Huang is associate professor of Division of Rhinology, Department of Otolaryngology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. He also serves as director of the Division of Paediatric Otolaryngology. He obtained his degree in Medicine at the University of Chang Gung University (Taiwan). His PhD was issued by the University of Chang Gung University. His main research interests are the rhinologic and allergic diseases, including chronic rhinosinusitis, rhinitis, and obstructive sleep apnea.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to the upcoming Article Collection “Targeted Personalized Biologic Therapies: Changing the Game in Asthma Treatment” in the Journal of Asthma and Allergy.

This Collection, edited by the Editor-In-Chief Dr. Amrita Dosanjh, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, and technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.

Asthma is a chronic inflammatory lung condition that results in airway obstruction and difficulty breathing. Left untreated, severe asthma flares can lead to hospitalization and even death. Typical front-line treatments of asthma include corticosteroids (which cause immunosuppression with long-term use) and bronchodilators (such as albuterol inhalers). While biologic therapy is relatively new in asthma treatment, Global Initiative For Asthma (GINA) guidelines include biologics as therapeutic options. There are several biologics currently available and in development for the treatment of asthma.

While the call is open to receive manuscripts across the broad spectrum of asthma-modulating biologics, the Editors are particularly interested in manuscripts relating to the following areas:

• Signaling pathways and cellular targets
• Novel mechanisms of action of new candidate biologics
• Anti IL-4 and IL-13 combination biologics and monoclonal antibodies
• Treatment and dosing strategies based on asthma typing
• Biologic switching and combination therapy
• Long-term efficacy and safety studies

Submitting authors are eligible for a 20% discount on the Article Publishing charge by applying the following code at the point of submission SRNMA. If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor Ashley Ambros at [email protected].

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.

Please submit your manuscript on our website. The deadline for submitting manuscripts is 1 April 2026.

View all papers in this article collection

The Journal of Hepatocellular Carcinoma is pleased to announce an upcoming Article Collection dedicated to the transformative role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have significantly impacted the treatment landscape for HCC. By blocking the signals that prevent T-cells from attacking cancer cells, these inhibitors enhance the immune system's ability to combat tumors. These therapies have shown potential in improving survival rates, reducing tumor burden, and providing durable responses in patients who previously had few effective options.

Given the impact and continued role of immune checkpoint inhibitors in treating HCC, we welcome submissions of original research articles, reviews, and perspectives that contribute to the understanding and advancement of these therapies. Of particular interest would be:

1. Papers focusing on peri-operative immunotherapy approaches in early-stage HCC to improve resectability, induce pathologic responses at time of surgery, and/or reduce rate of recurrence after resection.
2. Papers related to the intermediate/advanced HCC setting focusing on potential mechanisms of:

• Resistance to immunotherapy in advanced HCC based on different risk factor, e.g. viral vs. non-viral related HCC and MASH-related HCC.
• Synergy between immunotherapy and targeted and other systemic therapies.
• Synergy between immunotherapy and localized therapy approaches to improve response rates and survival outcomes.

This Article Collection will be included in a wider Game Changer Series focused on breakthrough therapies across medicine. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor & Francis and Dove Medical Press, increasing the discoverability and visibility of your research.

Please view the journal Aims and Scope and author submission guidelines. The deadline for submissions is 1 June 2026.

Please submit your manuscript on our website. Submitting authors are eligible for a 20% discount on the Article Publishing Charge. To apply this discount, enter the code SDSZG when prompted during submission.

Please contact Commissioning Editor Cassie Houtz at [email protected] with any questions.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Anti-inflammatory Biologics – A Game Changer for Chronic Inflammation", in the Journal of Inflammation Research.

This Collection, edited by the Editor-In-Chief Prof. Ning Quan, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, and technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.

Chronic inflammation is the hallmark of many diseases. These conditions can be crippling to patients. Traditional anti-inflammatory drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids, are non-specific, causing further systemic problems with continued use. By contrast, biologic therapies harness the specificity necessary to relieve inflammation while also reducing off-target and non-specific effects.

While this call is open to receive manuscripts highlighting all anti-inflammatory biologics, the Editors are particularly interested in manuscripts relating to the following areas:

• Tumor necrosis factor inhibitors
• Interleukin inhibitors
• Monoclonal antibody specificity studies
• Novel mechanisms of action of new candidate biologics
• The role of biosimilars in treating inflammatory disease
• Indications and contraindications
• Cell-based therapies to quell inflammation

Submitting authors are eligible for a 20% discount on the Article Publishing charge by applying the following code at the point of submission: OTIPZ. If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor Ashley Ambros ([email protected]). Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript. Please submit your manuscript on our website. The deadline for submitting a manuscript is 1 April 2026.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Bone-Immune System Crosstalk in Musculoskeletal Health and Disease", in the Journal of Inflammation Research.

Acute inflammation is a fundamental reparative response to injury in musculoskeletal tissues, orchestrating the recruitment of immune cells and the coordinated activity of osteoblasts, osteoclasts, and chondrocytes to remodel and restore damaged bone and cartilage. This intricate process is governed by a sophisticated network of immune signaling pathways and immunometabolic cues, maintaining a delicate homeostatic balance. The emerging field of osteoimmunology is dedicated to deciphering this critical crosstalk.

A bidirectional and dynamic dialogue between hematopoietic immune cells and resident skeletal cells is essential for effective tissue repair and the maintenance of musculoskeletal health. Disruption of this communication—whether by genetic predisposition, chronic inflammation, metabolic dysfunction, or pathogen invasion—can tip the balance from regenerative healing to pathological tissue destruction. This dysregulation lies at the heart of numerous debilitating conditions, leading to chronic pain, loss of function, and significant morbidity, underscoring an urgent need for deeper mechanistic understanding.

The goal of this Article Collection is to bring to light the pivotal role that bones and the musculoskeletal system play in health and disease, and the translational implications of osteoimmunology, immunometabolism, and inflammation-mechanobiology. Key topics include, but are not limited to:

• Coordination of inflammatory processes and skeletal/immune cells involved in bone tissue repair
• Conditions such as osteoarthritis and osteoporosis, characterized by inflammation and destruction of bone and cartilaginous tissue
• Bone and joint infections such as septic arthritis and osteomyelitis
• Arthritic conditions such as rheumatoid arthritis, spondyloarthritis (including ankylosing spondylitis), and gout/gouty arthritis

Keywords

• Osteoimmunology
• Bone-Immune Crosstalk
• Musculoskeletal Inflammation
• Arthritis
• Bone tissue repair

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website. The deadline for submitting a manuscript is 1 February 2027.

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisor

Dr. Chen Yan, The First Affiliated Hospital of Guangxi Medical University

[email protected]

Dr. Yan Chen is an orthopedic surgeon and Associate Editor of the Journal of Inflammation Research. His research focuses on osteoimmunology, bone regeneration, and mechanobiology of the bone marrow microenvironment. He has led multiple translational research projects exploring bone–immune interactions in musculoskeletal diseases and serves as a reviewer and editor for several international journals. His work integrates clinical orthopedics with cutting-edge molecular and spatial technologies to advance understanding of skeletal inflammation and repair.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Cellular and Molecular Drivers of Lung Inflammation in Respiratory Diseases", in the Journal of Inflammation Research.

Lung inflammation is a hallmark characteristic feature of many respiratory diseases, from asthma and chronic obstructive pulmonary disease (COPD) to pulmonary fibrosis and acute respiratory distress syndrome (ARDS). While inflammation serves as a protective role in response to infection or injury, dysregulated or persistent inflammatory responses can lead to progressive lung damage and impaired respiratory structure and function. Understanding the cellular and molecular drivers behind lung inflammation is crucial for developing targeted therapies that can modulate these pathways without compromising host defense. This topic explores the intricate network of immune and structural cells, signaling pathways, and other cofounding factors that orchestrate inflammatory responses in the lung. This study will offer valuable insight into both disease mechanisms and potential intervention points.

This topic is important because it establishes the foundational understanding of lung inflammation, a key driver of the onset, progression, and severity of numerous respiratory diseases that together pose a significant global health burden.
Studying this topic also matters as it provides following additional advantages:
• Better Understanding of Disease Mechanisms
• Development of Targeted Therapies
• Early Diagnosis and Biomarkers tools
• Understanding Environmental and Infectious Triggering agent

The subject of this Collection, "Cellular and Molecular Drivers of Lung Inflammation in Respiratory Diseases," explores the complex cellular and molecular processes that drive and regulate lung inflammation. It covers key subtopics including immune cell activation, structural cells dysfunction, cytokine and chemokine signaling, and the impact of environmental and infectious triggers on pulmonary inflammation. Special attention will also be given to emerging therapeutic targets and biomarker discovery. This scope is well-aligned with the Journal of Inflammation Research, which emphasizes cutting-edge studies on inflammation-related processes. The ail of this collection will be to encourage the submission of original research articles, comprehensive reviews, and brief reports that will provide new insights into the cellular and molecular understanding of lung inflammation in both acute and chronic respiratory diseases.

Keywords

1. Lung inflammation
2. Respiratory diseases
3. Immune cell signaling
4. Cytokines and chemokines
5. Biomarkers of lung disease

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, using the promo code 5DF61 to indicate that the manuscript is intended for this Article Collection. The deadline for submitting a manuscript is 15 June 2026.

Guest Advisors

Dr. Ashish Kumar, North Dakota State University

[email protected]

I am a Doctoral Graduate Research Assistant in pharmaceutical sciences, specializing in the pathophysiology of asthma. My research explores the dynamic relationship between lung physiology and hormonal influences in disease conditions, aiming to advance respiratory pharmacology and personalized medicine.

Dr. Nilesh Sudhakar Ambhore,University of Minnesota

[email protected]

I am a dedicated and self-motivated research scientist with over 8 years of extensive experience in pharmacology, molecular biology, small molecule drug discovery, and target validation. My proven expertise encompasses the entire preclinical drug development process, including development of in vivo disease models, mechanism of action investigation, endpoint analysis, and disease modelling.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Inflammaging in Cardiovascular and Chronic Disease", in the Journal of Inflammation Research.

Inflammaging is a persistent, low-grade sterile inflammation associated with aging. It is characterized by elevated circulation of proinflammatory cytokines, chemokines and other inflammatory mediators in the circulation, reflecting a fundamental imbalance in intercellular communication and inflammatory control. Multiple lines of evidence indicate that inflammaging arises from a convergence of factors including immune cell dysregulation, immunosenescence, chronic infections, cellular senescence and genetic predisposition. Other than this, metabolic and environmental contributors such as central obesity, increased gut permeability, shifts in microbiota composition further exacerbates this process. At the molecular level, excessive production of reactive oxygen species, dysfunctional mitochondria play pivotal role in chronic inflammation. This persistent inflammatory state not only accelerates cellular senescence but also impairs immune system, leading to severe implications in tissue homeostasis. Thus, inflammation is recognized as an intrinsic driver of aging process and key contributor to pathogenesis of multiple chronic diseases.

Inflammaging is the major contributor to cardiovascular disease (CVD), the leading cause of morbidity and mortality worldwide. In 2021 alone, CVDs were responsible for 20.5 million deaths, accounting for roughly one-third of all global deaths. Beyond CVD, inflammaging is also recognized as a risk factor for several chronic conditions including cancer, kidney disease, diabetes mellitus, depression, dementia, sarcopenia, and frailty. Despite its well documented pathologic role across diverse diseases the precise molecular mechanism that regulate inflammaging remains incompletely understood and relatively understudied. Therefore, a comprehensive understanding of these processes holds great promise for the development of novel treatment strategies that could significantly improve the clinical outcome. Targeting inflammaging is a particularly appealing as it offers potential not only to prevent CVD but also to slow the broader health decline associated with ageing. Importantly interventions that modulating inflammation may be most effective if implemented early in the trajectory of age-related physiological decline.

This Article Collection aims to focus on the latest developments in understanding the role of inflammaging in the pathogenesis of cardiovascular and chronic inflammatory diseases. We welcome contributions that explore inflammaging across molecular, cellular and disease levels, with a focus on uncovering its mechanism and identifying innovative therapeutic strategies. By advancing knowledge in this area, the collections seeks to highlight novel targets for preventing and alleviating CVD, chronic inflammation and age-related diseases.

Submissions to this topic may include, but are not limited to, the following potential areas of research:

• Molecular drivers of inflammaging
• Biomarkers of inflammaging for early detection of cardiovascular and age-related diseases
• Emerging signalling pathways linking chronic low-grade inflammation, oxidative stress and mitochondrial dysfunction in aging vascular system
• Interplay between immune cell senescence and inflammaging in chronic disease progression
• Novel animal models and experimental tools for studying inflammaging mechanisms.
• Therapeutic strategies for counteract inflammaging, such as cytokine inhibitors, senolytics or anti-inflammatory drugs aimed at restoring vascular and systemic health
• Dietary and lifestyle interventions including the impact of prebiotics, and probiotics on inflammaging and healthy aging

This Article Collection welcomes submissions of the following article types: Original Research Articles, Brief Research Reports, Case Reports, Reviews and Mini-reviews.

Keywords

• Inflammaging
• Cardiovascular disease (CVD)
• Immunosenescence
• Senolytics
• Chronic inflammatory diseases

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, using the promo code 2E6D0 to indicate that the manuscript is intended for this Article Collection. The deadline for submitting a manuscript is 1 June 2026.

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisor

Dr. Vigneshwaran Vellingiri, University of Illinois, Chicago

[email protected]

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Inflammatory Disorders and Diseases of Environmental Etiology", in the Journal of Inflammation Research.

Chronic inflammation is a key pathological feature underlying development and progression of chronic diseases including cardiovascular, respiratory, and neurodegenerative disorders. Inflammation is triggered by various environmental insults such as long-term exposure to toxic particles (PM2.5, ultrafines or nanoparticles), industrial chemicals (immunotoxicants), biological agents and infections, and climate change. On the other hand, occupational exposures to toxic particles or fibers, industrial and agricultural chemicals are among the major factors associated with chronic inflammatory disorders in adults. Certain communities living in the areas with inadequate zonal policies, or working in settings with higher and prolonged exposure to such pollutants, are at a greater risk of developing chronic inflammatory disorders. Additionally, children born in or living in such areas have arrested growth and higher rate of developmental disorders.

Published studies have consistently reported that exposed individuals may suffer chronic inflammation in different organs due to differential modulation of innate or adaptive pathways locally or systematically leading to development or exacerbation of inflammatory and/or developmental disorders. Chronic inflammatory and developmental disorders with environmental origins are poorly characterized in terms of their etiology, underlying mechanisms, potential therapeutic targets and targeted therapeis due to unique pathological manifestations in these disorders.

Environmental etiology of chronic inflammatory and developmental disorders is an important public health concern that needs to be addressed. Vulnerable communities often suffer from greater exposure risks and limited healthcare access leading to underdiagnosis of inflammatory and developmental disorders. Advancements in public health and mechanistic research to address these issues may unravel the causative factor(s), pathological mechanisms, and exposure limits of the key environmental factors responsible for disease burden. Additionally, such research advancements could help unravel potential therapeutic targets and facilitate development of targeted therapies for environmentally-induced chronic disroders. Research in these directions will promote the health equity and minimize the disease burden.

Original Research articles: Original articles may be focused on either mechanistic or epidimiological studies addressing the chronic inflammatory and developmental disorders associated with exposure to pollutants including particulates (natural or engineered) or chemical agents (metals, PFAS, pesticides, etc.), infectious agents or their antigens, climate change, or other environmental factors. Experimental studies using cellular or animal models should define the resemblance of the models with the real-world exposure scenario in human population. Animal studies could be focused on addressing the toxicological aspects, identifying molecular targets, biomarkers of exposure or effect, and/or targeted therapies, and proposing potential intervention/mitigation strategies. Epidimiological studies could focus on identifying the populations at risk of chronic inflammatory or developmental disorders and the associated environmental exposures and risk factors. Besides focusing on the current levels of exposure in the populations at risk, epidemiological studies may also focus on developing/recommending the permissible limits of these toxicants in residential and occupational settings.

Comprehensive Review Articles: Review articles addressing the pathologies of chronic inflammatory or developmental disordrs of environmental origin using experimental models could incorporate source of release of toxicant in the environment, exposure routes, biological effects and organ toxicities, mechanistic aspects, and therapeutic targets. Reviews based on human epidemiological studies may focus on consideration the zonal policies, vulnerable populations, current problem of unequal disease burdern due to toxicants, environmental regulation of the toxicants, and biomonitoring data addressing the level of exposure to humans and the environment. Comprehensive reviews may take into account both experimental and human studies. It is strongly recommended to propose potential strategies to improve the public health and promote health equity.

Keywords:

1. Experimental models of inflammatory effects of pollutant exposures
2. Respiratory, cardiovascular, metabolic, or neurological inflammatory disorders.
3. Developmental immunotoxicity disorders
4. Immune dysfunction in adulthood due to early life environmental exposures
5. Transgenerational immune effects of environmental origin

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, using the promo code 874E2 to indicate that the manuscript is intended for this Article Collection. The deadline for submitting a manuscript is 15 June 2026.

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors:

Afzaal N. Mohammed, University of Arizona COM-Phoenix

[email protected]

Dr. Mohammed is a ResearchScientist III at University of Arizona COM-Phoenix. His research interest centered around broad range or topics including developmental biology, respiratory toxicology and pathogenesis, public health, and drug discovery. His major contribution is in the field of developmental biology where is addressed emerging public health issues related to respiratory and neurological disorders using rodent models. Currently, he is focused 1) Identifying novel drugs and biological agents to treat developmental respiratory disorders. 2) Addressing the respiratory disorders associated with occupational exposure to carbon nanomaterials.

Jagjit S. Yadav, University of Cincinnati College of Medicine 

[email protected]

Dr. Yadav is Professor in the Department of Environmental and Public health, Division of Environmental genetics and Molecular Toxicology, at the University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. He has been serving as a Deputy Director of the NIH’s P30 Center for Environmental Genetics at UC and Director of the Inhalation Toxicology Resource Unit. His research lab focuses on Pulmonary pathogenesis and immunotoxicology research as related to environmental health. He is also interested in understanding the role of host microbiome and genetic background in respiratory toxicity/infections/disease susceptibility from exposure to environmental pollutants (particles/nanoparticles, chemicals, microbial agents/antigens) using in vitro and in vivo (rodent) models and role of Gut-Lung axis in lung inflammatory disorders/disease.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Integrating Artificial Intelligence into Inflammation and Cancer Immunology: From Biomarkers Discovery and Mechanistic Insights to Precision Therapeutics", in the Journal of Inflammation Research.

Inflammation exerts a complex and context-dependent influence on both oncogenesis and the efficacy of cancer therapies. Acute inflammatory responses may enhance anti-tumor immunity; however, chronic inflammation is more commonly implicated in tumor initiation, progression, and the facilitation of immune evasion. Persistent inflammatory signaling contributes to the development of an immunosuppressive tumor microenvironment (TME) by promoting the infiltration of immunoregulatory cell populations, including regulatory T cells, myeloid-derived suppressor cells, and M2-polarized macrophages. This immunosuppressive milieu hinders the therapeutic effectiveness of immune checkpoint inhibitors and adoptive cell therapies such as chimeric antigen receptor T cells. Inflammatory cytokines such as IL-6, IFN-, and TNF-α also play dual roles, with context-dependent capacities to either promote immune resistance or augment immune activation.

Consequently, the modulation of inflammatory pathways holds promise for the development of patient-specific therapeutic strategies aimed at enhancing responses to anti-cancer treatments. For example, the combination of anti-inflammatory agents with immune checkpoint inhibitors may be particularly beneficial in patients exhibiting elevated baseline levels of inflammation. Among the most promising anti-inflammatory approaches is the use of epigenetic inhibitors, including histone deacetylase (HDAC) inhibitors and DNA methyltransferase (DNMT) inhibitors, which have demonstrated synergistic potential when used in combination with immunotherapies to overcome resistance mechanisms. Importantly, the identification of inflammation-associated biomarkers is essential for effective patient stratification. Such biomarkers would enable the rational design of combinatorial treatment regimens and improve the predictive capacity for therapeutic responses in the context of cancer immunotherapy.

The complex regulatory networks that control inflammation within TME are pivotal to the rational design of combinatorial strategies. Recent advances in artificial intelligence (AI), multi-omics technologies, and computational biology now offer powerful tools for the identification and validation of inflammation-associated biomarkers, as well as for elucidating the epigenetic alterations that drive their activation. These insights can be leveraged to inform the development of targeted therapeutic approaches, thereby facilitating the identification of individuals most likely to benefit from specific immunoepigenetic interventions.

This Article Collection seeks interdisciplinary research that investigate the role and underlying mechanisms of epigenetic alterations in the regulation of inflammation and tumor immunity. We welcome original research articles, reviews, clinical trial studies, and case reports. Submissions are also encouraged that examine the application of AI in predicting therapeutic responses and guiding precision immuno-oncology strategies.

Keywords

1. Inflammation and Tumor Immunity
2. Epigenetic Modulation
3. Artificial Intelligence in Oncology
4. Tumor Microenvironment and Metabolism
5. Diagnostic and Prognostic Biomarkers

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, using the promo code 34582 to indicate that the manuscript is intended for this Article Collection. The deadline for submitting a manuscript is 15 April 2026.

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Microbiome-Immune Crosstalk: Mechanisms, Therapeutic Modulation, and Translational Strategies in Chronic Inflammatory and Infectious Diseases", in the Journal of Inflammation Research.

The human microbiome, encompassing the diverse communities of bacteria, viruses, fungi, and other microorganisms inhabiting our body, plays a pivotal role in maintaining immune homeostasis and influencing disease outcomes. Emerging evidence has revealed that the intricate crosstalk between the microbiome and the immune system critically shapes host responses to infection, inflammation, and cancer. Dysbiosis, or imbalance in microbial communities, has been linked to chronic inflammatory diseases, autoimmune disorders, impaired wound healing, and variable responses to immunotherapies.

Understanding the mechanisms underlying microbiome-immune interactions is essential for developing innovative therapeutic strategies. Targeted modulation of microbial communities, whether through probiotics, prebiotics, postbiotics, or fecal microbiota transplantation, offers promising opportunities to enhance immune function and improve patient outcomes. Moreover, advanced multi-omics approaches are enabling a deeper understanding of host–microbe signaling pathways, revealing potential biomarkers and translational targets for precision medicine.

The interplay between the microbiome and the immune system is fundamental to human health, influencing everything from infection susceptibility to chronic inflammation and response to therapy. Dysregulation in this crosstalk can drive disease progression, reduce treatment efficacy, and contribute to poor clinical outcomes. By understanding these interactions, researchers can identify novel therapeutic targets, develop microbiome-based interventions, and enhance the effectiveness of immunotherapies.

Addressing microbiome-immune crosstalk is particularly important for precision medicine, as it enables the tailoring of treatments based on an individual’s microbial and immune profile. This approach has the potential to revolutionize the management of chronic inflammatory diseases, infectious conditions, autoimmune disorders, and cancer, ultimately improving patient outcomes and reducing healthcare burdens.

This Collection welcomes high-impact original research, reviews, mini-reviews, perspectives/commentaries, methodology papers and graphical reviews/visual communications focusing on the diverse scientific and translational innovations microbiome-immune signaling. Key themes include, but are not limited to:

1. Mechanistic insights into microbiome–immune system interactions;

2. Gut–organ axes and systemic immune regulation;

3. Microbiome influence on immunotherapy efficacy and vaccine response;

4. Dysbiosis-driven chronic inflammatory and autoimmune diseases;

5. Host–microbe signaling pathways as therapeutic targets;

6. Microbiome-targeted interventions: probiotics, prebiotics, postbiotics, and fecal microbiota transplantation (FMT);

7. Multi-omics approaches to study microbiome–immune networks;

8. Translational and clinical studies leveraging microbiome modulation.

Keywords

1. Microbiome–Immune Crosstalk

2. Dysbiosis

3. Immunomodulation

4. Chronic Inflammatory Disease

5. Precision Medicine

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, using the promo code E6AEE to indicate that the manuscript is intended for this Article Collection. The deadline for submitting a manuscript is 16 November 2026.

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors

Dr. Vinay Kumar, Penn State University, College of Medicine, 500 University Dr, Hershey, PA-17033, USA

[email protected]

Dr. Vinay Kumar is a Researcher (junior faculty) at the Heart and Vascular Institute, Pennsylvania State University, where his work focuses on dissecting dysregulated innate and adaptive immune networks in myocardial infarction (MI) and chronic heart failure (HF). His research emphasizes understanding the roles of distinct T-cell subsets and the time-dependent phenotypic shifts these cells undergo during chronic HF. Additionally, Dr. Kumar is dedicated to developing innovative immunomodulatory strategies to reverse pathological immune alterations and facilitate their translation from bench to bedside.

Dr. Anuradha Tyagi, Department of cBRN, Institute of Nuclear Medicine & Allied Sciences, Delhi 110054, India

[email protected]

Dr. Anuradha Tyagi is a biomedical researcher specializing in inflammation biology, wound healing, and host–pathogen interactions. Her work demonstrates that timely modulation of the inflammatory phase is crucial for proper wound closure and tissue repair, particularly in conditions like radiation dermatitis. She has highlighted the therapeutic potential of secondary bile acids in chronic wound management, showing their ability to inhibit biofilm formation, neutralize bacterial virulence factors, modulate pro-inflammatory cytokines, and promote angiogenesis. Dr. Tyagi’s research advances our understanding of immune responses, microbial dynamics, and tissue regeneration, with important translational implications for chronic wound therapy.

Dr Yash Gupta, Department of Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA-17033, USA

[email protected]

Dr. Yash Gupta is a leading translational researcher specializing in gut–liver axis disorders, with a primary focus on precision probiotics and endotoxemia in non-alcoholic fatty liver disease (NAFLD). His work includes the development of novel lipid membrane–camouflaged biomimetic nanoparticles for microRNA delivery to intestinal epithelial cells, enabling targeted therapeutic modulation of intestinal tight junction integrity. Dr. Gupta has also conducted seminal studies on microRNA-mediated suppression of kisspeptin receptors in pancreatic cancer, elucidating how comorbidities such as obesity and hypertension influence tumor survival. He has contributed to defining the role of Bifidobacterium bifidum–PPAR-γ signaling pathways, advancing probiotic-based strategies for inflammatory bowel disease. Additionally, Dr. Gupta has served as a key collaborator in multi-institutional research initiatives, including investigations into erythropoietin signaling in vagus nerve Schwann cells and its role in restoring intestinal motility following surgical injury.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Neutrophils in a New Light: Emerging Roles in Inflammation", in the Journal of Inflammation Research.

Neutrophils are among the most abundant and evolutionarily conserved components of the innate immune system, long recognized for their frontline role in microbial defense and acute inflammation. However, our understanding of these cells has significantly evolved. Beyond their classical functions, neutrophils are now appreciated as highly plastic and multifunctional cells with the capacity to influence a wide range of immune responses, including those involved in chronic and sterile inflammation, tissue repair, autoimmunity, and even cancer.

This proposed Article Collection of the Journal of Inflammation Research aims to highlight the growing complexity of neutrophil biology and its implications for understanding and treating inflammatory diseases. By assembling a focused collection of high-quality original research articles, reviews, and short communications, this issue will provide readers with a comprehensive and up-to-date overview of the novel roles of neutrophils across diverse inflammatory contexts.

The field of neutrophil research is currently undergoing a paradigm shift. Advances in single-cell RNA sequencing, in vivo imaging, and functional assays have revealed striking heterogeneity among neutrophil populations, suggesting that they are far from being a homogenous cell type. Moreover, their ability to engage in crosstalk with other immune cells, influence adaptive responses, shedding neutrophil extracellular traps (NETs), and contribute to chronic inflammatory states has far-reaching implications for disease progression and therapy.

Despite this, neutrophils remain understudied compared to other immune cells, particularly in chronic disease settings where their roles are less obvious but no less critical. A dedicated special issue in the Journal of Inflammation Research would provide a much-needed platform for consolidating recent discoveries, showcasing state-of-the-art methodologies, and highlighting clinical relevance. Such an issue is well aligned with the journal’s mission to advance understanding of inflammatory mechanisms and foster translational insights into inflammation-related disorders.

This Article Collection will explore the evolving landscape of neutrophil biology with particular emphasis on novel and disease-relevant functions. The field in which submissions are welcomed address the following (but not limited to) subtopics:
1) Neutrophil heterogeneity and plasticity: Insights from single-cell and spatial profiling.
2) Neutrophil roles in chronic inflammation and autoimmunity: Contributions to diseases such as lupus, rheumatoid arthritis, and vasculitis.
3) NETs in inflammation: Molecular mechanisms, regulation, and pathological consequences.
4) Tissue-specific neutrophil behavior: Adaptation and function in lungs, liver, gut, CNS, and tumors.
5) Neutrophil interactions with adaptive immunity: Mechanisms of T cell modulation and antigen presentation.
6) Neutrophils in infection and viral inflammation: Including roles in COVID-19, sepsis, and chronic infections.

This Article Collection will serve as a comprehensive reference for scientists and clinicians working across immunology, inflammation, infectious disease, and translational medicine. By focusing on neutrophils, a cell type once considered simple but now recognized as highly influential, this issue aims to stimulate further research and innovation in the field of inflammation.

Keywords

1. Neutrophils Biology
2. Innate Immunity
3. Inflammation Resolution
4. Neutrophil Heterogeneity
5. Neutrophil Extracellular Traps (NETs)

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, using the promo code 5480B to indicate that the manuscript is intended for this Article Collection. The deadline for submitting a manuscript is 15 June 2026.

Guest Advisor

Dr. Tomasz W Kaminski, Thrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI

[email protected]

Tomasz W. Kaminski earned his doctoral degree from the Medical University of Bialystok, Poland. During his PhD training, he focused on studying hemostasis disturbances in chronic kidney disease. He joined the Sundd Lab as a postdoctoral associate in 2019. Dr. Kaminski’s research centers on innate immune mechanisms in platelets and neutrophils, as well as the pathophysiology of thrombo-inflammation. He employs state-of-the-art intravital microscopy techniques to capture real-time interactions between neutrophils and platelets during the initial phases of immune system activation. His work exhibits a truly interdisciplinary nature, as he investigates the neutrophil and platelet biology in hemophilic arthropathy, sickle cell disease and influenza. Dr. Kaminski has been recognized with numerous awards from both national and international societies and institutions. Furthermore, his research endeavors receive support from external funding sources.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Targeting the IL-4/IL-13 Axis in the Treatment of Type 2 Inflammation", in the Journal of Inflammation Research.

This Collection, edited by the Editor-In-Chief Prof. Ning Quan, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, and technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.

Type 2 inflammation occurs when immune cells, including eosinophils and mast cells, are activated, producing the cytokine IL-4 and Il-13. These cytokines are responsible for signaling the production of eosinophils, mast cells, and IgE antibodies, that lead to the release of more pro-inflammatory cytokines. Type 2 inflammatory conditions affect 10-30% of the global population, and include common conditions such as allergy, asthma, eczema, and eosinophilic esophagitis. By targeting IL-4 and IL-13, overactive immune systems can be regulated, and many patients will see a better quality of life.

While this call is open to receive manuscripts highlighting all aspects of drugs targeting the IL-4/Il-13 axis, the Editors are particularly interested in manuscripts relating to the following areas:

• Clinical studies on the efficacy and safety of IL-4 and/or IL-13 inhibitors
• Novel drug mechanistic actions
• Biologics directed against cells or pathways involved in the IL-4/IL-13 axis
• New drug candidates directed against IL-4 and/or IL-13
• Tailoring treatment in individuals with multiple Type 2 inflammatory conditions
• Drugs to treat non-allergic type 2 inflammation, such as nasal polyps
• Treatment strategies and potential side effects

Submitting authors are eligible for a 20% discount on the Article Publishing charge by applying the following code at the point of submission: YXVCF. If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor Ashley Ambros ([email protected]). Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript. 

Please submit your manuscript on our website. The deadline for submitting a manuscript is 1 April 2026.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "A Multidisciplinary Approach to Reducing Suicide Risk Among Adolescents: Strategies, Challenges, and Solutions", in the Journal of Multidisciplinary Healthcare.

Youth suicide is a pressing crisis today. Globally, the World Health Organization (WHO) reported that more than 720,000 people die each year by suicide, and suicide is now the third leading cause of death among 15–29 year olds (WHO, 2025). Over the past decade, youth trends have shown a sharp increase. In the United States, the suicide rate for 10–14-year-olds tripled between 2007–2018 before plateauing; for 15–19-year-olds, the rate rose ~57% (2009–2017) and remained high through 2021. These figures underscore that risk is no longer sporadic, but rather a persistent pattern in the current generation of adolescents (Centers for Disease Control and Prevention, 2024).

Current social and digital changes are shaping a risk ecology directly relevant to adolescent suicide. Near-constant internet exposure and increasingly widespread smartphone ownership are altering daily rhythms, reducing sleep quality and duration, and increasing exposure to harmful content, including cyberbullying, glorification of self-harm, and negative social comparison. Sleep disturbances, loneliness, and distorted self-esteem are strong predictors of suicidal ideation and self-harm behavior, so an intensification of these factors in adolescents should be considered a driver of increased risk. At the same time, reduced face-to-face interactions with peers and decreased community participation weaken traditionally protective support networks. The loss of meaningful connections diminishes adolescents’ sense of belonging and heightens perceived helplessness, two psychosocial mechanisms known to contribute to suicide ideation and attempts. The migration of interactions to digital spaces can also delay help-seeking and reduce opportunities for early detection by parents, teachers, and health professionals, while content distribution algorithms have the potential to amplify exposure to risky material among vulnerable groups.

Preventing suicide in adolescence is crucial because of its profound consequences for individuals, families, and society as a whole. Timely and evidence-based interventions can reduce risk factors, strengthen protective mechanisms, and ultimately save lives. In addition to alleviating psychological and social burdens, effective prevention strategies contribute to the development of healthier communities and reduce long term strain on healthcare systems. Multidisciplinary collaboration that brings together psychiatry, psychology, education, social work, public health, and policy studies offers the most comprehensive path toward sustainable solutions.

This Article Collection welcomes contributions that present innovative strategies, address current challenges, and propose solutions to reduce suicide risk among adolescents from a multidisciplinary perspective. Submissions may include empirical studies, systematic reviews, policy analyses, and practice-based insights.

• Relevant subtopics include, but are not limited to:
• Early detection and screening
• School- and community-based interventions
• The role of digital technologies
• Cultural and socioeconomic dimensions
• Ethical considerations in prevention programs

By integrating diverse approaches, this Collection aims to advance scholarly knowledge, foster collaboration, and support the development of effective strategies for safeguarding adolescent mental health.

References

1. Centers for Disease Control and Prevention. (2024). Youth Risk Behavior Survey (YRBS) data summary & trends report: 2013–2023. https://www.cdc.gov/yrbs/dstr/pdf/YRBS-2023-Data-Summary-Trend-Report.pdf

2. WHO. (2025). Suicide. https://www.who.int/news-room/fact-sheets/detail/suicide/

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 1 August 2026.

Please submit your manuscript on our website, quoting the promo code 33EF1 to indicate that your submission is for consideration in this Article Collection. Standard Article Publishing Charges apply.

If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Guest Advisors

Mr. Rohman Hikmat, Prince of Songkla University, Indonesia

Prof. Iyus Yosep, Universitas Padjadjaran, Indonesia

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Allied Health Matters: Showcasing Value, Driving Impact", in the Journal of Multidisciplinary Healthcare.

The term “allied” refers to being joined or associated with others for a common goal. It implies a supportive relationship between individuals and groups, characterized by cooperation, collaboration, and mutual support. Allied health professionals exemplify this concept and are at the heart of healthcare delivery, making significant contributions to patient outcomes, organizational efficiencies, and driving system-wide innovation. This Article Collection aims to highlight and celebrate the essential value that allied health services bring to individuals and communities, emphasizing the profound and lasting impact these professionals have on both healthcare systems and the lives of those they serve. 

We welcome submissions that showcase the transformative impact of allied health practices through cutting-edge research, evidence-based practices, end-user-centered approaches, innovative clinical models and workforce solutions, interdisciplinary collaboration, policy advancements, and technological integration. 

Topics of interest include, but are not limited to: 

• Innovative models of care and interventions: Highlighting new and emerging practices, as well as workforce solutions, that improve patient care and outcomes
• Interdisciplinary collaboration: Exploring the value of teamwork across healthcare professions and its positive impact on care delivery
• Educational Advancements: Demonstrating innovative teaching strategies and curriculum developments that enhance allied health training and professional development
• Technological integration: Exploring how technology and digital health tools are transforming allied health practices and patient engagement
• Cultural Competency and Equity: Examining practices that promote inclusivity, cultural sensitivity, and health equity within allied health services
• Consumer Experiences and Perspectives: Showcasing research on how allied health services impact patients' lived experiences, satisfaction, and engagement in care
• Policy and Advocacy: Addressing how allied health professionals influence healthcare policy, access to services, and advocacy for underserved populations.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 15 April 2026.

Please submit your manuscript on our website, quoting the promo code RNTHT for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Guest Advisors

Prof. Saravana Kumar, University of South Australia

Ms. Esther Jie Tian, University of South Australia

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Building a Sustainable Allied Health Workforce: Recruitment, Retention, and Resilience", in the Journal of Multidisciplinary Healthcare.

The Allied Health Professions (AHPs) provide specialist emergency, diagnostic, treatment, and rehabilitative services that help people and whole communities from birth to end of life. AHPs make up a large proportion of the international health workforce, yet their vital contribution is too often marginalized in a public discourse that tends to refer only to "doctors and nurses." As a result, the focus on prevention and rehabilitation is also less well understood by patients and the public who focus on hospital-based, acute medical care. Further research is needed to inform policy and practice in sustaining the whole AHP workforce including assistant practitioners and support staff. 

As the demand for Allied Health Services continues to grow there is a need to understand how best to build and maintain the Allied Health workforce, including non-traditional routes into the professions, diversification of educational options and challenging conceptions of siloed and stressful roles that lead to poor retention. There are multiple challenges across different communities and contexts including rural and coastal and urban deprived places, and evidence is needed to support planning, decision-making and investment in new roles and ways of working. 

This Article Collection will explore the sustainability of the Allied Health workforce, with topics including retention, routes into the Allied Health Professions, burnout and other mental health difficulties facing the Allied Health workforce. The impact of workforce shortages, strategies for improving recruitment and diversity, the role of leadership and professional development in building resilience, and innovations in service delivery, including the integration of digital health and interprofessional collaborations are relevant. This collection aims to gather robust AHP-specific research that evidences the issues facing the sustainability of the AHP workforce, and the outcomes of local, national, and international workforce innovations. 

Specialties within the Allied Health Professions include: 

• Art therapists
• Dietitians
• Dramatherapists
• Music therapists
• Occupational therapists
• Operating department practitioners
• Orthoptists
• Osteopaths
• Paramedics
• Physiotherapists
• Podiatrists
• Prosthetists and orthotists
• Radiographers
• Speech and language therapists 

We welcome original articles, reviews, perspectives, and commentaries.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 1 July 2026.

Please submit your manuscript on our website, quoting the promo code C5C22 to indicate that your submission is for consideration in this Article Collection. Standard Article Publishing Charges apply.

If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Guest Advisors

Dr. Sarah Etty, Sheffield Hallam University, UK

Prof. Sally Fowler-Davis, Anglia Ruskin University, UK

View all papers in this article collection

The Journal of Multidisciplinary Healthcare is pleased to welcome you to submit your research to the Article Collection "Contemporary Multidisciplinary Strategies in Cardiovascular and Internal Medicine From Early Detection to Advanced Intervention".

Contemporary healthcare increasingly requires multidisciplinary strategies to address the growing complexity of cardiovascular and systemic diseases. Advances in diagnostic technology, medical therapy, interventional procedures, and integrated clinical care have transformed the management of patients from early detection to advanced intervention. In particular, the collaboration between cardiology, internal medicine, radiology, critical care, and other healthcare disciplines plays a crucial role in improving diagnostic accuracy, optimizing treatment decisions, and enhancing patient outcomes across diverse clinical settings.

This topic is important because cardiovascular disease and chronic medical conditions remain leading causes of morbidity and mortality worldwide. Early identification of disease, appropriate risk stratification, and timely intervention require coordinated efforts among multiple specialties supported by modern imaging, laboratory evaluation, and evidence-based clinical pathways. Multidisciplinary care models have been shown to improve efficiency, reduce complications, and provide more personalized treatment, especially in complex patients with multiple comorbidities. As healthcare systems continue to evolve, there is a growing need for research that integrates clinical expertise, technological innovation, and collaborative decision making.

This Article Collection welcomes original research, reviews, clinical studies, and perspectives related to multidisciplinary approaches in cardiovascular and internal medicine. Topics of interest include, but are not limited to:

• Cardiac imaging
• Preventive cardiology
• Heart failure
• Coronary artery disease
• Structural heart disease
• Critical care
• Multimodality diagnostics
• Digital health
• Artificial intelligence in healthcare
• Integrated care pathways
• Collaborative clinical management

Submissions addressing translational research, real world clinical practice, and innovations that improve patient outcomes within multidisciplinary healthcare are particularly encouraged.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 1 February 2027.

Please submit your manuscript on our website, quoting the promo code 78BF5 to indicate that your submission is for consideration in this Article Collection. Standard Article Publishing Charges apply.

If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Guest Advisor 

Dr. Ricardo Adrian Nugraha, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Cybersecurity in Healthcare: Ensuring Patient Safety and Data Privacy", in the Journal of Multidisciplinary Healthcare.

All computer systems are vulnerable to cyberattacks, but healthcare systems are especially at risk due to the pervasive use of interconnected digital health systems for service delivery, insurance billing, pharmaceutical ordering, diagnostics test reporting, and telehealth. Medical device usage, remote patient monitoring, patient portals, and the increasing number of connected smart devices provide multiple entry points for cyber actors. Moreover, healthcare targets are ten times more valuable than financial targets because they can enable fraudulent billing. 

Healthcare security specialists may wish for a universal application to scan computer systems and detect all cyber threats, but that app does not exist. The reason is that cybersecurity issues are intricate and multifaceted, involving human factors, system vulnerabilities, technological vulnerabilities, physical access issues, and legal compliance challenges. 

Information sharing and remote access make healthcare systems more susceptible to viruses and phishing. Cyberattacks in one system can have a domino effect, resulting in issues in multiple connected internal and external systems. As an illustration, the February 2024 ransomware data breach at Change Healthcare, a company that supplied revenue cycle and payment management services to over 900,000 healthcare providers and 5,500 hospitals, significantly impacted healthcare systems in several states. This breach, the largest ever reported, affected approximately 190 million individuals, and resulted in revenue losses due to delays in processing clinical, financial, and operational transactions. 

At a minimum, cyberattacks in healthcare can delay care due to healthcare databases being held for ransom. The worst-case scenario is when the Internet of Medical Things is hijacked and causes malfunction. Disruptions to healthcare systems harm the financial stability of the affected healthcare facility and pose serious risks to patient safety and data privacy. This was a concern as far back as 2000 when the U.S. Secret Service disabled the Wi-Fi capabilities of the pacemaker in Vice President Dick Cheney’s chest. 

During cyberattacks, patient information can be compromised, lost, stolen, or held for ransom, endangering the ability to diagnose and treat the patient efficiently and safely. The Department of Health and Human Services Office for Civil Rights' analysis of healthcare data breaches revealed a substantial increase in the number and severity of data breaches over the last fourteen years, and the average cost is higher than data breach costs for other industries. 

This Article Collection welcomes original research articles and systematic reviews. Topics of interest include, but are not limited to: 

• Empirical studies exploring topics related to healthcare patients, systems, and data privacy and security.
• Comprehensive reviews summarizing the current state of healthcare cybersecurity.
• Comparing blockchain and active Artificial Intelligence to more traditional intrusion detection mechanisms.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 1 April 2026.

Please submit your manuscript on our website, quoting the promo code JJGXV for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Guest Advisors

Prof. Diane Dolezel, Texas State University, USA

Prof. Scott Kruse, Texas State University, USA

Prof. Rohit Pradhan, Texas State University, USA

View all papers in this article collection

The Journal of Multidisciplinary Healthcare is pleased to welcome you to submit your research to the Article Collection "Global Advances in Pharmacogenomics: From Discovery to Clinical Implementation and Improved Patient Outcomes".

Pharmacogenomics has emerged as the primary driver of treatment individualization, moving beyond a "one-size-fits-all" approach to a model where drug selection and dosages are tailored to an individual’s genetic profile. While the field has seen rapid growth in identifying genetic variants that influence drug-metabolizing enzymes and drug targets, the focus is now shifting toward the practical integration of these findings into routine healthcare. This Article Collection explores the full spectrum of PGx, from foundational variability studies to the latest in diagnostic methodologies.

The importance of this topic lies in its potential to bridge the gap between genomic discovery and clinical utility. By optimizing therapeutic efficacy and minimizing adverse drug reactions (ADRs), pharmacogenomics serves as a critical tool for improving patient safety and healthcare cost-effectiveness globally. Understanding the genetic diversity across different populations is essential to ensure that the benefits of personalized medication management are equitable and scientifically sound for all patients.

Specific Topics of Interest include:

• Clinical Utility: Real-world evidence of PGx-guided therapy in specialties such as oncology, cardiology, and psychiatry.
• Testing Methodologies: Development and validation of innovative, scalable, or cost-effective pharmacogenetic testing platforms.
• Genetic Variability: Studies on the prevalence and impact of polymorphisms in drug-metabolizing enzymes and transporters across diverse global populations.
• Implementation Science: Strategies for integrating PGx into clinical workflows, including electronic health record (EHR) integration and clinical decision support.
• Policy and Ethics: Ethical, legal, and social implications (ELSI), along with policy recommendations for national healthcare systems
• Medication Safety & ADR Management: The role of multidisciplinary teams in monitoring and preventing adverse drug reactions as a foundation for personalized therapy.

This Article Collection seeks to highlight the essential multidisciplinary collaboration between clinical pharmacists, physicians, molecular biologists, and bioinformaticians required to move pharmacogenomics from theory to practice. We invite submissions that demonstrate how integrated healthcare teams utilize genetic data to optimize therapeutic outcomes and patient safety across diverse clinical settings. The Collection particularly welcomes Original Research, Reviews, Clinical Trial Reports, Methodologies, Perspectives, and Expert Opinions that provide robust evidence for implementation. Systematic Reviews that synthesize current knowledge of genetic variability and its clinical implications are also highly encouraged.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 31 December 2026.

Please submit your manuscript on our website, quoting the promo code 21442 to indicate that your submission is for consideration in this Article Collection. Standard Article Publishing Charges apply.

If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Meet the Guest Advisor
Dr. Mohamed Nagy is a clinical pharmacogenomics expert with extensive experience in research, teaching, and clinical practice. He is the Pharmacy Director at the Children's Cancer Hospital Egypt (CCHE) 57357, where he also founded and heads the Personalized Medication Management Unit. Dr. Nagy's research interests lie in pharmacogenomics, particularly in the application of genetic information to optimize drug therapy in pediatric oncology patients. Dr. Nagy serves on the board of the African Pharmacogenomics Network and is the chair of the global committee of the Pharmacogenomics Global Research Network.

The Guest Advisors declare no conflict of interest regarding this work.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Harnessing Database Mining for Advancing Clinical Practice: From Insights to Therapeutic Innovation", in the Journal of Multidisciplinary Healthcare.

The integration of advanced database mining techniques into clinical practice is reshaping how healthcare professionals diagnose, treat, and manage diseases. Modern clinical databases - encompassing electronic health records (EHRs), genomic profiles, treatment outcome registries, and real-time patient monitoring data - hold immense, untapped potential to uncover actionable insights that directly improve patient care. This Article Collection focuses on cutting-edge methodologies and applications of database mining to bridge the gap between data-driven discoveries and their practical implementation in therapeutic decision-making, ultimately enhancing precision, efficacy, and equity in clinical practice. 

The urgency of leveraging database mining in clinical settings lies in its capacity to address critical healthcare challenges. Traditional approaches to treatment optimization often rely on generalized protocols, which may fail to account for individual patient variability, comorbidities, or emerging patterns in population health. By systematically analyzing large-scale clinical datasets, researchers and practitioners can identify novel biomarkers, predict treatment responses, and tailor interventions to specific patient subgroups. For example, mining oncology databases may reveal correlations between genetic mutations and drug efficacy, enabling personalized cancer therapies, while analyzing longitudinal EHR data could uncover early warning signs of treatment complications. Furthermore, in resource-limited settings, database-driven insights can guide cost-effective, evidence-based care. Despite this potential, challenges such as data heterogeneity, ethical constraints, and the translation of mined patterns into clinical workflows remain significant barriers to widespread adoption. 

This Article Collection invites submissions that explore the transformative role of database mining in advancing therapeutic strategies and clinical outcomes. Key subtopics include, but are not limited to: 

• Multidisciplinary Literature Informatics: Cross-disciplinary approaches such as bibliometric analyses to map trends in disease research, therapeutic innovations, and knowledge gaps across fields like pharmacology, genomics, and public health.
• Mining Large-Scale Biomedical Databases: Methodological advances and applications leveraging datasets such as NHANES (nutrition and health trends), GBD (global disease burden), UK Biobank (genomic and health data), TriNetX (real-world clinical data), and other repositories to uncover disease mechanisms, treatment patterns, and population health insights.
• Data-Driven Discovery of Disease and Therapeutic Targets: Computational strategies including network pharmacology, bioinformatics analyses, and multi-omics integration to identify novel drug candidates, repurpose existing therapies, or elucidate disease pathways.
• Machine Learning for Precision Therapeutics: Predictive models to forecast individual patient responses to treatments (e.g., chemotherapy efficacy, adverse drug reactions) or stratify high-risk populations (e.g., early detection of sepsis, cardiovascular events) using clinical, genomic, and demographic data.
• Ethical and Technical Challenges in Clinical Data Mining: Addressing biases in heterogeneous datasets, ensuring interoperability across platforms, and balancing data utility with patient privacy in global health contexts.

We welcome original research articles, method and methodology papers, and reviews that demonstrate rigorous data mining approaches with clear clinical relevance. Submissions should emphasize scalable solutions, reproducibility, and direct implications for improving therapeutic decision-making, aligning with the journal’s commitment to fostering innovation at the intersection of data science and clinical care.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 1 April 2026.

Please submit your manuscript on our website, quoting the promo code MFNEB for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Guest Advisors

Prof. Qingwen Tao, China-Japan Friendship Hospital, Beijing, China

Dr. Guangyao Chen, China-Japan Friendship Hospital, Beijing, China

Dr. Caixian Qiu, Beijing University of Chinese Medicine, China

View all papers in this article collection

The Journal of Multidisciplinary Healthcare is pleased to welcome you to submit your research to the Article Collection "Strengthening Multidisciplinary Healthcare Teams: Workforce Integration, Team Collaboration, and Equitable Care".

Multidisciplinary healthcare increasingly depends on teams composed of professionals with different cultural, linguistic, educational, and lived-experience backgrounds. These differences shape how teams communicate, make decisions, collaborate, and partner with patients and families. This Article Collection explores how healthcare organizations and teams can strengthen workforce integration and team collaboration to support safer, higher-quality, and more equitable care across primary, acute, community, and long-term care settings.

This topic is important because workforce shortages, migration, and cross-border recruitment are reshaping health systems worldwide. Many services increasingly rely on internationally educated health professionals, multilingual teams, and new forms of task-sharing. Without adequate preparation and support, teams may face communication breakdowns, role ambiguity, inequitable opportunities, and reduced psychological safety, affecting staff wellbeing and patient outcomes. Source countries may also experience workforce depletion, service gaps, disrupted team functioning, and loss of training investments. Better evidence is needed on how organizations can support ethical recruitment, effective workforce integration, language access, mutual learning, and sustainable workforce partnerships.

We invite submissions on strengthening multidisciplinary healthcare teams, with particular interest in:

1. Workforce integration and ethical recruitment, including the integration of internationally educated health professionals and impacts on source-country systems and teams;

2. Language access, language discordance, and communication practices; and

3. How cultural competence, cultural humility, inclusive leadership, and diversity management influence team collaboration, staff experience, patient safety, and equitable care.

Cross-cutting topics include organizational readiness, implementation strategies, policy, and measurement. We welcome original research, mixed-methods studies, implementation and quality improvement studies, policy analyses, and systematic, scoping, or realist reviews.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 1 February 2027.

Please submit your manuscript on our website, quoting the promo code 983A7 to indicate that your submission is for consideration in this Article Collection. Standard Article Publishing Charges apply.

If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Guest Advisor

Assistant Prof. Dr. Helena Kristina Halbwachs, University for Applied Sciences, Vienna, Austria

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Advancing Inclusion in Pediatric Pain Research, Training, and Practice", in the Journal of Pain Research.

Much of our current understanding of pediatric pain mechanisms and interventions is informed by an evidence base that does not adequately reflect the broader population of youth living with acute and chronic pain. Individuals who are marginalized due to sociocultural characteristics including (but not limited to) racialized identity, ethnicity, indigeneity, age, sex, gender identity, disability status, educational attainment, socioeconomic position, immigration and refugee status, and geographic location are underrepresented in pain research. These same groups are also at highest risk for experiencing profound inequities in pain care and outcomes. 

Numerous calls to action have been made to improve inclusion in the design, conduct, reporting, and dissemination of pain research. Alongside efforts to meaningfully engage communities in research and recruit and retain diverse study participants, these calls highlight the importance of diversifying the research environment itself to accelerate translation of findings to real-world efforts to alleviate pain for all youth. Additionally, culturally aware mentoring resources and training for providers in culturally attuned, evidence-based pain care are imperative to foster the talents of trainees from diverse backgrounds and adequately prepare the next generation of pain scientists and clinicians. Ultimately, inclusive pediatric pain research, training, and practice seeks to ensure that innovations in pain science and care meet the needs of all youth with pain and their families. 

This Article Collection seeks to advance this cause by highlighting inclusive approaches to pediatric pain research, training, and practice. Articles that focus on underrepresented groups (e.g., infants, young adults, indigenous populations, people of color, people with disabilities, LGBTQ2A+), biopsychosocial risk and resilience factors associated with chronic primary or secondary pain in young people, use of innovative methodologies or technologies to improve the quality and equity of pediatric pain care, projects that exemplify community engagement in knowledge production and/or mobilization, and approaches to enhancing diversity and inclusion within pediatric pain research and clinical workforce are especially welcome.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 15 September 2026.

Please submit your manuscript on our website, quoting the promo code KQQFZ for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

If you have any questions about this Article Collection, please contact Krista Thom at [email protected].

Guest Advisors 

Aimee Hildenbrand, Nemours Children’s Health, USA

Shreela Palit, Nemours Children’s Health, USA

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Nanotechnology, Science and Applications on "Advances in Green Synthesized Nanomaterials".

Nanotechnology has revolutionized various fields, including medicine, electronics, and environmental science. However, traditional methods of synthesizing nanomaterials often involve toxic chemicals and high energy consumption, leading to significant environmental and health concerns. In response, green synthesis methods have emerged as a sustainable alternative, utilizing natural biological systems such as plants, bacteria, and fungi to produce nanomaterials. These methods not only reduce the environmental footprint but also offer unique properties and functionalities to the synthesized nanomaterials.

As the world faces the challenges of climate change and environmental degradation, the need for sustainable and eco-friendly technologies has become increasingly important. Green synthesis methods align with the principles of green chemistry, aiming to minimize waste, reduce energy consumption, and use non-toxic reagents. These methods hold the potential to revolutionize various industries by providing safer and more sustainable alternatives to conventional nanomaterials.

To help raise the profile of this important area of research, Nanotechnology, Science and Applications is publishing a timely Article Collection on green synthesized nanomaterials.

Potential topics include, but are not limited to, the following:

• Biological Methods for Nanomaterial Green Synthesis
• Characterization of Green Synthesized Nanomaterials
• Green Synthesized Nanomaterials in Medicine
• Environmental Applications of Green Synthesized Nanomaterials
• Green Synthesized Nanomaterials in Energy and Electronics
• Sustainability and Lifecycle Analysis of Green Synthesized Nanomaterials

The Collection is led by the Editor in Chief, Professor Kattesh Katti, who is globally recognized as the 'Father of Green Nanotechnology'.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 1 July 2026.

Please submit your manuscript on our website, using the promo code MDEXJ for 20% off the advertised article processing charge and to indicate that your manuscript will be considered for the “Advances in Green Synthesized Nanomaterials” Collection. We will welcome relevant Original Research, Reviews and Editorials. 

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Nanotechnology, Science and Applications on "Current Advances in Nanotechnology: Prospects and Challenges of Nanotherapeutics in Treating Cancers", organized by Prof. Veena Agrawal (University of Delhi, India).

Cancer is a major health issue globally, with an estimated 20 million new cases and 9.7 million deaths in 2022. By 2050, projections indicate a significant increase to over 35 million new cases. Discovering novel medicines is an urgent need. Nanomedicine has emerged as a new multidisciplinary field capturing the attention of scientists. Nanotherapeutics have capabilities for effectively transporting medicines or gene fragments to tumor tissues via passive or active targeting processes; thus there are immense possibilities for enhancing treatment outcomes while causing minimum harm to healthy tissues. Nanoparticles can also be employed for advanced imaging techniques, such as MRI and PET scans, providing better visualization of internal organs and tissues. The engineered nanoparticles can be employed as contrast agents in cancer diagnostics to enable high sensitivity and high-resolution imaging examinations and tumor detection. Novel approaches for tumor labeling and detection are also made possible by the use of nanoprobes. While nanotechnology shows great potential, clinical translation faces challenges related to biocompatibility, toxicity, and the complexity of the tumor microenvironment.

Nanotechnology holds great potential where it enables targeted drug delivery, development of nano-biosensors for early disease detection, and advanced imaging techniques such as MRI and PET scans. Nanoparticles can be designed for improved cancer detection, and enhanced immune responses. Nanoparticles can be employed in the context of radiation sensitization and photothermal therapy to enhance the therapeutic efficacy of malignant tumors. The combination of nanotechnology and conventional tumor therapy can not only enhance the properties of chemoradiotherapy drugs but also reduce the incidence of poisoning and other side effects. These NPs can rapidly cross the human biological barriers, even in a targeted manner and continuously release the content to maintain the appropriate blood concentration of the drug.

Potential subtopics related to recurrent miscarriage include (but are not limited to):

• Bio/molecular nanosystems, nanoparticles including nanoscale bio/therapeutics and nano drug carriers, extracellular vesicles, smart and stimuli responsive nanobiosystems
• Nanotoxicity, nanotoxicology, biomedical sensors including sensor fusion
• Nanomedicine
• Gene therapy
• Biomimetic nanoengineering
• Single particle and single cell analysis, biomedical imaging, nanobiotechnology
• Photothermal therapy
• Nanomedicines in Skin cancer
• Nanomedicines in Lung cancer

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 30 June 2026.

Please submit your manuscript on our website, using the promo code E639F to indicate that your manuscript will be considered for this Article Collection.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest Advisor

Prof. Veena Agrawal, University of Delhi

[email protected]

Professor Veena Agrawal, Senior Professor (R)of Botany (Level-15), University of Delhi, specializes in medicinal plant biotechnology, nanobiotechnology (green synthesis of nanoparticles and their efficacy against, different cancer cells, malaria vectors and diabetes), isolation and characterization of natural biomolecules, sex-linked molecular markers and genetic diversity analysis. She has published over 125 research articles in leading international journals with high impact factors, including Artificial Cells, Nanomedicines, Material Science and Engineering, Industrial Crops, Plant cell reports, Current Cancer Drug Target, Plant Science, Plant Physiology and Biochemistry, Process safety & Environmental Research, etc., Twenty five Ph. D and 21 M.phil. students obtained their degrees under her supervision in different disciplines. She is a Fellow of the Linnean Society of London (FLS) and a member of many international and national academic societies. She is on the editorial board of many journals including Arti. Cells Nanomedicines and Biotechnology. She is on the expert panels of international/national institutions for reviewing and evaluating research projects and Ph,D. theses. She has immensely contributed research to international and national platforms through presentations at conferences, seminars, and publications, as well as registering patents and receiving many awards and recognitions.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Nanotechnology, Science and Applications on "Uniting Natural Products and Biotechnology for the Next Generation of Nanomedicine", organized by Dr. Przemysław Sitarek (Medical University of Lodz, Poland) and Dr. Tomasz Kowalczyk (University of Lodz, Poland).

This Article Collection focuses on the convergence of nanotechnology, natural bioactive compounds, and biotechnology to develop advanced therapeutic approaches for a wide range of diseases. The integration of plant-derived phytochemicals, animal-based molecules, and recombinant proteins into nanoscale delivery systems opens new frontiers in precision medicine, offering improved biocompatibility, targeted delivery, and enhanced therapeutic efficacy. Recent advancements in biotechnology have enabled the design and production of engineered proteins and biomolecules with high specificity and functional versatility, further enriching the potential of nanomedical platforms. When combined with the diverse pharmacological properties of naturally sourced compounds, these hybrid nanosystems present promising strategies for treating cancer, infectious diseases, inflammatory conditions, metabolic disorders, and neurodegenerative diseases. This Collection invites original research, reviews, and perspectives that explore the design, synthesis, characterization, and biomedical application of nature-inspired and bioengineered nanostructures. The aim is to provide a multidisciplinary outlook on how the fusion of nanotechnology with natural and recombinant therapeutic agents can drive innovation in diagnosis, treatment, and regenerative medicine.

This Article Collection title encapsulates a timely and significant convergence of nanotechnology, biotechnology, and nature-derived bioactive compounds originating from plant and animal sources. In the context of escalating global health challenges—such as cancer, antimicrobial resistance, chronic inflammation, and neurodegenerative disorders—there is a pressing demand for the development of therapeutic strategies that are not only safe and effective, but also precisely targeted.

Natural molecules exhibit potent biological activity and favorable biocompatibility; however, their clinical potential is often limited by low stability and bioavailability. Advances in biotechnology and nanocarrier systems offer powerful tools to overcome these limitations by enhancing molecular stability, enabling controlled delivery, and improving therapeutic precision. The incorporation of recombinant proteins further broadens the therapeutic arsenal, supporting the design of personalized and multifunctional treatment modalities.

This title reflects the essence of an interdisciplinary approach that synergistically integrates nature’s pharmacological potential with the precision and adaptability of modern scientific innovation. It signals the emergence of a new era in nanomedicine—one in which nanoscale and molecular-level technologies converge to yield next-generation solutions for complex and treatment-resistant diseases.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 30 June 2026.

Please submit your manuscript on our website, using the promo code F4163 to indicate that your manuscript will be considered for this Article Collection.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest Advisors

Dr. Przemysław Sitarek, Medical University of Lodz

[email protected]

Przemysław Sitarek is an Associate Professor at the Medical University of Łódź (Poland), where he heads the Department of Medical Biology at the Faculty of Pharmacy. His interdisciplinary research spans biotechnology and nanotechnology, with a strong focus on biologically active compounds, recombinant proteins, and metabolic engineering. He is particularly interested in investigating metabolic pathways and developing nature-inspired biomedical solutions to address contemporary therapeutic challenges. His work contributes to advancing the role of both natural and engineered molecules in next-generation nanomedicine.

 Dr. Tomasz Kowalczyk, University of Lodz

[email protected]

Tomasz Kowalczyk, PhD, is an assistant professor in the Department of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Łódź and Department of Medical Biology, Faculty of Pharmacy, Medical University of Lodz. Research interests: Biotechnological production of natural biologically active compounds from plant and other natural sources Development of plant-based and microbial expression systems for production of valuable secondary metabolites and recombinant proteins Application of nanotechnology in combination with biotechnology.

View all papers in this article collection

We are pleased to announce a new Article Collection in Nature and Science of Sleep, dedicated to the game-changing role of Continuous Positive Airway Pressure (CPAP) therapy in the management of obstructive sleep apnea (OSA). Since its clinical introduction, CPAP therapy has revolutionized patient care, offering significant benefits in improving sleep quality, reducing daytime fatigue, and enhancing overall cardiovascular health for eligible patients.

Given the importance of CPAP therapy in managing obstructive sleep apnea, Nature and Science of Sleep invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these transformative therapies.

The Collection, edited by Editor-In-Chief Professor Ahmed BaHammam, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.

While the call is open to receive manuscripts across the broad spectrum of CPAP therapy in obstructive sleep apnea, the Editors are particularly interested in manuscripts relating to the following areas:
• Pathophysiological mechanisms of CPAP and alleviation of OSA symptoms
• Randomized controlled trials assessing the clinical effectiveness of CPAP therapy in OSA
• Observational studies examining the relationship between CPAP use and outcomes in the real-world setting.
• Studies focused on CPAP adherence and patient adherence
• Personalized CPAP approaches - Given the growing recognition that OSA treatment needs individualization beyond the traditional "one-size-fits-all" approach.
• Technology integration and telemedicine - The role of remote monitoring, mobile health applications, and digital therapeutics in improving CPAP adherence.
• Health economics and accessibility - Studies examining cost-effectiveness and strategies to improve access, particularly in developing countries where simpler, lower-cost CPAP devices show promise.
• Cardiovascular outcomes research - More robust studies addressing the ongoing debate about CPAP's cardiovascular benefits, particularly focusing on adherent patients.

Submitting authors will be eligible for a 20% discount on the Article Publishing charge by entering the code B2707. The code must be applied at the point of submission.

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

Please review the journal's Aims and Scope and author submission instructions prior to submitting a manuscript. Please submit your manuscript through the Dovepress website. The manuscript submission deadline is 1 April 2026.

If you have any queries regarding the Article Collection or would like to discuss a submission, please email the Commissioning Editor at [email protected].

View all papers in this article collection

We are pleased to announce a new Article Collection in Nature and Science of Sleep, focused on the role of orexin receptor antagonists in the management of insomnia.

Where behavioral interventions are not effective, pharmacological treatments can offer an alternative for insomnia patients. However, while benzodiazepines and "Z-drugs" can be effective in the short term, long-term use is associated with side effects including the development of tolerance and addiction. Orexin receptor antagonists, a relatively new class of medications, have reduced dependance and tolerance-inducing effects, showing promise for longer-term use.

Given the emerging importance of orexin receptor antagonists in managing insomnia, Nature and Science of Sleep invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these therapies.

The Collection, edited by the Editor-In-Chief Professor Ahmed BaHammam, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies and drugs.

While the call is open to receive manuscripts across the broad spectrum of orexin receptor antagonists in insomnia, the Editors are particularly interested in manuscripts relating to the following areas:
• Studies exploring the neurobiological pathways and mechanisms through which orexin receptor antagonists exert their effects.
• Studies evaluating the efficacy of orexin receptor antagonists in different patient populations.
• Studies assessing the safety and tolerability of orexin receptor antagonists.
• Comorbid conditions - Studies examining orexin antagonists in patients with insomnia and concurrent sleep disorders or psychiatric conditions.
• Comparative effectiveness research - Head-to-head studies with other insomnia treatments.
• Long-term safety profiles - Extended follow-up studies given the relatively recent introduction of these medications.

Submitting authors will be eligible for a 20% discount on the Article Publishing charge by entering the code 20F21. The code must be applied at the point of submission.

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

Please review the journal's Aims and Scope and author submission instructions prior to submitting a manuscript. Please submit your manuscript through the Dovepress website. The manuscript submission deadline is 1 April 2026.

If you have any queries regarding the Article Collection or would like to discuss a submission, please email the Commissioning Editor at [email protected].

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Addiction in the Digital Age: Emerging Challenges in Neuropsychiatry" in Neuropsychiatric Disease and Treatment.

Behavioral addictions encompass a range of compulsive behaviors that, similar to substance use disorders, are characterized by neurobiological and psychological mechanisms. Despite the many positive effects of the rise of digitalization, problematic internet use, smartphone, video game, and social media addictions have been observed to increase steadily. In addition, gambling, exercise, shopping, eating, pornography, and sexual behavior addictions represent other significant types of behavioral addictions. The World Health Organization has emphasized that such addictions may affect a substantial proportion of the global population. Although each type of behavioral addiction exhibits unique features, they share common core characteristics, including emotional dysregulation, impulsivity, compulsivity, and disruptions in biological, psychological, social, and spiritual functioning. Addictions emerge from individuals’ pathological pursuit of reward and/or relief. Rewarding stimuli exert their effects through positive reinforcement mechanisms, while genetic variations related to the dopaminergic system, GABA, and other neurotransmitters shape behavioral outcomes. Understanding this multifaceted phenomenon requires an interdisciplinary approach encompassing neuroscience, psychology, and social sciences. Examining the prevalence of behavioral addictions, their associated components, and the underlying neuropsychiatric mechanisms through international research is expected to contribute significantly to a better understanding and prevention of addictions.

Global research reveals a significant increase in the prevalence of behavioral addictions. Technological advancements in the digital age put young people, the future of our world, at risk for various behavioral addictions, particularly technology addictions. These addictions, due to their increasing prevalence and their negative impact on individuals and society, are becoming a serious public health problem. In addition to exhibiting similar mechanisms of action to substance use disorders, such as dysregulated reward processing and impulsivity, they also increase mental health problems and lead to significant reductions in overall well-being and quality of life. The fact that they particularly affect younger generations and the ever-increasing rate of addiction highlights the urgent need for clinicians to address this issue. Therefore, addressing the prevalence of behavioral addictions, their associated factors, the neuropsychiatric mechanisms that contribute to them, and effective prevention and intervention are crucial to reducing their individual and societal burden and promoting healthier behavioral patterns.

With the rapid rise of digitalization, problematic internet use, smartphone, and social media addictions have steadily increased. Additionally, gambling, excessive exercise, shopping, eating, sexual behavior addictions represent other significant forms of behavioral addiction that may affect a substantial proportion of the global population, as highlighted by the World Health Organization. Despite their diversity, these conditions share core features such as emotional dysregulation, impulsivity, compulsivity, and impairments in biological, psychological, social, and spiritual functioning. Behavioral addictions stem from the pathological pursuit of reward and/or relief, often linked to dopaminergic pathways, GABAergic activity, and genetic variations influencing neurotransmission. Understanding this multifaceted phenomenon requires an interdisciplinary approach involving neuroscience, psychiatry, psychology, and social sciences. This Article Collection welcomes original research, systematic reviews, expert opinions, and extended reports that investigate the prevalence, underlying mechanisms, and related components of behavioral addictions through an international lens.

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code 980B8 to indicate that your submission is for consideration in this Article Collection. The deadline for submitting manuscripts is 31 August 2026.

Please contact Sam Zhang at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors

Zeynep Öztürk, Erzurum Technical University

[email protected]

Dr. Zeynep Öztürk is an Assistant Professor of Psychiatric Nursing at Erzurum Technical University's Faculty of Health Sciences. She focuses on psychiatric nursing, mental health, addictions, resilience, spirituality in health, and elder care. She has published extensively in leading international journals in her field. She has authored over 20 publications indexed in Scopus and Web of Science. Dr. Öztürk also serves as a reviewer for several international journals and has led multiple clinical research projects.

Abdelaziz Hendy, Ain Shams University

[email protected]

Dr. Abdelaziz Said Hendy is an Assistant Professor of Pediatric Nursing at Ain Shams University, Egypt, and Assistant Professor at the College of Nursing, Qassim University, Saudi Arabia. He specializes in neonatal and pediatric nursing, nursing education, and public health. He serves as Academic Editor at PLOS ONE, Associate Editor at SAGE Open Nursing, and Editorial Board Member at BMC Nursing. With more than 50 publications indexed in Scopus and Web of Science, including contributions to The Lancet, his research focuses on advancing evidence-based neonatal and pediatric care. He is also an active reviewer for leading international journals and a member of the Scientific Council for the Neonatal Nursing Fellowship.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Antipsychotic Treatments - Transforming Schizophrenia Management in the Modern Era" in Neuropsychiatric Disease and Treatment.

We are pleased to announce a new Article Collection in Neuropsychiatric Disease and Treatment, dedicated to the game-changing role of antipsychotic treatments in the management of schizophrenia.

Since their clinical introduction, antipsychotic treatments have revolutionized care for patients with schizophrenia, offering benefits in reducing psychotic symptoms, stabilizing mood and emotions, improving cognitive and occupational functioning, and suicide prevention.

Given their global importance, Neuropsychiatric Disease and Treatment invites submissions of original research articles, reviews, and perspectives exploring the mechanisms of action, clinical efficacy, safety, and real-world application of antipsychotics in the management of schizophrenia.

The Collection, edited by the Editor-In-Chief Dr. Roger Pinder, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.

While the call is open to receive manuscripts across the broad spectrum of antipsychotic treatment in schizophrenia, the Editors are particularly interested in manuscripts relating to the following areas, including but not limited to:

• Novel antipsychotic drug mechanisms, pharmacology, and targets
• Clinical effectiveness of antipsychotic drugs on reduction of psychotic symptoms and emotional regulation
• Impact of antipsychotic treatments on cognition, functional recovery, and neurobiological changes
• Efficacy and safety of antipsychotics for optimizing treatment and minimizing side effects
• Long-acting injectable (LAI) antipsychotic drugs for improving treatment adherence and patient outcomes
• Innovations and technologies in personalized antipsychotic treatment

Please submit your manuscript on our website. Submitting authors will be eligible for a 20% discount of the Article Publishing Charge by applying the following code at the point of submission TQYVE. If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor Sam Zhang at [email protected].

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submissions is 1 April 2026.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Artificial Intelligence and Machine Learning in Neuropsychiatric Disease Diagnosis, Prognosis, and Treatment" in Neuropsychiatric Disease and Treatment.

Artificial intelligence (AI), machine learning (ML), and data mining (DM) have become pivotal tools in revolutionizing the diagnosis, treatment, and management of neuropsychiatric diseases. These technologies, capable of handling vast amounts of complex data, offer innovative solutions to traditional clinical approaches. The intersection of AI, ML, and neuropsychiatry is expanding rapidly, bringing about groundbreaking advancements in understanding conditions such as Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Anxiety and Depressive Disorders, Schizophrenia, and other cognitive disorders. By leveraging data-driven techniques, it is now possible to detect patterns in patient data that were previously difficult to identify, enabling early detection, personalized treatment, and improved patient outcomes. This Article Collection will explore how AI, ML, and DM are being applied to neuropsychiatric diseases, highlighting recent research and methodologies.

The importance of this topic lies in its potential to address some of the most pressing challenges in neuropsychiatric healthcare. Traditional diagnostic methods, based on clinical judgment and limited patient data, often fail to capture the complexity of brain disorders. The integration of AI and ML techniques, such as neural networks, deep learning, and reinforcement learning, promises to enhance diagnostic accuracy, predict disease progression, and optimize treatment strategies. Additionally, the ability of AI and ML to analyze multimodal data, including genetic, neuroimaging, and behavioral data, could lead to the discovery of novel biomarkers and personalized therapeutic interventions. As these technologies become more refined, they hold the potential to revolutionize how neuropsychiatric conditions are understood and treated.

This Article Collection will focus on the cutting-edge applications of AI, ML, and DM in the field of neuropsychiatry. We welcome original research, survey papers, meta-analyses, and review articles that explore the following subtopics including but not limited to:

• AI/ML in Neuropsychiatric Disease Diagnosis and Prognosis: Studies on how AI models, including deep learning and reinforcement learning, can be used to predict disease onset, progression, and therapeutic response.
• AI/ML Models for Biomarker Discovery: Utilizing machine learning algorithms to identify novel biomarkers for neuropsychiatric conditions, focusing on genetic, neuroimaging, and clinical data integration.
• Personalized Treatment through AI/ML: Exploration of AI-driven approaches in tailoring treatments for patients based on their unique genetic, clinical, and environmental factors.
• Data Mining Techniques in Cognitive Disorder Management: Application of advanced data mining algorithms to clinical datasets for the early detection and monitoring of conditions like schizophrenia, bipolar disorder, and depression.
• Neuroimaging and Neuroinformatics in AI/ML: Development of AI/ML algorithms to analyze neuroimaging data (e.g., MRI, PET scans) for better understanding of brain structures associated with neuropsychiatric disorders.
• Challenges and Ethical Considerations in AI/ML in Neuropsychiatry: Addressing issues related to data privacy, ethical implications, and bias in AI/ML models when applied to sensitive health data.

This Article Collection will appeal to researchers, clinicians, and technologists interested in how AI and ML can improve the diagnosis, treatment, and management of neuropsychiatric diseases.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are existing members of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submissions is 30 June 2026.

Please submit your manuscript on our website, quoting the promo code HXCWA for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

Guest Advisors

Dr Sathishkumar V Easwaramoorthy, Sunway University

[email protected]

Professor Vetriselvan Subramaniyan, Sunway University

[email protected]

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Cognitive Enhancement in Psychiatric Disorders" in Neuropsychiatric Disease and Treatment.

Cognitive impairment (CI) is prevalent in patients with various psychiatric conditions, e.g., schizophrenia, mood disorders, developmental disorders, and substance abuse. As CI is a major determinant of functional outcome, many years have been devoted to identifying treatment methods, including pharmacotherapy, rehabilitation and neuromodulation, that would effectively alleviate CI. While the evidence for the benefits of cognitive rehabilitation (remediation) therapy is relatively abundant, limited information has been available on cognition enhancing drugs (i.e., cognitive enhancers) that produce substantial effects on CI in psychiatric disorders.

Further efforts are needed to increase the chance of success of clinical trials evaluating cognitive enhancers, non-invasive brain stimulation methods, psycho-social intervention (cognitive rehabilitation/remediation). Importantly, such efforts should include the development of novel compounds or neuromodulation methods that show a greater ability to enhance cognitive function. Considerations should also be directed to the refinement of the study design, e.g., rational patient stratification and optimization of outcome measures. To effectively attain these goals, cutting-edge knowledge of the neurobiology of CI associated with psychiatric illnesses is required.

Prospective papers will deal with genetic, molecular, imaging, physiological, psychological, and/or behavioral issues regarding the mechanisms, assessment, and treatment of CI in psychiatric illnesses. Types of articles include Original Research, Reviews, Study Protocols, and Letter to the Editor. Also, Expert Opinion and Perspectives may be requested by Guest Advisor with an invitation basis. Overall, this Topic will provide the up-to-date knowledge on the mechanisms of CI associated with psychiatric illnesses and its treatment strategies, which will help facilitate social inclusion of patients and caregivers.

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code 3A5AF to indicate that your submission is for consideration in this Article Collection. The deadline for submitting manuscripts is 31 August 2026.

Please contact Sam Zhang at [email protected] with any queries and discount codes regarding this Article Collection.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Environmental Factors in Neuropsychiatric Pathophysiology and the Role of Alternative Therapeutic Approaches" in Neuropsychiatric Disease and Treatment.

Neuropsychiatric disorders, including depression, anxiety, schizophrenia, and bipolar disorder, arise from a complex interplay of genetic, neurobiological, and environmental factors. Among these, environmental influences play a pivotal role in shaping brain function and mental health. Exposure to psychological stress, trauma, sleep dysfunction, toxicants, infections, and socioeconomic factors can contribute to neuropsychiatric pathophysiology by altering neurochemical balance, inflammatory pathways, and neuronal signaling and plasticity. While conventional treatments such as pharmacotherapy and psychotherapy remain the cornerstone of management, alternative therapeutic approaches are gaining recognition for their potential to complement traditional treatments. New concepts in nutritional psychiatry, gut microbiome, mindfulness-based therapies, transcranial magnetic stimulation, exercise, and herbal medicine have led to propositions and explorations of alternative interventions for treating mental health disorders based upon their neuroprotective and neuromodulatory effects. This Article Collection aims to explore the intricate relationship between environmental factors and neuropsychiatric disorders, while also evaluating the efficacy and mechanisms of alternative therapeutic approaches for holistic, personalized treatment.

With increased life expectancies coupled with detrimental life-style changes, there has been a tremendous rise in the global burden of neuropsychiatric disorders. They have become a leading cause of disability worldwide, affecting millions of individuals. Environmental influences (e.g., chronic stress, pollution, urbanization, socioeconomic disparities, trauma, sleep issues, poor nutrition, etc.) play a crucial role in both the development and progression of these multifactorial and heterogeneous of neurological conditions. While pharmacotherapy and psychotherapy remain standard treatments, they are not always effective for all patients and may have side effects. Novel alternative treatments are being proposed regularly and are gaining scientific validation for a more comprehensive, patient-centered approach to neuropsychiatric care. Thus, identification of modifiable environmental risk factors and exploring alternative therapies can lead to prevention and early intervention, and more effective, personalized, and holistic treatment strategies.

This Article Collection will explore the complex interaction between environmental exposures and neuropsychiatric pathophysiology while evaluating the potential of alternative treatment approaches. The subtopics include, but are not limited to, (i) environmental factors contributing to neuropsychiatric disorders: chronic stress, trauma, and early-life adversity, influence of pollutants, heavy metals, and endocrine disruptors, urbanization, socioeconomic status, and lifestyle factors, (ii) neurobiological mechanisms linking environmental stressors to psychiatric disorders: neuroendocrine changes, alterations in neurotransmitter (dopamine, serotonin, glutamate) systems and neuroplasticity, oxidative stress, neuroinflammation and gut microbial dyshomeostasis, and (iii) alternative therapeutic approaches for neuropsychiatric disorders: nutritional psychiatry (ketogenic diet, micronutrients, and omega-3 fatty acids, etc.), mindfulness-based interventions and meditation, mental and physical activity, gut microbiome modulation, non-invasive brain simulation (TMS, tDCS, etc.), herbal medicines. Both reviews and original research will be entertained.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are existing members of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submissions is 30 April 2026.

Please submit your manuscript on our website, quoting the promo code NRCCP for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

Guest Advisors

Dr. Faraz Ahmad, Vellore Institute of Technology, India

[email protected]

Dr. Faraz Ahmad’s research focusses on understanding the molecular mechanisms of synaptic pathology in a range of neuronal disorders, ranging from early-life stress to ageing-induced cognitive decline. He’s also interested in devising and evaluating phytotherapy-based strategies for neuroprotection.

Dr. Shafiul Haque, Jazan University, Saudi Arabia

[email protected]

Dr. Shafiul Haque has been offering 15+ years of accomplished experience in health sciences/ biomedical sciences /life sciences research, academia, bio-business with flare of research strategy and scientific management, team leadership, design & development of biological research projects/products, research application support and R&D project management.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Neuromodulation in Neuropsychiatric Disorders" in Neuropsychiatric Disease and Treatment.

We are pleased to announce a new Article Collection in Neuropsychiatric Disease and Treatment, dedicated to the game-changing role of neuromodulation therapies in the management of neuropsychiatric disorders.

The collection, edited by the Editor-In-Chief Dr. Roger Pinder, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.

While the call is open to receive manuscripts across the broad spectrum of neuromodulation in neuropsychiatric disorders, the Editors are particularly interested in those that are being used within the clinic:

• Transcranial magnetic stimulation (TMS) for depression and obsessive-compulsive disorder (OCD)
• Electroconvulsive therapy (ECT) for depression and other mood disorders
• Vagus nerve stimulation (VNS) for depression and epilepsy
• Deep brain stimulation (DBS) for Parkinson’s disease and OCD
• Cranial electrotherapy stimulation (CES) for depression, anxiety, and insomnia

Submissions on other neuromodulation therapies in treating neuropsychiatric disorders are also welcome. The subtopics of interest include but are not limited to:

• Neurological mechanisms and pathways
• Clinical benefits and long-term outcomes
• Cognitive and emotional effects
• Risks, side effects, and safety considerations
• Technical innovations and personalized approaches

Please submit your manuscript on our website. Submitting authors will be eligible for a 20% discount of the Article Publishing Charge by applying the following code at the point of submission NZIEY. If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor Sam Zhang at [email protected].

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submissions is 1 April 2026.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Radiation Therapies for Cancer" in OncoTargets and Therapy.

Radiation therapy remains a cornerstone in the treatment of various cancers. With continuous advancements in technology and a deeper understanding of cancer biology, radiation therapies are becoming more precise and effective. This Article Collection seeks to explore these advancements, including novel radiation techniques, toxicity management, and integration of radiation therapies with other treatment modalities.

We invite papers on topics including but not limited to:

• Innovative radiation techniques, including proton therapy, carbon ion therapy, and stereotactic body radiotherapy (SBRT).
• Technological innovations in radiation oncology, including the development and implementation of technologies such as artificial intelligence, machine learning, and image-guided radiation therapy (IGRT) in clinical practice.
• Radiation therapy and immunotherapy combinations.
• Personalized radiation therapy
• Radiation-induced toxicity management

The deadline for submissions is 1 December 2025. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code MMCTR for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection entitled “Breaking Down the Intricacies of Catabolic Enzymes”, organized by Editor-in-Chief Dr. Martin Bluth in Pharmacogenomics and Personalized Medicine.

Genetic polymorphisms are one way in which people vary from one another. While initial thoughts of "variance" might include a person’s physical features, it is well established that the body’s internal processes are also subject to differ dependent on a multitude of factors. This could include traits that follow them from birth, but also polypharmacy, or even diet.

In line with the advances in modern medicine and genetic testing, research has started to explore the plethora of information linked to catabolic enzyme polymorphisms. This can involve specifying polymorphisms of interest, such as the Cytochrome P450 (CYP) family such as those including the location on the chromosome, possible allelic variations and the impact of these polymorphisms on their parent compound, metabolites or other molecules.

Genetic polymorphisms affect many parts of human function, irrespective of specific health status. This stresses the importance of such polymorphisms further, for both promoting wellbeing in times of health, but to also understand how to approach certain illnesses given the variance in each individual case. This Collection aims to explore the role of catabolic enzyme polymorphisms for a wide variety of disease areas, such as oncology, pulmonology, immunology, psychology, cardiology and more.

The advances in medicine can also leave researchers asking more questions. As more drug compounds reach regulators and medicine agencies, should we be considering how enzyme polymorphisms influence the efficacy and reaction of new medicines? What dangers exist when you inhibit or enhance an enzyme reaction? When considering these possibilities for new medicines, it is also imperative to acknowledge the range of possible reactions and their severity, given that polymorphisms highlight how differences between people should not be underestimated. In turn it is hoped that this Article Collection can promote best practices when prescribing treatments, by placing leading research in this collection.

It is also hoped that research can investigate catabolic enzyme polymorphisms with a wider lens, to understand global trends in such polymorphisms and our understanding of variance on a larger scale. Thus, exploring upcoming topics of interest in this field, such as genomic testing and the use of bioinformatics in predictive technologies, elucidating the intricacies of such interaction are now within reach. These possibilities may provide more control to the individual, their medical practitioners, drug manufacturers by acknowledging human variance stretches beyond what meets the eye. These investigations, questions and early research outcomes highlight the importance of this topic for sustaining our health as a population.

The journal is seeking original submissions and review articles from all disease areas on the following topics related to catabolic enzyme polymorphisms:

• Identifying and understanding polymorphisms (e.g., single-nucleotide polymorphisms)
o All aspects of enzyme metabolism (e.g., catabolism, anabolism)
o Associated mutations, location and allelic compositions
o Functions of interest (e.g., CYPs, steroidogenic enzymes)
• Incidence and variance of poor metabolizers
• Biochemical impact of polymorphisms (e.g., on parent compound, metabolites)
• Impact of polymorphisms on drug reaction symptoms, severity and consequences
o Variance in pro-drug and active drug reactions
• Non-drug consumables (i.e. diet, infectious diseases) and polymorphisms
• How epigenetic and infectious processes affect polymorphism function
• Treatment efficacy and polymorphisms
o Role of polypharmacy on reactions
o Personalized dosages, drug classes and emergency medical care
• Global trends and variation in polymorphisms
• Progress in polymorphism genomic testing and associated benefits and costs
• Use of bioinformatics and modelling systems for predictive testing

All manuscripts submitted to this Article Collection are subject to desk assessment and peer review processes as part of our standard editorial process. We kindly ask all submitting authors to review the Aims and Scope of the journal, alongside the Author Information prior to completing your submission.

The deadline for submissions is 31 May 2024.

Please submit your manuscript on our website, quoting the promo code XSMPT for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Navigating Complexity: Real-World Evidence of Biologics in Elderly and Multimorbid Psoriasis Patients" in Psoriasis: Targets and Therapy.

The therapeutic landscape of psoriasis has been revolutionized by the advent of biological agents, offering unprecedented levels of skin clearance and quality of life improvement. However, randomized controlled trials (RCTs) often employ strict inclusion criteria, leading to the underrepresentation of specific patient subgroups commonly encountered in daily practice, such as the elderly (including the "oldest old") and patients with significant multiple comorbidities. As the global population ages and the systemic nature of psoriasis becomes increasingly evident, bridging the gap between controlled trial environments and clinical reality is imperative. This Article Collection focuses on Real-World Evidence (RWE) regarding the use of biologics in these complex scenarios. We aim to gather data that elucidates how biological therapies perform outside the rigid constraints of RCTs, specifically targeting vulnerable populations where evidence-based guidance is often limited or extrapolated.

This Collection is crucial because clinicians frequently face the challenge of treating psoriatic patients who do not fit the "standard" profile of RCT participants. The management of psoriasis in the elderly is complicated by immunosenescence, polypharmacy, and frailty, while the presence of comorbidities—ranging from cardiovascular and metabolic diseases to malignancies—poses significant safety concerns and therapeutic dilemmas. Understanding the bidirectional relationship between psoriasis treatment and comorbidities is vital: not only how comorbidities influence effectiveness, safety and drug survival, but also how biologics might modify the natural history of associated conditions (e.g., potential cardio-protective effects or cancer risks). Collecting high-quality real-world data is essential to validate the long-term safety profile of these drugs, tailor treatments to individual phenotypic profiles, and ultimately optimize the risk-benefit ratio for the most fragile patients.

This Article Collection welcomes submissions that investigate the practical application of biological therapies in psoriasis, with a specific lens on complex patient profiles. We encourage the submission of Original Research, Reviews, and Real-World Case Series. Key subtopics of interest include, but are not limited to:
• Effectiveness and Safety in the Elderly: Impact of immunosenescence on biologic response and infection risk in geriatric populations;
• Comorbidities and Treatment Response: How metabolic syndrome, diabetes, chronic kidney disease (CKD) or cardiovascular disease influence effectiveness, safety and drug survival;
• Impact of Biologics on Comorbidities: Research into the potential protective effects of systemic inflammation reduction on organs and systems affected by chronic diseases, as well as the risk of disease progression;
• Malignancy: Real-world data on the safety of biologics in patients with a history of cancer or concurrent malignancies;
• Polypharmacy: Drug-drug interactions and management strategies in multimorbid patients.

Keywords

1. Real-world evidence
2. Biologics
3. Psoriasis comorbidities
4. Geriatric dermatology
5. Drug survival

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 5 November 2026.

Please submit your manuscript on our website, quoting the promo code 5E799 to indicate that your submission is for consideration in this Article Collection.

Guest Advisors

Dr Zeno Fratton, University of Udine

[email protected]

Dr. Zeno Fratton is a physician based at the Institute of Dermatology, University of Udine (Italy). His research focuses on chronic inflammatory skin diseases, particularly plaque psoriasis and biological therapies in the elderly and other special populations. He has authored numerous papers in high-impact journals and serves as a reviewer for top-tier publications. He graduated with honors from the University of Verona under the guidance of Prof. Paolo Gisondi and is an active member of the Italian Society of Pediatric Dermatology (SIDerP).

Dr. Stefano Bighetti, University of Brescia

[email protected]

Dr. Stefano Bighetti is a dermatologist at the Dermatology Department, University of Brescia (Italy), with a clinical and academic focus on chronic inflammatory skin diseases, particularly atopic dermatitis and psoriasis, and on non-invasive therapeutic strategies including phototherapy and laser-based therapies. He has authored and co-authored several peer-reviewed publications in the international dermatology literature, with contributions spanning clinical research and real-world evidence. He serves on the Editorial Board of the Italian Journal of Dermatology and Venereology and acts as a peer reviewer for multiple dermatology journals. He is engaged in academic and educational activities within national scientific societies, supporting initiatives in continuing medical education and evidence-based dermatology.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "PsoPsych: Insights on psychological processes, health and support in people with psoriatic disease" in Psoriasis: Targets and Therapy.

It is widely recognized that psoriasis is "more than just skin deep", with a growing body of evidence supporting the link between psoriatic conditions and mental health. We know there is a bi-directional relationship between psoriasis, related co-morbidities, and common psychological conditions, such as depression and anxiety, due to shared inflammatory pathways. Psychological processes (thoughts, feelings and behaviors) play a key role in the clinical and patient self- management of psoriasis.

Over recent decades, there have been calls to increase the provision of specialist psychological support within dermatology settings and dedicated psychodermatology services to help people to cope with, and overcome, psychological and psychiatric challenges associated with psoriatic disease. However, societal, organizational, service and individual barriers exist, meaning progress is slow. Concerted efforts by policy makers, dermatology and other health organisations, clinicians, researchers and industry partners are needed to deliver the support people need to live well with psoriatic conditions.

This Article Collection focuses on the latest research addressing psychological impact, health and support in people with psoriasis and psoriatic arthritis. It is important to expand our understanding of:
• The psychological burden of psoriatic conditions and related co-morbidities.
• The interplay between psychological and physiological mechanisms in PsO/A.
• The challenges, and solutions to, managing the psychological aspects of these conditions, from the perspective of different dermatology stakeholders.
• Existing sources of psychological support.
• New and existing interventions designed to improve psychological outcomes.
• Patients’ psychological support needs and preferences.

This will continue efforts to raise awareness of this topic within the field of dermatology, identify knowledge gaps and new avenues for research, and strategies and approaches for supporting patients.

We encourage submissions of quantitative, qualitative and mixed methods research involving people living with psoriatic disease anywhere in the world. We particularly encourage submissions that:
• Build on current understanding of the psychological impact, and specifically those that identify, test and implement strategies to help patients/families/clinicians to mitigate and manage this impact.
• Focus on the development, evaluation and implementation of psychological interventions delivered via a range of mediums, and how interventions bring about change. We particularly encourage submissions on health behavior change/interventions given that support of this kind is typically generic or lacking within health services.
• Report on existing mental health support within dermatology, including, but not limited to, counselling, psychology, psychiatry and specialist psychodermatology provision. Of interest are examples of multi- and inter- disciplinary working.
• Explore patient peer and social support networks (in person or online), especially the arguably underrecognized role of patient organizations in supporting people with psoriasis.
• Enhance our knowledge of pharmacological treatments for people with psoriatic disease and comorbid psychological/psychiatric illness.

• Highlight epidemiological trends in mental/psychiatric diagnoses in psoriatic patients.

Keywords

1. Psoriasis
2. Psoriatic arthritis
3. Mental health
4. Psychological support
5. Psychodermatology

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 1 June 2026.

Please submit your manuscript on our website, quoting the promo code B40CC to indicate that your submission is for consideration in this Article Collection. 

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisor

Dr Rachael Hewitt, School of Healthcare Sciences, Cardiff University, Wales UK

[email protected]

Dr Hewitt is a Post-Doctoral Research Associate and Trainee Health Psychologist at Cardiff University with expertise in patient-practitioner communication, health behaviour change, complex intervention development and supporting patient self-management. She leads applied psychology and interdisciplinary research within the field of medical dermatology, especially psoriasis, and previously co-led the wellbeing arm of a specialist clinic for psoriatic disease within the Welsh Institute of Dermatology. Rachael led the national implementation of PsoWell™, training dermatology staff in Motivational Interviewing (MI) to address the psychological aspects of psoriasis and continues to deliver MI training internationally. Her research also explores clinicians’ personal models of psoriasis and patient-reported outcome measure development. She has authored 21 peer-reviewed publications, secured over £350,000 in research funding, and her work has been recognized internationally, including a Rising Star Scholarship award to present at the 25th World Congress of Dermatology.

View all papers in this article collection

We are pleased to announce a new Article Collection in Psychology Research and Behavior Management, dedicated to the game-changing role of GLP-1 receptor agonists (GLP-1 RAs) in psychological treatment and behavior management. Since their clinical introduction, GLP-1 RAs have revolutionized patient care beyond metabolic and cardiovascular diseases, offering significant benefits in reward regulation, cognitive functions, behaviour control, and mental health for eligible populations.
Given the global importance of GLP-1 RAs in management of psychological disorders, Psychology Research and Behavior Management invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these transformative therapies.

The collection, edited by Editor-In-Chief Dr. Igor Elman, will be included in Taylor & Francis’ Game Changer Series. This series features Article Collections focused on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

While the call is open to receive manuscripts across the broad spectrum of GLP-1 Receptor Agonists in mental health, the Editors are particularly interested in manuscripts relating to the following areas:

• Effects of GLP-1 Receptor Agonists on Psychological Factors in Patients with Metabolic Disorders
• Effects of GLP-1 Receptor Agonists on Mental Health Disorders
• Temporal trends in GLP-1 Receptor Agonists’ Effects on Mental Health
• GLP-1 Receptor Agonists’ Effects on Reward Function, Suicidality, Anxiety, or Depression

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website. The deadline for submitting manuscripts is 1 April 2026.

Submitting authors will be eligible for a 20% discount of the Article Publishing Charge by applying the following code at the point of submission 25CF5. If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor Sam Zhang at [email protected].

View all papers in this article collection

Dove Medical Press is pleased to announce a new Article Collection in Research and Reports in Urology, dedicated to the transformative role of focal therapy in the management of prostate cancer. Since its clinical introduction, focal therapy has revolutionized patient care, offering benefits in preserving urinary and sexual function, minimizing treatment-related morbidity, and enabling targeted cancer control.

Given the importance of focal therapy in managing prostate cancer, Research and Reports in Urology invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these paradigm-shifting therapies. 

This collection, edited by Editor-in-Chief Professor Panagiotis J Vlachostergios, is part of the new Game Changer series of Article Collections, spotlighting breakthrough therapies that redefine standards of care and deliver game-changing improvements in patient outcomes. 

While the call welcomes manuscripts across the broad spectrum of focal therapy in prostate cancer, the Editors are particularly interested in submissions addressing the following priority areas:

• Patient selection and biomarkers: advances in MRI-guided targeting, genomic profiling, and risk stratification for focal therapy candidacy.
• Energy modalities and technologies: comparative outcomes of HIFU, cryotherapy, laser ablation, and irreversible electroporation.
• Long-term oncologic outcomes: disease-free survival, recurrence patterns, and integration with active surveillance protocols.
• Complications and side effects: Short-term (urinary retention, infection) vs. long-term risks (erectile dysfunction), management strategies for adverse events.
• Technological advancements: AI in treatment planning and imaging interpretation, robotics/real-time imaging integration and nanotechnology, combination therapies (e.g., focal ablation + immunotherapy)

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submissions is 1 April 2026.

Please submit your manuscript on our website, quoting the promo code BICXO for a 20% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

View all papers in this article collection

We are pleased to announce a new Article Collection in Risk Management and Healthcare Policy, dedicated to the game-changing role of Artificial Intelligence (AI) in the management of healthcare risk. Since their clinical introduction, AI technologies have revolutionized patient care, offering significant benefits in early disease detection, optimizing personalized treatments, and enabling real-time risk prediction to support healthcare providers in decision-making.

Given the importance of AI in healthcare risk management, Risk Management and Healthcare Policy invites submissions of original research articles, reviews, and perspectives exploring AI applications in managing risks, and their impacts on the healthcare system.

The Collection, edited by Editor-In-Chief Dr Gulsum Kubra Kaya, will be included in Taylor & Francis’ Game Changer Series. This series features Article Collections focused on breakthrough applications or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

While the call is open to receive manuscripts across the broad spectrum of AI applications in healthcare risk, the Editors are particularly interested in manuscripts relating to the following areas:

• AI applications in reducing diagnostic errors and adverse events
• AI-driven predictive modeling
• Ethical frameworks and policy implications of AI in clinical decision-making
• AI-driven remote monitoring systems for chronic disease management
• The impact of AI applications or technology on the healthcare system.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submissions is 1 June 2026.

Please submit your manuscript on our website, quoting the promo code 65A27 for a 20% discount on the Article Publishing Charge and to indicate that your submission is for consideration in this Article Collection.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection "Healthcare for Cardiorenal Chronic Patients: A Challenge for Social Expenditure", organized by Prof. Caterina Carollo and Prof. Siddiq Anwar in Risk Management and Healthcare Policy.

Cardiorenal syndromes represent a growing global health challenge, characterized by the complex interplay between heart and kidney dysfunction. These conditions are becoming increasingly prevalent, requiring long-term management and multidisciplinary care. The treatment of cardiorenal patients often involves collaboration among various healthcare professionals, which contributes to rising healthcare costs and places significant strain on social expenditure. This Article Collection aims to explore innovative solutions that balance optimal treatment outcomes with sustainable healthcare costs, addressing a pressing issue that affects healthcare systems worldwide, regardless of whether they are public or private.

The rising prevalence of cardiorenal syndromes poses significant challenges to healthcare systems worldwide. These conditions require long-term management and multidisciplinary care, which can strain healthcare resources and increase social expenditure. This Article Collection seeks to address these challenges by fostering research that identifies cost-effective strategies for managing cardiorenal patients. By advancing our understanding of integrated care models and innovative healthcare policies, this Collection aims to provide a foundation for improving patient outcomes while ensuring the sustainability of healthcare systems. The insights gained will be invaluable for policymakers, healthcare providers, and researchers working to mitigate the global impact of these chronic conditions.

We invite submissions that explore integrated and transitional care approaches for cardiorenal patients, including strategies to reduce hospital stays and enhance the quality of life for individuals with chronic heart and kidney failure. Topics of interest include home healthcare models, the role of nursing and healthcare professionals, and innovative interventions to optimize patient outcomes. Additionally, we welcome research articles, reviews, and perspectives that examine the challenges of managing cardiorenal syndromes and propose solutions for sustainable healthcare management. By addressing these diverse aspects, this Collection aims to foster a multidisciplinary dialogue that advances both clinical practice and healthcare policy.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submissions is 31 October 2026.

Please submit your manuscript on our website, quoting the promo code 6F64B to indicate that your submission is for consideration in this Article Collection.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest Advisors

Dr. Caterina Carollo, University of Palermo, Italy

[email protected]

Dr Prof. Caterina Carollo is a nephrologist and researcher with extensive expertise in cardiorenal physiology, hypertension, and microcirculation. She holds a PhD in Cardiovascular and Renal Clinical Pathophysiology and has authored numerous publications in high-impact journals, focusing on innovative approaches to nephrocardiology and oxidative stress. Dr. Carollo is also an experienced educator, currently teaching Nephrology at the University of Palermo, and has played a pivotal role in organizing and leading prominent scientific conferences in her field.

Dr. Siddiq Anwar, Khalifa University, United Arab Emirates

[email protected]

Dr. Siddiq Anwar is a Consultant Nephrologist and Clinical Professor at Sheikh Shakhbout Medical City, with academic appointments at Khalifa University, UAE University, and Gulf Medical University, and a Visiting Fellowship at the ADIA Lab focusing on AI-driven cardiorenal care optimization. He has led transformative digital health programs across GCC healthcare systems, specializing in integrated chronic disease management, population health outcomes, and sustainable care delivery models. Dr. Anwar co-founded RenAIssance AI research laboratory and has extensive experience developing cost-effective healthcare solutions across the Middle East, Africa, and South Asia.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Risk Management and Healthcare Policy on "Resilient Health Systems and Policy Responses in Public Health Crises", organized by Prof. Munjae Lee (Yonsei University, South Korea).

Public health crises place significant pressure on healthcare systems, disrupting the continuity of essential services and exposing structural vulnerabilities across care delivery. Events such as pandemics amplify existing inequalities in access to care, inefficiencies in resource allocation, and limitations in infrastructure readiness. These disruptions are further compounded by uncertainty and systemic risks that challenge traditional models of healthcare delivery. Addressing these challenges requires integrated strategies that strengthen health system resilience, enhance risk management capacity, and enable adaptive and data-informed responses to rapidly evolving health needs. This Article Collection aims to explore evidence-based approaches to improving health system resilience while ensuring continuity of essential services during public health crises.

The importance of resilient and risk-responsive healthcare systems has become increasingly evident as large-scale crises generate widespread social and economic disruption. These conditions place pressure on healthcare delivery systems, strain workforce capacity, and exacerbate inequities in access to care. Such challenges reveal critical gaps in risk governance, policy coordination, and system-level decision-making under uncertainty. Without adaptive and data-informed policy frameworks, these disruptions may lead to long-term consequences, including rising healthcare costs, reduced system efficiency, and widening health inequalities. Strengthening healthcare systems therefore requires coordinated policy responses, effective governance mechanisms, and strategic resource allocation to ensure system resilience and sustainable recovery.

This Article Collection invites original research, policy analyses, short reports, case studies, and perspectives that examine health system resilience, risk governance, and policy responses during public health crises.

Topics of interest include, but are not limited to:

• Health system preparedness, resilience, and continuity of essential services during public health crises
• Risk governance, emergency policy coordination, and decision-making under uncertainty
• Healthcare utilisation, access inequities, and service disruption in crisis settings
• Community-based care models and service continuity, including mental health as one component
• Workforce resilience, patient safety, and adaptive healthcare delivery
• Risk-informed resource allocation, triage policy, and health economic evaluation during emergencies
• Data-informed surveillance, forecasting, and decision support with clear policy relevance
• Comparative evaluations of crisis response policies across healthcare systems

By integrating multidisciplinary perspectives, this Collection aims to generate actionable insights that support policy-relevant, data-informed decision-making and strengthen resilient healthcare systems in the face of future public health crises.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submissions is 31 January 2027.

Please submit your manuscript on our website, quoting the promo code 75080 to indicate that your submission is for consideration in this Article Collection.

Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.

Guest Advisor

Prof. Munjae Lee, Yonsei University

[email protected]

Dr. Munjae Lee is an Associate Professor in the Department of Biohealth Industry at Yonsei University. His research focuses on healthcare system resilience, risk management, and digital health innovation in the biohealth sector. He has led multiple national and international research projects on healthcare policy, medical device ecosystems, and AI-enabled healthcare innovation, with a particular emphasis on system-level decision-making under uncertainty. Dr. Lee serves as an Associate Editor and Editorial Board Member for several international journals, contributing to advancing research in health systems, policy, and innovation.

View all papers in this article collection

We are pleased to announce a new Article Collection in Therapeutics and Clinical Risk Management, dedicated to the role of biologic treatments in the management of allergic disease. Since their clinical introduction, biologic treatments, particularly monoclonal antibodies, have transformed patient care, offering targeted therapies and improved outcomes for conditions including allergic asthma, allergic rhinitis, atopic dermatitis and urticaria.

Given the importance of biologics in managing allergic disease, we are welcoming submissions of original research articles, reviews, and perspectives exploring the mechanisms of action, clinical efficacy, safety, and real-world application of these therapies.

The Collection, edited by the Editor-In-Chief Prof. Garry Walsh, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

While the call is open to receive manuscripts across the broad spectrum of biologic treatments in allergic disease, the Editors are particularly interested in manuscripts relating to the following areas:
• Mechanisms of action and biomarkers for personalized treatment
• Clinical efficacy and safety profiles
• Real-world evidence and patient-reported outcomes
• Cost-effectiveness and health economic evaluations
• Reviews, perspectives and editorials discussing emerging therapies and future directions

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code 7A889 to indicate that your submission is for consideration in this Article Collection.

The deadline for submitting manuscripts is 1 April 2026.

If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor, Catherine Teng at [email protected].

View all papers in this article collection

We are pleased to announce a new Article Collection in Vascular Health and Risk Management, dedicated to the game-changing role of pharmacotherapy in the management of heart failure. Since their clinical introduction, heart failure medications have revolutionized patient care, leading to improved survival, reduced hospitalization and improved quality of life in eligible patients, especially in those with reduced ejection fraction.

Given the global importance of pharmacotherapy in managing heart failure, Vascular Health and Risk Management invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these transformative therapies.

The collection, edited by Editor-In-Chief Professor Roland Asmar, will be included in Taylor & Francis’ Game Changer Series. This series features Article Collections focused on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

While the call is open to receive manuscripts across the broad spectrum of pharmacotherapy in the management of heart failure, the Editors are particularly interested in papers in the following areas:

• Heart failure pathophysiology as it relates to potential therapeutic targets
• Emerging drugs for acute and chronic heart failure
• Efficacy and safety of heart failure pharmacotherapy, with special attention given to studies on patients with comorbidities
• Papers focused on the implementation of heart failure medications in clinical practice

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

Please review the journal scope and author submission instructions prior to submitting a manuscript. Submitting authors are eligible for a 20% discount on the Article Publishing charge. Please use the promo code VBOLK when prompted during the submission.

Please submit your manuscript on our website. The deadline for submitting manuscripts is 1 April 2026.

Please contact Zhiyuan Zhang at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisor

Roland Asmar, Foundation-Medical Research Institutes (F-MRI), Switzerland

View all papers in this article collection